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Cancer has become a public health problem worldwide. The side-effects 
and drug-resistance of current anticancer drugs such as cisplatin make it 
desirable to develop next-generation cancer therapy. Recently, half-
sandwich ruthenium, iridium and osmium complexes have exhibited 
promising anticancer potency, of which [Os(η6-p-cymene)(4-(2-
pyridylazo)-N,N-dimethylaniline)I]+ ([2-I]+, also known as FY26) 
showed 49× higher cytotoxicity than cisplatin towards 809 cancer cell 
lines. The potency of [2-I]+ was influenced by the concentration of 
intracellular tripeptide glutathione (γ-L-Glu-L-Cys-Gly, GSH). This 
thesis explores the chemical related mechanism of action of [2-I]+ and 
mainly studies the reactions of [2-I]+ with GSH. 
Complexes related to the reaction of [2-I]+ with GSH under physiological 
conditions were synthesized and characterized, including the chlorido [2-
Cl]+, hydroxido [2-OH]+ and thiolato adduct 2-SG. For these osmium 
complexes, their extinction coefficients, retention times and mass spectra 
were determined and the proportionality between HPLC peak and 
concentrations is established. These studies provides the basis for the 
following exploration of the chemical behaviour of [2-I]+.  
 [2-I]+ is inert under physiological conditions, but the presence of GSH 
dramatically increases (> 100×) the extent of hydrolysis of [2-I]+. A 
VI 
similar behaviour was also observed for chlorido analogue [2-Cl]+, but 
not for the imino analogue [2-impy-I]+, which indicates the importance 
of the azo ligand. Meanwhile, acidic conditions inhibited the promotion 
of hydrolysis of [2-I]+ by GSH, which might be due to the deprotonation 
of GSH. Combined with DFT calculations, a novel mechanism of action 
based on deprotonated GS- attack on the -N=N- azo bond to activate inert 
organo-osmium azopyridine complexes is proposed.  
More surprisingly, free radicals O2
-, •OH and •H are detected in reactions 
of osmium azopridine complexes ([2-I]+, [2-Cl]+ and [2-OH]+) with GSH 
by EPR in presence of a spin trap, but no radicals were observed for the 
imino analogue or free azopryridine ligand. These results highlight the 
importance of azo bond and the osmium centre. Meanwhile, an N2 
atmosphere and acidic conditions hampered the free radical generation. 
A mechanism in which osmium azopyridine complexes induce electron 
transfer from GSH to O2 and produce GSSG and O2
-  is proposed.  
The sulfenylhydrazide intermediate in the reaction of [2-I]+ with GSH 
was captured by Os LIII-edge X-ray absorption spectroscopy. This result 
supports a mechanism involving attack of deprotonated GS- on the azo 
bond of [2-I]+ to activate hydrolysis and produce free radicals. The 
studies in this thesis provide insights to a novel mechanism of action of 
this class of half-sandwich organo-osmium anticancer complexes. 
VII 
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1.1. Cancer and Cancer Therapies 
The project in this thesis involves explorations of the mechanism of 
action of organo-osmium anticancer complexes. Cancer is the leading 
or second cause of death in over 80 countries including Europe, 
America and China, and has become a major public health problem 
worldwide. In 2018, there are an estimated 18.1 million new cancer 
cases and 9.6 million cancer deaths.1  In 2019, 1,762,450 new cancer 
cases and 606,880 cancer deaths are projected to occur in the United 
States.2 What cancer is (Section 1.1.1) and what currently cancer 
therapies there are (Section 1.1.2) will be introduced briefly. 
 
1.1.1. Hallmarks of Cancer 
Cancer is group of diseases with abnormal cell growth and unregulated 
cells spreading, as defined by World Health Organisation. Over 200 
different types of cancers have been found in human body.3 In order for 
a normal cell to transform into a cancer cell, the genes that regulate cell 
growth and differentiation must be altered.4,5 More than 90% genetic 
mutations of cancer induction are contributed from environmental 
factors like chemicals, diet and obesity, infection, radiation,  hormones 
and physical agents.6-10  The remaining 10% is due to inherited 
genetics.6 During the multistep development of human tumours, 
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biological capabilities are acquired, and corresponding hallmarks are 
observed and summarized (Figure 1.1).  
 
Figure 1.1. Hallmarks of cancer and corresponding cancer therapies.11 
 
These hallmarks of cancer cells include proliferative signalling, the 
evasion of growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, and activating invasion and 
metastasis.11 With the conceptual progress, in recent years two 
emerging hallmarks of potential generality have been added. These are 
reprogramming of energy metabolism, and the evasion of immune 
destruction.11 Underlying these hallmarks are genome instability, which 
generates the genetic diversity that expedites their acquisition, and 
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inflammation.11,12 When cancer begins, it produces few specific 
symptoms so that it is common for people diagnosed with cancer to 
have been treated for other diseases. The hallmarks and characteristics 
of cancer benefit both cancer diagnosis and cancer therapies.   
 
1.1.2. Cancer Therapies 
Currently the methods applied for clinical anticancer treatment include 
surgery, radiotherapy, chemotherapy and immunotherapy. Surgery has 
long been a stable form to remove malignant tumours and relieve 
patients from the bulk of cancer immediately. The goal of surgery can 
be either the removal of only the tumour, or the entire organ. In theory, 
cancers can be cured if entirely removed by surgery, but this is not 
always possible in view of cancer metastasis. In clinical cancer 
treatment, surgery is generally used, together with chemotherapy and 
radiotherapy. Radiotherapy employs ionizing radiation to kill cancer 
cells by damaging the DNA of cancerous tissue.13,14 One successful 
example of internal radiation therapy is radioactive iodine, which is 
often used to treat certain types of thyroid cancer.15,16 Immunotherapy 
involves artificially stimulating the immune system to fight cancer 
based on the fact that cancer cells often have tumour antigens on their 
surface which can be detected by the immune system.17,18 
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Immunotherapies can be categorized as active or passive. The passive 
immunotherapies use monoclonal antibodies, lymphocytes and 
cytokines to enhance existing anti-tumour responses. The U.S. Food 
and Drug Administration (FDA) has approved many anticancer 
monoclonal antibodies including Alemtuzumab, Atezolizumab, 
Avelumab, Ipilimumab, Ofatumumab, Nivolumab, Pembrolizumab, 
Rituximab and Durvalumab.19,20 Active immunotherapy directs the 
immune system to attack tumour cells by targeting tumour antigens. 
The drugs approved for active immunotherapy consist of 
Tisagenlecleucel (Kymriah), Axicabtagene ciloleucel (Yescarta) and 
Sipuleucel-T (Provenge).21-23 In 2018, the Nobel Prize in Physiology or 
Medicine was awarded jointly to James P. Allison and Tasuku Honjo 
for their great contributions to cancer immunotherapy. 
Chemotherapy is currently the most widely used and powerful cancer 
treatment, especially when patients face the problems of tumour 
metastasis and recurrence after surgery and radiotherapy. 
Chemotherapy literally means drug treatment, but now the term 
chemotherapy has come to mean a treatment of cancer by using anti-
cancer medicines known as cytotoxic medicines. Cisplatin-based 
chemotherapy is the first-line treatment for many cancer types, of which 
cytotoxicity is achieved through DNA attack.24  Due to non-selectivity 
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regarding normal cells, millions of patients suffer from unwanted the 
side-effects induced by chemotherapy including tiredness, 
nephrotoxicity, neurotoxicity, ototoxicity, hair loss and vomiting.25 The 
desire for high selectivity has stimulated the emergence of targeted 
cancer therapy. The hallmarks of cancer cells provide a theoretical 
foundation and practical feasibility to develop cancer-targeted 
chemotherapy.  For example, cancer cells share a hallmark of 
proliferative signalling substance caused by the overpression of EGFR 
(epidermal growth factor receptor).26 Erlotinib (Tarceva) has been 
developed as EGFR inhibitor and used to prevent cancer cell 
proliferation selectively.27 Based on the cancer hallmark of genome 
instability and mutation, PARP (poly ADP-ribose polymerase) inhibitor 
Olaparib (Lynparza) has been approved for ovarian cancer treatment.28 
The development of targeted drugs moves the chemotherapy from 
observation-driven to target-driven, and provides a promising way to 
kill cancer cells selectively.  
 
Figure 1.2. The structures of some anticancer drugs 
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1.2. Anticancer Metallodrugs 
Metal ions play important roles in biological processes, and the use of 
metals in pharmaceutical potions can even be traced back to ancient 
civilizations of Mesopotamia, Egypt, India, and China 2500 B.C.29 The 
modern development of metallodrugs began with the discovery of 
salvarsan to treat infectious diseases in 1912,30 and greatly stimulated 
by the application of cisplatin as anticancer therapy from 1965.31,32 
Metal ions in metallodrugs, especially transition metal ions, usually 
have more oxidation states than carbon, which provides potential for a 
higher level of versatility. Such an advantage renders metallodrugs of 
particular interest, and these have been developed rapidly in recent 
years. Currently platinum complexes are used as a component of nearly 
50% of all cancer treatments,33 gadolinium complexes are administered 
over 20 million doses per year as MRI (Magnetic Resonance Imaging) 
contrast agents and 99m-technetium radiopharmaceuticals are used in 
about 20 million radiodiagnostic procedures each year for γ-ray 
imaging.33 Hundreds of metallodrugs have achieved great success in 
many fields. In this part of the thesis, only anticancer metallodrugs will 
be described. Intracellular targets (Section 1.2.1), design principles 
(Section 1.2.2) and typical examples (Section 1.2.3) of anticancer 
metallodrugs will be introduced. 
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1.2.1 Targets of Metallodrugs 
1.2.1.1. DNA 
Deoxyribonucleic acid (DNA) is a macromolecule with two DNA 
strands that coil around each other to form a double helix, in which the 
two strands, also called polynucleotides, are composed of monomer 
nucleotides. Each nucleotide contains one of four nitrogen-containing 
nucleobases (cytosine [C], guanine [G], adenine [A] or thymine [T]), a 
sugar called deoxyribose, and a phosphate group. The adjacent 
nucleotides in a chain are joined to each other by covalent bond 
between the sugar moiety of one nucleotide and the phosphate group of 
the next. The opposite nucleotides in two separate chains are bound to 
each other by hydrogen bonds, according to base pairing rules (A with 
T and C with G). Due to the non-symmetrically double helix structure, 
two grooves are observed in DNA. The major groove is 22 Å wide, and 
the minor groove is 12 Å wide.34 
DNA stores the biological information used for cell growth, 
development, functioning and reproduction, and it is replicated during 
the cell division. Since cancer cells keep devising and spreading, DNA 
have been used as one of targets for anticancer drugs. The view that 
nuclear DNA is the important functional and pharmacological target of 
platinum anticancer drugs has been proved and generally accepted. 
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Cisplatin typically binds to primary sequences containing 2 to 3 
nucleotides such as GG, AG and GNG sequences (More details are 
shown in Section 1.2.3.1). Basically, there are two ways that 
metallodrugs bind with DNA, one of which involves covalent binding 
to the nitrogen donor groups and the other is via π-π stacking 
interactions with DNA nucleobases to distort DNA’s geometry and 
structure. Both types of binding can inhibit DNA replication, which 
leads to S-phase cell-cycle arrest and causes DNA damage, which 
induces cell apoptosis.35  
  
Figure 1.3. The non-symmetrically double helix structure of DNA (Wikipedia). 
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1.2.1.2. Proteins 
Proteins are large biomolecules consisting of one or more long chains of 
amino acid residues. In human cells, proteins are composed of 21 kinds 
of amino acids. The sequence of amino acids determined by the 
corresponding gene is the primary structure of the protein. The 
secondary structure of the protein is determined by protein chain 
folding processes including α-helix and β-sheets. The tertiary structure 
is referred to compact globular structure folded from α-helix and β-
sheets and quaternary structure consists of the aggregation of two or 
more individual polypeptide chains (sub-units) that operate as a single 
functional unit. Each different protein has a unique structure to perform 
different functions, and even the structure basis same kinds of protein 
also varies in different type cells.  
 
Figure 1.4. The crystal structure of human glutathione reductase (PDB code: 2AAQ) 
with a gold complex (GoPI) bound at (a) site 1 with Cys 58, Cys 63 and (b) site 2 
with Cys 284.  
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Some proteins are overexpressed in cancer cells to meet their special 
nutrition and energy requirements, which provides good selective 
targets for anticancer drugs. Enzymes reducing disulfide bonds in cells, 
like thioredoxin reductase and glutathione reductase, are essential for 
cell growth and survival. They are usually upregulated in several types 
of cancer cells, and hence become targets of gold(I)-based anticancer 
complexes. The mechanism of action involves gold binding to cysteine 
residues at the enzymes active sites (Figure 1.4).36     
 
1.2.1.3. Cell Redox Systems 
Besides DNA and proteins, the intracellular redox system has emerged 
as a novel target and provides broader opportunities to overcome cancer 
problems. The redox system consists of biomolecules with their 
reduced/oxidized form, for example GSH/GSSG and NADH/NAD+. 
One major function of such redox systems is to control the balance of 
reactive oxygen species (ROS) which are chemically reactive species 
containing oxygen such as peroxides, superoxide, hydroxyl radicals, 
singlet oxygen. ROS play important roles in signal transduction and 
intracellular metabolism.37 However, too high levels of ROS are likely 
to induce cellular damage such as: 1) damage to DNA or RNA, 2) 
oxidation of polyunsaturated fatty acids in lipids to disturb intracellular 
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membrane, and 3) oxidation of amino acids in proteins to change their 
structure and  functions38 
 
Figure 1.5. Structures of NAD+ and NADH 
 
Many signalling pathways linked to tumourigenesis can regulate the 
metabolism of ROS, which results in the imbalances between ROS 
generation and elimination.39 Cancer cells maintain high levels of ROS 
and depend heavily on antioxidant defence systems. Thus, a new 
anticancer therapy of elevating the ROS levels in the cells to perturb 
redox processes has emerged, which is known as “oxidative therapy”.40 
Significant increases in endogenous ROS can push cancer cells above a 
cellular tolerability threshold and induce cell death. On the other hand, 
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normal cells with lower ROS levels appear to have a higher capacity to 
cope with additional ROS-generating insults than cancer cells do.40  The 
organo-iridium complex [(η5-Cpxbiph)Ir(phpy)(Cl)] (Cpxbiph = 
biphenyltetramethylcyclopentadienyl, with phpy = C^N-chelated 
phenylpyridine) have been reported to catalyse hydride-transfer 
reactions using NADH as a cellular hydride source to promote peroxide 
generation and eventually induce cancer cell death.41  
 
Figure 1.6. Selective killing of cancer cells by ROS. There is evidence that cancer 
cells have higher levels of ROS than normal cells (represented in black) and there is 
a threshold of ROS in which cells cannot survive. Increasing the levels of ROS 
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1.2.2. Design of Metallodrugs 
Many successful metallodrugs have been discovered by chance, and the 
discovery stories for some of them, like cisplatin, are purely accidental. 
On the basis of first generation serendipious hits, further generations of 
drug developments have been achieved through exploring the 
mechanism for potency, as well as reasons for unwanted side-effects. 
Currently, many efforts have been made to move the metallodrug 
development process from the initial serendipitous discoveries to more 
rational drug design process. The process of incorporating metal ions 
into metallodrugs generally involves the following steps:29  
 Finding a druggable target 
 Designing metal complexes for the perfect fit 
 Exploring the druggability of the target 
 Studying thermodynamic stability and kinetic lability 
  Constructing preclinical testing 
 Constructing clinical testing 
In the design part, the first two steps mainly involve finding a druggable 
target and designing metal complexes for the perfect fit.  The targets of 
metallodrugs could be DNA, proteins and biomolecules related to the 
redox system (Section 1.2.1),42 and in the reaction of metallodrugs with 
targets, there are four fundamental mechanisms of action involved: 1) 
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binding to biological thiol groups, 2) chelating with target molecules, 3) 
generating reactive oxygen species, and 4) producing lipophilic ions.29 
Recently, a new fundamental mechanism has emerged that a metal 
centre may not be involved in any direct interactions with the target but 
provides a platform for organizing the organic ligands in the 3D space 
as mimics of natural protein inhibitors.43 
For the perfect fitting with targets, the design of a metallodrug is based 
on the choice of the metal, its oxidation state, the types and numbers of 
coordinated ligands, and the coordination geometry. The metal ions can 
widely range from 13 essential ones, e.g. Cu and Fe, to precious metals 
like Pt and Os. The types of the ligands can include wide a range of 
donors, with coordinating atoms such as carbon, nitrogen, oxygen, 
phosphorus, sulfur and halogens. Compared to organic molecules, the 
geometry of metal complexes is more diverse in 3D space. The basis of 
this diversity is from the coordination number of the metal which can be 
up to 8 or 9, while the “coordination number” of carbon is 4 or less. 
Besides linear, trigonal-planar and tetrahedral geometries which are 
generated in organic compounds, purely relying on carbon and dictated 
by the principles of hybridization, other configurations are created in 
metal complexes including square pyramidal, trigonal bipyramidal, 
octahedral, pentagonal bipyramidal, square antiprismatic and tricapped 
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trigonal prismatic. With more substituents, and modification of these 
substituents, the variety in stereoisomers and stereochemical flexibility 
in general increases to open up a diversity in 3D structures.  
Designed metallodrugs need to fit their targets, but firstly are required 
to reach their targets. Once the drugs are injected and pass through the 
bloodstream, they eventually enter into cells, but biological substances 
like human serum protein can modify the metal drugs through 
substitution reactions. Outer sphere ligand interactions of the 
metallodrugs are also important to be considered in the design 
process.29,44  
 
1.2.3. Typical Examples of Metallodrugs 
1.2.3.1. Cisplatin and Derivative Complexes 
Cisplatin is on the World Health Organization's List of Essential 
Medicines, i.e. the most effective and safe medicines needed in a health 
system, and has become the best-selling anticancer drug at present. The 
history of cisplatin can be briefly outlined as it was first synthesized in 
1835 by Michele Peyrone;45 then its structure with a square planar 
geometry was deduced in 1893 by Alfred Werner;46 its anti-tumour 
potency was discovered in 1969 by Barnett Rosenberg;32 clinical trials 
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were designed and performed in 1971 and permission for medical use 
was approved by the FDA in 1978.46  Cisplatin-based chemotherapy is 
used to treat various types of cancers, including sarcomas, some 
carcinomas (e.g., small cell lung cancer, squamous cell carcinoma of 
the head and neck and ovarian cancer), lymphomas, bladder cancer, 
cervical cancer and germ cell cancer.47 Against testicular cancer, 
cisplatin is particularly effective and improves the cure rate from 10 to 
85%.48  
 
Figure 1.7. Schematic representation of cisplatin hydrolysis and adducts induced in 
DNA. a) intrastrand crosslinking of two adjacent guanines; b) intrastrand 
crosslinking of adjacent adenine and guanine; c) 1,3 intrastrand crosslinking of two 
guanines separated by another intervening base; d) monofunctional adduct; e) 
interstrand cross-link; f) DNA-platinum-protein cross-link.49 
 
Chapter 1: Introduction 
18 
The mechanism of action of cisplatin features attack of the Pt-Cl bond 
by H2O first, and then the aquated product, which is a potent 
electrophile, can react with nucleophiles such as nitrogen donor atoms 
on DNA base residues. The most prevalent cisplatin-induced DNA 
adduct is an intrastrand cross-link (CL), in which the platinum(II) ion is 
coordinated to the N7 positions of the imidazole ring of two adjacent 
guanines (60-65% of all adducts), or to a lesser extent of one adenine 
and one guanine (20% of all adducts). Other less frequently produced 
same-strand adducts are the GpXpG 1, 3 intrastrand CL (where there is 
another intervening base in between the two platinated guanines; 2%) 
and monofunctional adducts on guanines (approximately 2%). In 
addition, around 2-6% of adducts involve guanines on opposite DNA 
strands, so-called interstrand CLs preferentially formed in the 5’-GC/5’-
GC sequences.49 Besides these DNA-platinum(II) adducts, ternary 
DNA-platinum-protein cross links can also be formed.49 The binding of 
cisplatin to DNA makes structural distortions of DNA to arrest the cell 
cycle at the S-phase, and causes unrepaired DNA damage to activate the 
apoptosis of cells.50 This mechanism of action is considered as the 
major contribution to the cisplatin cytotoxicity. However, the non-
selectivity of this mechanism affects both cancer and normal cells and is 
associated with toxic side effects such as vomiting, neuropathy, and 
myelosuppression. In particular, irreversible kidney damage is a major 
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concern which limits the dosage that can be used.25 Cisplatin resistance 
is another concern limiting its application. Initial cisplatin 
responsiveness is high but the majority of cancer patients will 
eventually relapse with cisplatin-resistant disease. Many mechanisms of 
cisplatin resistance have been proposed including changes in cellular 
uptake and efflux of the drug, increased detoxification of the drug, 
inhibition of apoptosis and increased DNA repair.51-53 In order to 
overcome the side effects and drug-resistance of cisplatin, cisplatin 
derivatives have been developed and have achieved success in clinical 
application with less side effects than cisplatin. The second-generation 
platinum(II) complexes carboplatin and oxaliplatin have been approved 
and third generation platinum complexes such as nedaplatin, lobaplatin, 
heptaplatin and dicyloplatin are still undergoing clinical trials.33,54 
 
Figure 1.8. Molecular structures of platinum(II) anticancer drugs that are approved 
or undergoing clinical trials. 
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1.2.3.2. Metallocenes 
Metallocenes are series of metal complexes with two π-bonded 
cyclopentadienyl ligands on a metal atom. Their symmetrical structures 
makes metallocenes resemble a “sandwich” thus such complexes are 
frequently referred as “sandwich complexes”.55 The first documented 
metallocene complex is ferrocene that was discovered in 1951.56,57   
Structurally, the metallocene complexes can be classified into two 
classes. One class is “classical metallocenes”, in which the metal bonds 
to parallel Cp rings such as ferrocene, ruthenocene and cobaltocenium. 
The other class is the “bent metallocenes” which have other ligands 
bonded to the metal in addition to the Cp rings including titanocene, 
zirconocene, vanadocene, niobocene and molybdocene.58,59  
 
Figure 1.9. Molecular structures of classical metallocenes (left) and bent 
metallocenes (right).58 
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From the 1970s, the anticancer activity of metallocenes has been 
studied, and titanocene dichloride entered into phase II clinical trials for 
the treatment of renal and breast cancers.60 Unfortunately, the clinical 
response to titanocene dichloride was not significantly sufficient to 
justify continuation of the trials. The two main problems encountered 
with titanocene dichloride are poor aqueous solubility and hydrolytic 
instability.61 In order to address these problems, structural optimization 
to titanocene dichloride has been developed including bridging of the 
Cp rings to prevent Ti-Cp bond cleavage,62 replacing the chloride 
ligands with a more suitable oxalate ligand63 and synthesizing ionic 
titanocene complexes.64 The mechanisms of these titanocenes in the 
killing of cancer cells are versatile and still under exploration. They 
have been shown to be related to inhibition of DNA replication and 
transcription, induction of metallothioneins and downregulation of H4 
histone genes.65,66  
The discovery of metallocene activity is marked as a milestone in the 
history of anticancer metallodrugs because they mark the time of first 
use of organometallic anticancer complexes. Following ferrocene and 
titanocene dichloride, many other organometallic anticancer complexes 
have been developed, e.g. ferrociphens67 and the organo-osmium 
complexes studied in this thesis (Section 1.3.3).68  
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1.2.3.3. Ruthenium Anticancer Complexes  
From the 1950s, the anticancer activity of ruthenium (Ru) complexes 
has been recognised43,69, and accelerating interest in the development of 
Ru-based anticancer drugs is reflected by the growth of related 
publications over the past 20 years.70 So far, three Ru-based anticancer 
complexes (NAMI-A, KP1019 and KP1339, Figure 1.10) have reached 
clinical trials, and more candidates are still under preclinical studies. 
These Ru complexes provide alternatives to platinum-based drugs for 
anticancer therapy, and more promisingly they exhibit novel 
mechanisms of action to overcome the drug-resistance, and side effects 
observed with platinum drugs. 
NAMI-A, KP1019 and KP1339 are Ru(III) complexes and such 
complexes can be readily reduced to their more active Ru(II) 
counterparts for target binding. This reduction generally occurs in the 
tumour microenvironment of low oxygen concentration, acidic pH and 
high levels of glutathione.71-73 NAMI-A has low potency of cytotoxicity 
to cancer cells in vitro, but shows outstanding inhibition of cancer 
metastasis in vivo.74-76  KP1019 and KP1339 are analogous complexes 
based on the same complex anion, differing only by the counterion 
(sodium instead of indazolium), in view of the higher solubility of the 
latter. Several studies concerning the impact of KP1019/KP1339 on 
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cancer cells indicate a combined antiproliferative and cell-death-
inducing activity77,78 contributed by multi-mechanisms, including the 
ruthenium complexes reacting with DNA, disturbing intracellular redox 
balance, and the targeting cellular stress and survival signaling 
pathways.79-81  
 
Figure 1.10. The molecular structures of NAMI-A, KP1019 and KP1339. 
 
 
Scheme 1.1. RAPTA complexes and their mode of pH-dependent DNA binding. 
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Moreover, many research groups have also paid attention to the 
development of Ru(II) complexes, especially Ru(II)-arene complexes. 
These organo-ruthenium(II) complexes exhibit promising behaviour for 
medical applications but currently are still at the preclinical 
development. 
Dyson et al have synthesized a series of Ru(II) ŋ6-arene complexes 
characterized by coordinated 1,3,5-triaza-7-phosphatricyclo-
[3.3.1.1]decane (PTA), and two liable chloride ligands, known as 
RAPTA complexes.82,83 These complexes inhibit cell growth effectively 
by triggering G2/M phase arrest and apoptosis in Ehrlich ascites 
carcinoma cells lines,84 but are free of toxicity to healthy cells, even 
with prolonged exposure at millimolar concentrations.83,85 In terms of 
molecular mechanism, RAPTAs undergo hydrolysis in which the liable 
halide ligands are substituted by H2O. The hydroxido complex can then 
bind to DNA pH-dependently, and hence cause DNA damage.83  
Meggers et al have developed Ru(II) complexes which mimic natural 
organic product staurosporine that is highly potent a ATP-competitive 
inhibitor for various kinases such as  GSK-3 (glycogen synthase kinase 
3) and Pim-1 (proto-oncogene serine/threonine-protein kinase).86 One 
leading complex of these organo-ruthenium mimics, DW1/2, shows 
potent activity in inhibiting kinases and high cytotoxicity to cancer 
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cells.87 The co-crystal structures of both the R and the S enantiomers of 
the ruthenium complex DW1/2 with the human protein kinase Pim-1 
clearly show that these ruthenium complexes bind to their target in a 
fashion typical of organic enzyme inhibitors.88 Such Ru(II) complexes 
inspire a new concept of designing metal complexes in which the metal 
center is not involved in any direct interactions with the active site but 




Figure 1.11. Structure (PDB Code: 2BZI) of Pim-1 with bound organo-ruthenium 
complex (S)-DW1/2 (yellow colour), mimicking template compound Staurosporine 
(grey colour). 
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Sadler et al has developed Ru(II) ŋ6-arene complexes as anticancer 
agents. Half-sandwich complexes [(ŋ6-arene)Ru(en)(Cl)]+ (en = 
ethylenediamine,  arene = biphenyl or p-cymene) were synthesized and 
reported to undergo a cisplatin-like mechanism of action in which a 
labile chloride ligand in the complex is substituted by H2O to produce a 
Ru(II) aqua complex which can then bind to DNA and induce 
cytotoxicity.90,91 The high concentration of chloride outside cells (~103 
mM) suppresses the hydrolysis of Ru-Cl and enables the prodrug to 
reach its target. However, the lower concentration of chloride in the cell 
(~23 mM for cytoplasm and ~4 mM for nucleus) renders such 
hydrolysis processes feasible.63 It is interesting to mention that the 
binding of these Ru(II) arene complex with guanine can be enhanced by 
glutathione (More details in Section 1.5.2).92 On the basis of these [(ŋ6-
arene)Ru(en)(Cl)]+ complexes, sulfonamido substitutes are introduced 
and Ru(II) sulfonamido ethyleneamine complexes have been developed. 
These Ru(II) sulfonamido ethyleneamine complexes display a 
completely different mechanism of action that use formate as the 
hydride source to catalyse NAD+ reduction to NADH, and perturbing 
the intracellular redox balance. The cytotoxicity of Ru(II) sulfonamido 
ethyleneamine complexes can be enhanced by up to 50× in presence of 
low non-toxic doses of formate.93 Besides, a series of Ru(II) arene 
complexes bearing azopridine ligands have also been developed, and 
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these Ru(II) arene azo complexes have also been found to catalyse the 
oxidation of glutathione by dioxygen, and display good activity to 
inhibit cancer cell growth (More details in Section 1.4.2).94  
Overall, the application of metallodrugs in anticancer chemotherapy has 
been greatly stimulated by the success of cisplatin. Apart from the 
typical examples described above, arsenic-based anticancer complexes 
have also been approved.95,96 Gold and gadolinium complexes targeting 
thioredoxin reductase97 have reached clinical trials. Currently more and 
more metal elements have been considered to be developed as 
anticancer metallodrugs, and involve various kinds of intracellular 
targets to enrich chemotherapy progress. 
 
 
Figure 1.12. The molecular structure of organo-ruthenium complexes developed by 
the Sadler group.92-94 
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Figure 1.13. The molecular structures of arsenic(III), gold(I) and gadolinium(III) 
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1.3. Osmium 
This projects in this thesis are largely concerned with FY26, an 
osmium-based anticancer complex. Hence, osmium chemistry 
background (Section 1.3.1), other osmium-based anticancer complexes 
(Section 1.3.2) and previous studies of FY26 and its derivatives 
(Section 1.3.3) will be described. 
 
1.3.1. Background of Osmium Chemistry 
Osmium is a hard, brittle, bluish-white transition metal, atomic number 
is 76. In the osmium atom, there are 76 electrons configured as 
1s22s22p63s23p63d104s24p64d105s25p64f145d66s2. Because of having 
similar physical and chemical properties and tending to occur together 
in the same mineral deposits, osmium, ruthenium, rhodium, palladium, 
osmium, iridium and platinum are classified as “platinum group” 
elements. Osmium is the densest naturally occurring element, slightly 
denser than iridium (22.562±0.009 g/cm3 for iridium versus 
22.587±0.009 g/cm3 for osmium).98 Osmium's abundance in the Earth's 
crust is among the rarest, with an incidence of around 1 g per 200 
tonnes.99  Osmium was discovered in 1803 by Smithson Tennant and 
William Hyde Wollaston in London, England100, and named after Greek 
osme meaning “smell” because of the strong odour of osmium tetroxide 
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which can be easily formed from the pure metal on exposure to air. 
There are seven naturally occurring isotopes of osmium (Table 1.1), of 
which 192Os is the most abundant (40.78%) and 186Os the most stable 
with a long half-life (2.0±1.1)×1015 years, approximately 140000 times 
the age of the universe. The nuclei spins of 187Os and 189Os are 1/2 and 
3/2, respectively. Osmium forms compounds with a variety of oxidation 
states ranging from -2 to +8 (Table 1.2). The volatility and extreme 
toxicity of osmium has limited its applications. Osmium alloys such as 
osmiridium are very hard and be used in the tips of fountain pens, 
instrument pivots, and electrical contacts, since they can resist wear 
from frequent operation. Osmium tetroxide has been used in fingerprint 
detection101 and staining fatty tissue for optical and electron microscopy. 
For medicinal application, osmium tetroxide has been used in the 
treatment of arthritic joints as a mimic of superoxide dismutase.102 
Table 1.1. Isotopes of osmium 
Isotopes Natural Abundance (%) Nuclear Spin 
184Os 0.02% 0 
186Os 1.59% 0 
187Os 1.96% 1/2 
188Os 13.24% 0 
189Os 16.15% 3/2 
190Os 26.26% 0 
192Os 40.78% 0 
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Table 1.2. Oxidation states of osmium and examples of compounds 
Oxidation State Example Oxidation State Example 
-2 Na2[Os(CO)4] +4 K2OsCl6 
-1 Na2[Os4(CO)13] +5 OsF5 
0 Os3(CO)12 +6 K2[OsO2(OH)4] 
+1 OsI +7 OsOF5 
+2 OsI2 +8 OsO4 
+3 OsCl3    
 
1.3.2. Osmium Anticancer Drug Applications 
As a third-row metal, osmium has long been considered substitution-
inert and few studies concerning the anticancer activity of osmium 
complexes had been reported before 2005.103-105 However, in recent 
years many osmium complexes with promising anticancer potency have 
been developed. With extensions from ruthenium, which is a lighter 
congener of osmium, structurally-similar osmium analogues have been 
prepared from Ru(III) drug candidates NAMI-A and KP1019 (Figure 
1.14). The Os(III) analogue of  NAMI-A Os-NA1 shows outstanding 
antiproliferative activity, while the Os(II) complexes Os-NA2 and Os-
NA3 with more than one DMSO (dimethyl sulfoxide) ligands are 
inactive.106  In physiological conditions, NAMI-A is quickly hydrolysed 
into different ruthenium species, and these contribute to the 
pharmacological effects of NAMI-A. However, the fact that the inert 
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osmium analogy has higher cytotoxicity suggests that hydrolysis is not 
an essential prerequisite for performance of this calss of complexes.107  
 
Figure 1.14. Molecular structures of osmium(III) anticancer complexes based on 
ruthenium complexes NAMI-A and KP1019. 
 
For KP1019 analogues, Os(III) and also Os(IV)-azole-chlorido 
complexes have been studied. Surprisingly, in KP1019, indazole is 
coordinated to Ru(III) only though the N2 nitrogen atom, whereas in 
Os(IV) complexes, indazole is bound either via N1 atom in complexes 
Os-KP1 and Os-KP2, or an N2 atom in the complex Os-KP3. These 
complexes are stable in aqueous solution and show KP1019 comparable 
cytotoxicity towards human cancer cells.108 In a Hep3B SCID mouse 
Chapter 1: Introduction 
33 
xenotransplantation model, these complexes do not display any 
symptoms of toxicity. Complex Os-KP3 was found to inhibit tumour 
growth and Os-KP2 was found to reduce tumour necrosis and increases 
the survival time.109  
High-valent Os(VI) complexes based on the OsVI≡N fragment have 
been evaluated in vitro and in vivo in cancer models.110-112 Notably, 
these complexes show lower IC50 values than cisplatin. Their 
cytotoxicity has a good correlation with their cellular accumulation. The 
induction of cell cycle arrest in S phase and premitotic G2 phase is 
considered to result from DNA damage or degradation.112  
 
Figure 1.15. Molecular structures of OsVI≡N complexes. 
 
Apart from targeting DNA, proteins can also represent the targets of 
osmium anticancer complexes. Coordination of biologically active 
molecules such as small molecule protein inhibitors to metal centres is 
an attractive approach to achieve synergistic effects of both components, 
and to endow multitargeting properties to the drug molecules. 
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Coordination of bioactive ligands, such as paullones or indolocarbazole 
derivatives, to the metal centres is also useful to modulate their physical 
and biological properties, such as solubility, bioavailability and 
biological activity. Based on this principle, several kinds of osmium 
complexes have been developed as inhibitors of GSK-3β (glycogen 
synthase 3)113 and CDKs (cyclin-dependent kinases),114 binding histone 
proteins,115 disrupting protein-protein interaction of HIF-1α (hypoxia 
inducible factor-1α) with p300116 and antagonizing STAT5B (signal 
transducer and activator of transcription 5B) dimerization.117                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
 
Figure 1.16. Molecular structures of osmium complexes inhibiting proteins activity, 
disrupting protein-protein interactions, or antagonizing protein dimerization. 
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The Sadler group is one of the first to turn attention to osmium 
anticancer therapy, especially half-sandwich “piano-stool” osmium(II) 
arene complexes with a typical structure [(ŋ6-arene)Os(X)(Y)(Z)]n+. 
From 2006, N,N-chelating ligands (such as ethylenediamine and 
bipyridine) have been introduced, but these N,N-chelator-containing 
organo-osmium complexes are often inactive to cancer cells in view of 
their inertness towards hydrolysis.118,119 For example, one of the leading 
complexes, [Os(ŋ6-biphenyl)(ethylenediamine)Cl]+ has a cytotoxicity of 
IC50 = 9 μM towards ovarian cancer cells, with a rate of hydrolysis 100× 
slower than its Ru(II) counterpart.119 In order to improve the aqueous 
reactivity, O,O-chelating ligands (e.g. acetylacetonate and maltolato) 
have been introduced to replace N,N-chelating ligands. However, these 
O,O-chelated organo-osmium complexes still lack a potent level of 
cytotoxicity against cancer cells because they are readily hydrolysed 
and form an un-reactive hydroxido-bridged dimer in aqueous 
solution.119,120 Finally, N, O-chelating ligands (e.g. picolinate and 
oxinate) provide a balanced compromise for ready hydrolysis 
overcoming both over-active and too-inert problems. For example 
[Os(ŋ6-biphenyl)(picolinate)Cl]+ has activity towards cancer cells 
comparable to cisplatin.121-124 In order to further improve the 
performance of these organo-osmium anticancer complexes, cell-
penetrating peptides (CPPs) have been used as drug delivery vectors, 
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and conjugated adducts of Arg8 with [Os(ŋ
6-biphenyl)(picolinate)Cl]+ 
exhibit 10× increase of Os cell uptake, and a 15× increase of Os binding 
to DNA.125 
 
Figure 1.17. Typical structures of osmium(II) half-sandwich complexes [(ŋ6-
arene)Os(X)(Y)(Z)]n+ and selected examples of chelated ligands. 
 
From 2010, Os(II) arene phenyliminopyridine (IMPY) complexes have 
been reported to exhibit potent cytotoxicity, especially the lead complex 
[Os(ŋ6-bip)(IMPY-NMe2)I]PF6, which has a IC50 value of 0.14 µM 
towards A2780 cancer cells. The mechanism of action of these osmium-
imino complexes involve the transfer of hydride from NADH to O2, and 
generation of NAD+ and H2O2 to perturb the intracellular redox balance, 
in which case an osmium hydride complex is observed as an 
intermediate.126,127  
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Scheme 1.2. A proposed mechanism for the oxidation of NADH to NAD+ catalysed 
by an Os(II) arene iminopyridine complex.126 
 
Considering the chirality of the osmium centre, enantiomers of these 
osmium imino complexes have been isolated and the mirror-image 
complexes show similar potent anticancer activity.128 However, high 
enantioselectivity is observed for chiral organo-osmium anticancer 
complexes [Os(arene)(TsDPEN)] (TsDPEN = N-(p-toluenesulfonyl)-
1,2-diphenyl ethylenediamine, arene = biphenyl, p-cymene or m-
terphenyl) in the reduction of pyruvate, a key intermediate in metabolic 
pathways, to lactate.129 Moreover, multi-nuclear osmium arene 
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anticancer complexes have also been developed. Dinuclear hydroxido-
bridged Os(II) arene complexes are biologically inactive but the 
tetranuclear Os(II) arene complexes formed from linking two inert 
dinuclear Os(II) arene units show high antiproliferative activity by 
inducing DNA knotting.130    
 
1.3.3. FY26 and Its Derivative Complexes 
Amongst all the osmium-based anticancer complexes, the series of 
organo-osmium complexes bearing phenylazopyridine (AZPY) ligands 
has attracted the most medicinal interest in view of its the potent 
activity, high selectivity, and novel mechanism of action. With a variety 
of different substituents on AZPY ligands, about 40 Os(II) arene AZPY 
complexes have been synthesised. In the primary cytotoxicity screening 
test, only three complexes are inactive to A2780 ovarian cancer cells 
and eight complexes have IC50 values in the nano-molar range.
131,132 
The lead complexes [Os (η6-p-cymene) (5-EtO-pyridylazo-4-phenyl)I] 
PF6 ([1-I] •PF6) and [Os (η
6-p-cymene) (4-(2-pyridylazo)-NMe2)I] PF6 
([2-I] •PF6, FY26) are reported as candidate drugs with IC50 values of 
0.92 and 0.18 μM, respectively.68,132,133  Especially, FY26 is active in 
human A2780, A549 lung, HCT-116 colon, MCF-7 breast, PC-3 
prostate, RT-112 bladder and cisplatin-resistant A2780 ovarian cancer 
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cell lines at sub-micromolar concentrations.134 These osmium 
complexes are inert toward hydrolysis and their cytotoxicity is inhibited 
by pre-treatment with N-acetyl-cysteine (NAC) in cells.68 Combination 
with redox modulators L-buthionine sulfoximine (L-BSO), which can 
deplete GSH levels by inhibiting the enzyme γ-glutamylcysteine 
synthetase, can potentiate the anticancer activity and maximize the 
selectivity to normal cell of FY26. With L-BSO, the IC50 of FY26 
decreased from 160 nM to 69 nM and its selectivity factor was 
increased from 28.4× to 63.5×.135 The impact of NAC and GSH on the 
cytotoxic activity of FY26 implies that a redox mechanism is involved. 
In mice, FY26 can delay the growth of HCT116 human colon cancer 
xenografts.136  
 
Figure 1.18. Molecular structures of FY26 and its derivative complexes 
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FY26-exposed A2780 epithelial ovarian cancer cells undergo a 
metabolic shunt from glycolysis to oxidative phosphorylation.134 
Downstream events, measured by time-series reverse-phase protein 
microarrays, high-content imaging, and flow cytometry, show a 
dramatic increase in mitochondrially produced ROS (reactive oxygen 
species) and subsequent DNA damage with up-regulation of ATM 
(Ataxia Telangiectasia Mutated), p53, and p21 proteins. In contrast to 
platinum drugs, exposure to this organo-osmium compound does not 
cause significant apoptosis within a 72-h period, but superoxide 
production in cancer cells exposed to three other structurally related 
Os(II) compounds was found to be correlated with their antiproliferative 
activity. Experiments of FY26 labelled with the radionuclide 131I show 
that once being taken up by MCF-7 cancer cells, the iodide is pumped 
out very rapidly, which indicates a mechanism in which FY26 is 
activated in cancer cells involving I- release. GSH was found to 
promote the hydrolysis of FY26, and is also involved in FY26 
activation.132 But the mechanism by which GSH promotes the 
hydrolysis of FY26 and the pathways of the reactions between osmium 
complexes with GSH remain unknown.  
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1.4. Azo Group 
The work in this thesis is mainly focused on explorations of the 
mechanism of action of organo-osmium complexes bearing azo ligands, 
and involvement of the azo bond. First azo compounds (Section 1.4.1), 
and reduction of the azo bond (Section 1.4.2) will be briefly introduced.  
1.4.1. Azo Compounds 
Azo compounds are defined as: “derivatives of diazene (diimide), 
HN=NH, wherein both hydrogens are substituted by hydrocarbyl 
groups, e.g. PhN=NPh azobenzene or diphenyldiazene” by the 
International Union of Pure and Applied Chemistry (IUPAC). From 
September 2003, consumer goods which contain listed aromatic amines 
originating from azo dyes have been prohibited from manufacture and 
sale in European Union countries since azo dyes derived from benzidine 
are carcinogens. Exposure to them has classically been associated with 
bladder cancer.137 In addition to food, azo compounds have been widely 
used in many fields. One characteristic of azo compounds, especially 
aryl azo compounds, is π-delocalization of electrons which makes the 
aryl azo compounds have vivid colours, especially reds, oranges, and 
yellows. Azo compounds are most widely used as dyes and azo dyes are 
employed to treat textiles, leather articles, and some foods. In chemistry, 
related azo compounds are used as azo pigments which are structurally 
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similar to azo dyes but lack solubilizing groups. The azo group is 
sensitive to light and azobenzene compounds are characterized by 
photoactivated trans-cis isomerism.138-140 Upon irradiation with UV or 
visible light, the generally more stable trans-azobenzene complexes 
convert to less stable cis form. This tranformation can be reversed by 
thermal isomerism. With such properties, photo-sensitive azo polymer 
and azo-containing protein inhibitors have been developed.141-143  
Azo compounds have wide medicinal applications. For example, 
phenazopyridine is used in conjunction with an antibiotic or other anti-
infective medication at the beginning of treatment to help provide 
immediate symptomatic relief.144 The nitrogen atoms in the azo bond 
can also provide electrons and space to coordinate with metals. Many 
metal complexes containing azo ligands have been reported to have 
many types of biological activity.145-147 The Sadler group has used azo 
compounds to chelate ruthenium(II) and osmium(II) ions and hence 
develop potent anticancer complexes (e.g. FY26 in Section 
1.3.3).68,94,131 These metal azo complexes are found to modify the redox 
level and kill cancer cells, which indicates a novel mechanism of action 
compared to platinum drugs, providing a promising approach to 
overcome platinum-resistance in chemotherapy. 
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Figure 1.19. Molecular structures of anticancer metal complexes with azo ligands.   
 
1.4.2. Reduction of Azo Bonds 
The reduction of azo bonds plays important roles in many biological 
processes such as drug metabolism.148,149 Azoreductases are enzymes 
which reduce azo bonds and have been characterized in a range of 
prokaryotes and eukaryotes. Using NAD(P)H as hydride sources, 
azoreductases can catalytically reduce azo groups to hydrazo and amine 
functions at different stages.149,150 With more and more crystal 
structures of azoreductases being solved,151-154 the mechanism by which 
this kind of enzyme reduces azo bonds has become clear. Indeed, the 
activity of azoreductase is dependent on the concentration of FMN 
(flavin mononucleotide), of which N5 accepts a hydride from NAD(P)H 
and donates it upon reduction of the substrate. However, azo 
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compounds cannot be a substrate for reduction directly. This reduction 
requires tautomerisation of the azo compound to a quinoneimine and 
then provides a unifying mechanism with the reduction of quinone 
substrates by azoreductases.149,155 In addition azoreductases, cytochrome 
P450 and NADPH-cytochrome P450 reductase can mediate the 
reduction of azo groups too. But in this reaction, the initial reduction 
appears to proceed via the azo anion radical and oxygen apparently 
reverses this process with concomitant conversion of oxygen to the 
superoxide anion radical.156-158 With this behaviour, azo containing 
hypoxia-sensitive fluorescent probes have been designed and 
reported.159 
Many chemicals have also been reported to reduce azo bonds in the 
absence of enzymes. In organic synthesis, reductants such as hydrazine 
hydrate, zinc/ammonium salts and dihydrated nickel(II) chloride/ 
lithium/4,4’-di-tert-butylbiphenyl have been used to reduce azo 
compounds to obtain new hydrazo or amine compounds.160-162 Thiols, 
bisulfite and sulfite are found to reduce azo bonds in metal complexes, 
and during this process the fluorescence would be switched on/off. With 
such a mechanism, azo group linked dinuclear Ir(III) and Ru(II) 
complexes have been developed as intracellular thiol and sulphite 
probes.163-165 These probes have been evaluated in vitro and in vivo and 
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show high sensitivity and selectivity towards their target substrates. In 
cancer therapy, reduction of azo bonds by GSH is found to activate the 
covalent binding between DNA and Ru(II)-based photoactivated 
chemotherapy (PACT) agents.166 Azo ligands bearing half-sandwich 
ruthenium arene complexes catalyse the oxidation of GSH, which 
increases the intracellular ROS level, and exhibits highly cytotoxic 
actions towards to cancer cells. In the mechanism of action, GSH 
reduces the azo bond in the ruthenium complexes and is a key step for 
the catalysis process.94 
 
Scheme 1.3. Reduction of azo bonds by azoreductase, hydrazine hydrate, bisulfite 
and thiols. 
Chapter 1: Introduction 
46 
1.5. Glutathione 
The project in this thesis involves exploring the mechanism of action of 
organo-osmium anticancer complexes, especially studying the reaction 
between osmium complexes and glutathione. Fellowing the introduction 
of osmium complexes in Section 1.4, glutathione (Section 1.5.1), and 
reactions between glutathione and metal complexes (Section 1.5.2) will 
be introduced.    
 
1.5.1. Introduction to Glutathione 
Glutathione (GSH) is a tripeptide with a gamma peptide linkage 
between the carboxyl group of the glutamate side chain and the amine 
group of cysteine, with the carboxyl group of cysteine attached by a 
normal peptide linkage to a glycine. The pKa values of glycine carboxyl 
group, cysteine thiol group, glutamate carboxyl and amine group in 
GSH are pKa1=3.59, pKa2=9.65, pKa3=2.12 and pKa4=8.75, 
respectively.167 Glutathione is usually synthesized in two adenosine 
triphosphate-dependent steps.168 Firstly, gamma-glutamylcysteine is 
synthesized from L-glutamate and cysteine via the enzyme gamma-
glutamylcysteine synthetase (glutamate cysteine ligase, GCL). This 
reaction is the rate-limiting step in glutathione synthesis. Secondly, 
glycine is added to the C-terminal of gamma-glutamylcysteine via the 
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enzyme glutathione synthetase. GSH is the most abundant low 
molecular weight thiol in all mitochondria-bearing eukaryotes, existing 
at a concentration of ca. 5 mM in animal cells.169 It has been detected 
virtually in all cellular compartments such as cytosol, chloroplast, 
endoplasmic reticulum, vacuole, and mitochondria. There are reduced 
(GSH) and oxidized (GSSG) forms of glutathione. In the reduced form, 
the thiol group of cysteine is able to donate a reducing equivalent (H+ + 
e−) to other molecules, such as reactive oxygen species to neutralize 
them, or protein cysteines to maintain their reduced forms. After 
donating electrons, two GSH molecules are oxidized to form 
glutathione disulfide (GSSG) which can be reduced back to GSH by 
glutathione reductase, using NAD(P)H as an electron donor.170 The 
ratio of GSH versus GSSG in the cell is used to measure of intracellular 
oxidative stress.171 In healthy cells and tissue, more than 90% of the 
total glutathione pool is in the reduced form (GSH) and less than 10% 
exists in the disulfide form (GSSG).172  
 
Figure 1.20. Structure of GSH and the pKa values for each group in the 
molecule.167 
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GSH/GSSG is the key part of cellular redox systems and plays critical 
roles in cell signalling, metabolism, defence and survival. In cells, 
glutathione has following functions173:  
 Glutathione maintains levels of reduced free thiols in proteins like 
glutaredoxin and glutathione peroxidase. 
 Glutathione modulates heavy metal ion metabolism and detoxifies 
heavy metals in cells.      
 Glutathione is one of the major endogenous antioxidants produced 
by the cells to neutralize reactive oxygen species (ROS) and 
reactive nitrogen species (RNS). 
 Glutathione enhances the function of citrulline as part of the nitric 
oxide cycle. 
 Glutathione is used in metabolic and biochemical reactions such as 
DNA synthesis and repair, protein synthesis, prostaglandin synthesis, 
amino acid transport, and enzyme activation. 
 
1.5.2. Reactions of Glutathione with Metal Ion Complexes 
The sulphur, nitrogen and oxygen atoms in the GSH molecule provide 
coordination sites and make it be a suitable agent to bind various kinds 
of metals,174-176  Thus GSH has been widely described as a “heavy metal 
killer” in environmental pollution abatement and human health 
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protection.177-181 But when anticancer metallodrugs enter into cancer 
cells. GSH also binds these to form metal-SG adducts.182-184 These 
metal-SG adducts are usually too stable to have any biological activity 
and are quickly transported out of cells through the glutathione S-
conjugate export pump (GS-X pump).185 This GSH can be considered 
as the prime initiator of metallodrug degradation and drug-resistance.   
However, the potency of darinaparsin (an As-SG adduct) which has 
entered into clinical phase II trials still reminds us that not all metal-SG 
adducts are inactive.186  With more studies being carried out, the other 
aspect of GSH that benefits anticancer chemotherapy has been 
uncovered. GSH is the key molecule in cell redox system and likely to 
be used as a target for anticancer agents.187 Sometimes GSH plays roles 
as a “protector” or “activator” of metallodrugs for killing cancer cells. 
Some platinum(II) anticancer complexes such as oxaliplatin and 
Pt(ethylenediamine)Cl2 react with GSH as well as GSSG to form an 
glutathione-bridged diplatinum(II) macrochelate.188,189 This unusual 
Pt(II)-SG adduct, contrasting with the product formed from the reaction 
of cisplatin with GSH,184 is potentially reactive towards DNA bases. For 
oxaliplatin and Pt(ethylenediamine)Cl2, GSH protects more active 
species from reaching the DNA targeting sites. Furthermore, GSH is 
Chapter 1: Introduction 
50 
also reported to activate Pt(IV) complexes through reducing Pt(IV) 
prodrugs to active Pt(II) species.190    
Ruthenium(III) complexes KP1019 and KP1339 are amongst the first 
ruthenium-based anticancer drugs to be clinically developed. During the 
cytotoxicity of these complexes, the reduction of Ru(III) to more active 
Ru(II) is key step in which GSH plays an important role.191 Organo-
ruthenium(II) complexes [(ŋ6-arene)Ru(ethylenediamine)(Cl)]+ (arene = 
biphenyl or p-cymene) have potency comparable to carboplatin through 
binding to guanine bases in DNA.91,192 In the in vitro studies, the 
competition of GSH and guanine does not inhibit but enhances the 
binding of guanine to Ru(II) species. The mechanism of this interesting 
phenomenon is that GSH can firstly bind with Ru(II) complexes to form 
ruthenium thiolate (Ru-SG) adducts, and then this ruthenium thiolate 
adduct is subsequently oxidized to ruthenium sulfenate complex (Ru-
SOG) which provides a facile route for displacement of S-bound 
glutathione by guanine.92 More interestingly, GSH also appears to 
induce the oxidation process from Ru-SG to Ru-SOG by oxygen.193 The 
structural basis of the reactivity of ruthenium sulfenate complexes has 
been explored, and assigned to the differences of Ru-S bond length, 
charge donation and energies of the empty valence orbitals between 
thiolate, sulfenate and sulfonate complexes.194,195 In Section 1.4.2, GSH 
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activation of azo-containing ruthenium complexes through reducing the 
-N=N- azo bond has been introduced and this mechanism is also a good 
example of the importance of GSH to the anticancer potency of 
metallodrugs (Scheme. 1.4).    
Besides platinum and ruthenium, GSH-induced activation of other 
metal anticancer complexes has been observed,  For example, GSH is 
involved int the cell uptake of bismuth anticancer complexes196 and 
GSH greatly enhances the zinc(II) phthalocyanine photodynamic 
therapy  complexes which generate reactive oxygen species.197  
The reactions between GSH and organo-osmium azo complexes [Os 
(η6-arene) (phenylazopyridine) halide]n+ (arene = biphenyl or p-cymene, 
halide = Cl or I) studied in this thesis are also potentially very important. 
L-Buthionine-sulfoximine (L-BSO) is an inhibitor of key enzyme of 
GSH synthesis in the cell and normally used to decrease the 
intracellular concentration of GSH.198 For many metallodrugs, co-
incubation with L-BSO will increase their cytotoxicity, which is so 
called “L-BSO Potentiation”. Surprisingly, the “L-BSO Potentiation” 
for organo-osmium azo complexes is much lower than other metal 
complexes, and the cytotoxicity of some organo-osmium complexes is 
even decreased by co-incubation of cells with L-BSO.199 Such results 
indicate that GSH plays crucial roles in the mechanism of action of 
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organo-osmium azo complexes. Radionuclide 131I labelling experiments 
show that once taken up by cells, the iodide in organo-osmium azo 
complexes is released and pumped out very rapidly. In this process, 
GSH has been shown to promote hydrolysis of organo-osmium azo 
complexes.132 As a continuation of these studies, the work in this thesis 
is mainly to explore the mechanism of GSH activation of organo-
osmium azo complexes.  
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1.6. Project Aims 
A series of half-sandwich osmium complexes, of which the lead 
complex is [Os(η6-p-cymene)(4-(2-pyridylazo)-NMe2)I] PF6 ([2-I]•PF6, 
FY26), have been reported to have a high potential to represent an 
alternative choice to platinum drugs. The aim of the project in this 
thesis is to explore the mechanism of action of these “half-sandwich” 
osmium complexes, especially their reactions with an intracellular 
tripeptide GSH. Specific aims for each chapter are outlined below. 
In Chapter 3, complexes related to FY26, such as the aqua and thiolato 
adducts, are synthesised and characterized.  
In Chapter 4, the mechanism of action for the hydrolysis of osmium 
complexes in presence of GSH were explored via a combination of 
theoretical experimental approaches.  
In Chapter 5, the possibility of trapping free radicals from reactions of 
osmium complexes with GSH is explored under various conditions. 
In Chapter 6, the reactions of FY26 with GSH are studied using X-ray 
absorption spectroscopy and key intermediates for the reactions are 
probed. 
In Chapter 7, the finalised conclusions and future work proposed are 
summarized. 
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In this Chapter, the materials (Section 2.1), instrumentation (Section 2.2) 
and methods (Section 2.3) used in all experiments performed will be 
described. More details about individual experiments are available in 
each appropriate chapter. 
 
2.1. Materials 
2.1.1. Chemical Reagents 
OsCl3·3H2O was purchased from Alfa Aesar. Reduced glutathione 
(GSH), N-acetyl-L-cysteine (NAC), silver nitrate, 1,4-dithiothreitol 
(DTT), horse heart cytochrome c and bovine superoxide dismutase (SOD) 
were purchased from Sigma-Aldrich (Gillingham, UK). Pyridine-2-azo-
p-dimethylaniline was purchased from Alfa Aesar. Ammonium 
hexafluorophosphate, sodium methoxide and potassium iodate were also 
purchased from Sigma-Aldrich. Sodium hydroxide, sodium chloride, 
sodium phosphate dibasic, sodium phosphate monobasic, trifluoroacetic 
acid were purchased from Fisher Scientific Ltd. (Loughborough, UK). 
NMR tubes and deuterated solvents were purchased from Sigma Aldrich. 
The free radical trapping agent 5-(diethoxyphosphoryl)-5-methyl-1-
pyrroline-N-oxide (DEPMPO) was purchased from Enzo Life Sciences. 
The osmium ICP standard solution 1000±10 μg/mL in 15% HCl (v/v) 
was purchased from Inorganic Ventures. Solvents used for high 
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performance liquid chromatography (HPLC) and liquid chromatography-
mass spectrometry (LC-MS) were purchased from Fisher Scientific Ltd. 
Analysis grade doubly deionised water (18 M Ω cm-1) was obtained from 
either a Millipore Simplicity UV, or an USF Elga UHQ PS purification 
system. All other solvents and reagents for synthesis and analysis were 
purchased from commercial suppliers and used as received. 
 
2.1.2. Buffer Solutions 
Phosphate Buffer. Na2HPO4 (3.44 g, 24.3 mmol) and H2NaPO4·2H2O 
(0.89 g, 5.7 mmol) were dissolved into 100 mL doubly deionized water 
to get 300 mM phosphate buffer solution. NaCl (0.58 g, 10 mmol) was 
added if it was necessary to prepare physiologically relevant buffer 
solution. Diluted sodium hydroxide (NaOH) or nitric acid (HNO3) 
solutions were used to modify the pH value of buffer solutions. In NMR 
experiments, the deuterated phosphate buffer solution was prepared by 
dissolving phosphate salts in D2O firstly, then using freeze-drying to 
remove all solvent and finally adding D2O again to obtain the completely 
deuterated solution. The pH values of solutions were measured with pH 
meters (Section 2.2). Considering the effect of deuterium on the glass 
electrode, the pH* value (meter reading) measured in D2O solution was 
corrected to pH using the equation: pH = 0.929pH* + 0.4.1 
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Ammonium Acetate Buffer. CH3COONH4 (1.54 g, 20 mmol) was 
dissolved in 100 mL doubly deionized water to give a 200 mM 
ammonium acetate buffer solution, pH = 7.02. 
 
Citrate-Phosphate Buffer. Na2HPO4 (28.2 g, 200 mmol), citric acid 
(76.8 g, 400 mmol) were dissolved into 1 L doubly deionized water to 
give citrate (400 mM)-phosphate (200 mM) buffer solutions, pH = 2.95. 
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2.1.3 Osmium Dimer Complexes 
All the organo-osmium complexes studied in this thesis were synthesized 
from the precursor osmium dimer complexes prepared following 
reported literature methods.3-5 
[Os(η6-p-cym)Cl2]2. OsCl3.3H2O (500 mg, 1.43 mmol) and α-terpinene 
(1.6 mL, 1.43 mmol) were dissolved in methanol (6 mL). The solution 
was transferred into a microwave reaction vessel and then irradiated with 
microwave radiation for 5 min at 423 K. After reaction, the mixture was 
placed in a freezer (268 K) overnight, and an orange precipitate was 
observed. The precipitate was collected via vacuum filtration, then 
washed with ice-cold ethanol (2 × 5 mL) and diethyl ether (2 × 5 mL). 
Finally, the product was dried overnight in a vacuum desiccator. Yield: 
0.56 mg (98%). 1H NMR (DMSO-d6): δ = 6.07 (d, 4H, J = 6.0 Hz), 5.99 
(d, 4H, J = 5.9 Hz), 2.74 (m, 2H), 2.14 (s, 6H), 1.19 (d, 12H, J = 7.0 Hz). 
[Os(η6-p-cym)I2]2. The dimer [Os(η6-p-cym)Cl2]2 (103.8 mg, 0.135 
mmol) was dissolved into methanol (3 mL) which had been bubbled with 
N2 for 30 min, and then a solution of KI (2.68 g, 16.18 mmol) in deionised 
water (10 mL) was added. The mixture was transferred to a microwave 
reaction vessel and irradiated with microwave radiation for 5 min at 423 
K. The mixture was then placed in a fridge (273 K) overnight, and 
following this a red precipitate was observed. The precipitate was 
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collected via vacuum filtration and washed with H2O (2 × 5 mL), ice-
cold ethanol (2 × 5 mL) and diethyl ether (2 × 5 mL). Finally, the product 
was dried overnight in a vacuum desiccator. Yield: 129.8 mg (78%). 1H 
NMR (DMSO-d6): δ = 6.07 (d, 4H, J = 6.0 Hz), 6.04 (d, 4H, J = 6.0 Hz), 
2.77 (m, 2H), 2.29 (s, 6H), 1.22 (d, 12H, J = 6.9 Hz). 
 
2.1.4. Cell culture 
All the cell work conducted in this thesis was carried out by Dr. Isolda 
Romero-Canelón (The University of Warwick) and related materials 
were purchased by her. DMEM and RPMI-1640 cell culture media, L-
glutamine, foetal bovine serum, phosphate buffered saline solution (PBS), 
AccuMax cell dissociation solution, penicillin/streptomycin mixture, 
trypsin and trypsin/EDTA were all purchased from PAA Laboratories 
GmbH. Cell culture media were prepared with foetal bovine serum (50 
mL), penicillin/streptomycin mixture (5 mL) and L-glutamine (5 mL). 
All cancer cell lines were purchased from the European Collection of Cell 
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2.2. Instrumentation 
2.2.1. UV-visible Spectroscopy6   
A Cary 300 UV-Vis recording spectrophotometer was used with 1 cm 
path-length quartz cuvettes (0.5 mL) and a PTP1 Peltier temperature 
controller. Experiments were carried out at 288 K between 200-800 nm 
at a scan rate of 600 nm/min with 1 nm intervals unless otherwise stated. 
Spectra were recorded using UVWinlab software and processed using 
Origin 9.0. 
2.2.2. Inductively Coupled Plasma Optical Emission Spectroscopy 
(ICP-OES)7,8    
A Perkin Elmer (Optical Emission Spectrometer) Optima 5300 DV 
instrument was used to analyse osmium solutions in this thesis. All 
testing and standard samples were freshly prepared on the day in doubly 
deionised water with distilled HNO3 (3.2%), 5 mM thiourea and 0.28 mM 
ascorbic acid were used for osmium stabilization.9,10 The osmium 
standard (1000±10 μg/mL in 15% HCl (v/v) was purchased from 
Inorganic Ventures) and was diluted to the following concentrations for 
the calibration curve: 0, 25, 50, 100, 200, 400, 600, 800 and 1000 ppb. 
The samples were diluted by serial dilutions of typically 1 in 10 until their 
concentrations fitted within the calibration range and the % total 
dissolved solids were below 0.2%. Samples were made in triplicate and 
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the optical emission at 228.226 and 225.585 nm were detected and 
integrated. 
2.2.3. Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)7,11  
An Agilent Technologies 7500 series ICP-MS instrument was used to 
carry out the ICP-MS analysis of osmium in these investigations. All 
testing and standard samples were freshly prepared on the day in doubly 
deionised water with distilled HNO3 (3.2%), 5 mM thiourea and 0.28 mM 
ascorbic acid solutions were used for osmium stabilization. It helps 
prevent the formation of volatile osmium tetroxide through thiourea 
binding with osmium and ascorbic acid reducing OsIII to OsII. 9,10 The 
osmium standard (1000±10 μg/mL in 15% HCl (v/v) and purchased from 
Inorganic Ventures) was diluted to the following concentrations for the 
calibration curve: 1000, 800, 400, 200, 100, 50, 10, 1, and 0.1 ppb. The 
samples were diluted by serial dilutions of typically 1 in 10 until their 
concentrations fitted within the calibration range and the % total 
dissolved solids were below 0.2%. The ICP-MS instrument was set to 
detect 189Os with typical detection limits of ca. 8 ppt using no-gas mode. 
2.2.4. High Performance Liquid Chromatography (HPLC)12   
An Agilent Technologies 1200 series HPLC instrument with a VWD and 
100 µL loop, plus Agilent ZORBAX Eclipse Plus C18 250×4.6 mm 
column with a pore size of 5 µm was used to test the purity, monitor their 
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reactions. Mobile phases consisted of: (A) H2O with 0.1 % TFA, and (B) 
MeCN with 0.1 % TFA (HPLC grade materials were used) at a 1 mL/min 
flow rate. For product purification,1 mL loop and semi-preparative 
ZORBAX Eclipse XDB-C18 250 × 9.4 mm column were used on HPLC 
instrument with same mobile phases but at 2 mL/min flow rate. The 
methods for mobile phase’s gradient can be found Section 2.3.   
2.2.5. Liquid Chromatography-Mass Spectrometry (LC-MS)13  
Combined LC-MS analysis of the samples in this reactions was carried 
out on a Bruker Amazon X+ instrument coupled with an Agilent 
Technologies 1200 series HPLC instrument. The methods and conditions 
were consistent with the corresponding analysis on HPLC. Sample 
injections were 20 µL and the mass spectrometer was operated in 
electrospray positive mode with a scan range of 50-2000 m/z. 
2.2.6. Nuclear Magnetic Resonance (NMR) Analysis14   
1H NMR spectra were acquired at 400 MHz in 5 mm NMR tubes at 298 
K on a Bruker AV-400 spectrometer. Data processing was carried out 
using TOPSPIN version 2.1 (Bruker U.K. Ltd). 1H NMR chemical shifts 
were internally referenced to TMS via their residual solvent peaks: 
methanol (δ = 3.31 ppm), water (δ = 4.79 ppm), DMSO (δ = 2.50 ppm) 
and1,4-dioxane (3.71 ppm in H2O).
15 Likewise, for 13 C NMR chemical 
shifts: acetonitrile (δ = 118.26 ppm), acetone (δ = 206.26 ppm) and 
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methanol (δ = 49.00 ppm).151D 1H NMR spectra were recorded using 
standard pulse sequences and acquired with 16 transients into 32 k data 
points over a spectral width of 14 ppm. 1D 13 C NMR spectra were 
recorded using a JMOD pulse sequence and acquired with 256 transients 
into 64 k data points over a spectral width of 260 ppm. 
For 2D-NMR 1H-1H COSY spectra, a second frequency dimension is 
introduced and magnetic interactions between nuclei through structural 
connectivity are further considered. The peaks that are mutually spin-spin 
coupled are shown by cross-peaks which are symmetrically placed about 
the spectral diagonal. The cross-peaks usually include geminally (two-
bond) or vicinally (three-bond) coupled protons, but longer range 
couplings are not usually observed. 
2.2.7. Elemental Analysis16  
All samples analysed by elemental analysis were performed by Warwick 
Analytical Service using an Exeter Analytical elemental analyser 
(CE440). 
2.2.8. Electrospray ionization-Mass Spectrometry (ESI-MS)17   
Agilent 6130B single Quad (ESI) mass spectrometer was used to 
generally record the positive and negative ion electrospray mass spectra 
with a positive ion range of 500-1000 m/z and a negative ion range of 50-
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500 m/z. The samples were typically dissolved into methanol, deionised 
water or acetonitrile prior to analysis.     
2.2.9. High resolution Mass Spectrometry (HRMS)18   
HR-MS analysis was carried with Bruker MaXis plus Q-TOF mass 
spectrometer equipped with electrospray ionisation source. The mass 
spectrometer facility was operated in electrospray positive ion mode with 
a scan range 50-2,400 m/z. Source conditions were: end plate offset at -
500 V; capillary at -4000 V; nebulizer gas (N2) at 0.5 bar; dry gas (N2) at 
4 L/min; dry Temperature at 453 K. Ion tranfer conditions were: ion 
funnel RF at 200 Vpp; multiple RF at 200 Vpp; quadruple low mass set 
at 50 m/z; collision energy at 5.0 ev for MS and 10-20 ev for MS/MS, 
MS/MS isolation window 10; collision RF at 500-2000 Vpp; transfer 
time set at 50-150 µs; pre-pulse storage time set at 5 µs. Calibration was 
performed with sodium formate (10 mM) prior to analysis. 
2.2.10. Electron Paramagnetic Resonance (EPR) Spectroscopy8  
EPR spectra were recorded at room temperature on a Bruker EMX (X-
band) spectrometer fitted with a cylindrical Tm110 mode cavity (Bruker 
4103TM). Samples were contained in quartz capillary (I.D. 1.0 mm; O.D. 
1.2 mm; Wilmad Labglass) sealed with T-BluTac®, Typically, the EPR 
spectrometer was set as: modulation amplitude 2.0 G, microwave power 
0.63 mW, 1.0 × 105 receiver gain, conversion time 81.92 ms, time 
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constant 81.92 ms, sweep width 200 G, and a repeated number of 10 X-
scans with a resolution in Y of 5. EPR spectra were analysed and 
simulated using EASYSPIN software.19 
2.2.11. Microwave Reactor20  
A CEM Discover-SP microwave reactor was used to assist the synthesis 
of osmium dimer complexes with the following settings: maximum 
power = 150 W, maximum pressure = 250 PSI. Microwave radiation of 
5 mins at 150 °C was used in the osmium dimer synthesis reactions.  
2.2.12. pH Meters 
The pH value was generally measured using Martini instruments Mi 150 
pH/Temperature bench meter with a Mettler-Toledo U402-M3-S7/200 
chloride pH probe. In the pKa measurements by NMR, the pH values of 
samples were specifically measured by a portable HACH H138 minilab 
instrument. The pH meters were calibrated using 3 buffer solutions: pH 
4.01±0.02, 7.00±0.02, and 10.01±0.02. The probe was washed between 
measuring samples with methanol and deionised water, and stored in 1 
M KCl when not in use. All pH meter readings were recorded at room 
temperature (ca. 298 K). The electrode in the pH meters is glass electrode.   
The pH meter readings for D2O solutions were recorded without the 
correction for the effect of deuterium on the glass electrode, and are 
termed pH*. 
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2.3. Methods 
2.3.1. Products Purified by Flash Chromatography 
Complexes were purified using a Biotage Isolera instrument using 
BiotageⓇ KP-Sil 10g SNAP cartridges. The mobile phase consisted of: 
(A) dichloromethane and (B) methanol. The crude products mixing with 
ISOLUTE HM-N granules were introduced onto the top of the column. 
The solvent gradient in Table 2.1 was used with a 12 mL/min flow rate. 
The collected fractions were analysed by ESI-MS and the chosen 
fractions were then combined. The solvent was removed under reduced 
pressure. 








0 0 10 
0 10 20 
10 50 20-50 
50 50 20 
50 0 10 
 
2.3.2. Products Purified by HPLC  
The HPLC instrument equipped with semi-preparative ZORBAX Eclipse 
XDB-C18 250 × 9.4 mm column was used to purify products. Mobile 
Chapter 2: Experimental Section 
86 
phases consisted of: (A) H2O with 0.1 % TFA, and (B) MeCN with 0.1 % 
TFA at 2 mL/min. The solvent gradient in Table 2.2 was applied as the 
purification method. The samples were analysed at a detection 
wavelength of 254 nm with reference wavelengths set to 360 nm and 510 
nm. 
Table 2.2. The solvent B (acetonitrile) gradient for products purified by HPLC. 









2.3.3. Samples Analysed by HPLC  
HPLC instrument with Agilent ZORBAX Eclipse Plus C18 250×4.6 mm 
column was used to analyse the samples and reactions in this thesis. 
Mobile phases consisted of: (A) H2O with 0.1 % TFA, and (B) MeCN 
with 0.1 % TFA at 2 mL/min. Due to the different polarity of organo-
osmium bearing azo ligands and imino ligands, the solvent gradient 
methods are different for these two kinds of complexes. Osmium imino 
complexes were analysed at a detection wavelength of 254 nm with 
Chapter 2: Experimental Section 
87 
reference wavelengths set to 360 nm and 510 nm while osmium azo 
complexes were analysed at 610 nm with a reference wavelength set to 
360 nm. 
Table 2.3. The solvent B (acetonitrile) gradient used in HPLC for analysing 
osmium azo and imino complexes. 
Time (min) 
% (B) for 
azo complexes 
% (B) for 
imino complexes 
0 10 20 
30 80 60 
40 80 60 
41 10 20 
55 10 20 
 
 
Figure 2.2. The molecular structure of osmium imino and azo complexes analysed 
by HPLC in this thesis. 
 
2.3.4. N2 Protection Reactions 
 There were some studies of synthesis and analysis in this thesis needed 
to be protected from air by N2. A two-neck flask used for the reactions 
was dried, vacuumed and refilled with N2. A balloon filled with N2 was 
connected to the reaction atmosphere through a syringe needle and 
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protected the reaction. The solvents for the reactions were generally 
prepared by bubbling with N2 for a period of 30 min.  
The N2-protected NMR experiments were carried out using a specific 
NMR tube with a screw cap. The solids for experiments were transferred 
into this NMR tube first and then the tube was put into a long two-neck 
glass flask. A vacuum pump was used to remove the air from both the 
NMR tube and long glass flask, then N2 was refilled back to the system. 
After repeating three times, the NMR solvent was added and NMR tube 
cap was screwed while the N2 flow continued. 
 
 
Figure 2.3. The specific NMR tube (a) and long two-neck flask for N2-protection 
NMR experiments. 
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2.3.5. pKa Measurements 
A 2 mM solution of complex for pKa measurements was prepared in D2O, 
and 4 mM dioxane was added as NMR standard reference (1H chemical 
shift value 3.75 ppm).21 The solution was aliquoted into 8 samples of 600 
µL and the pH* values were adjusted sequentially by adding 1-10 µL of 
either KOD or DNO3 (0.01, 0.1, 1, 2, 3, 4, 6, 8 or 10 M) in D2O. The pH 
value was measured over a range of 1.5 - 13.5 using a pH meter with 
correction for the effect of deuterium on the glass electrode. Changes in 
the chemical shifts of protons in the complex were followed by 1H NMR 
analysis, and pH* values were corrected by equation: pH = 0.929pH* + 
0.4.1 The chemical shifts versus pH values were fitted to the Henderson-
Hasselbalch equation (equation 1)22,23 using Origin 9.0 with the 
assumption that the observed chemical shifts are weighted averages of 
the populations of the protonated and deprotonated forms. The pKa value 
is the pH value corresponding to exactly one-half of the HA is dissociated.   
δobs = δHA [HA] + δ[A-] [A-]/([HA] + [A-])          ( equation 1) 
where δobs is the observed chemical shift, δHA is the limiting chemical 
shift of the fully protonated form and δ[A-] is the limiting chemical shift 
of the deprotonated form.  
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2.3.6. X-ray Absorption Spectroscopy 
X-ray absorption (XAS) experiments at the Os L3-edge (10871 eV) were 
performed at the BM23 beamline of the European Synchrotron Radiation 
Facility (ESRF, Grenoble, France).24  XAS experiments were conducted 
in transmission mode, using a Si(111) double crystal monochromator to 
select the incident X-ray energy. The intensity of the incident beam I0 and 
the beam transmitted through the sample (I1) and a reference Hf metal 
foil (I2) was monitored by 30 cm ionization chambers. The liquid samples 
were filled in a 4-mm thick EXAFS cell and solid samples were 
compressed to a solid pie. Such setup allowed a precise energy calibration 
for each collected XAS spectrum. For the analysis of data, energy 
calibration and alignment, normalization to the edge jump, and extraction 
of the (k) functions for all the collected spectra was also performed by 
Dr. Elisa Borfecchia (Università degli Studi di Torino, Italy) using the 
Athena program.25 Spectra fitting was performed by Dr. Elisa Borfecchia 
(Università degli Studi di Torino, Italy) using the Arthemis software.26 
More details related to individual experiments can be found in Section 
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2.3.7. Density Functional Calculations  
All the computational calculations were carried out by Prof. Emilia 
Sicilia (Università della Calabria, Italy).  Gaussian 09 program has been 
employed to carry out all calculations in the framework of the density 
functional theory using the hybrid Becke three-parameter exchange 
functional27 and the Lee–Yang–Parr correlation functional, B3LYP.28 
Dispersion corrections for non-bonding interactions have been included 
through the Grimme approach using atom pair-wise additive schemes,29 
i.e. the DFT-D3 method. 
LANL2DZ effective core potential has been used for the Os atom,30 along 
with the split valence basis set. The standard triple-ζ quality 6-311+G** 
basis sets of Pople and co-workers have been used for the atoms directly 
participating in the process, whereas in order to reduce the computational 
effort, the 6-31G* basis sets have been employed for peripheral atoms. 
Vibrational frequencies at the same level of theory have been calculated 
for both establishing the nature of intercepted stationary points as minima 
and transition states and calculating zero-point energy (ZPE) and Gibbs 
free energy corrections. The intercepted transition states are first order 
saddle points on a potential energy surface (PES) and their vibrational 
spectrum was characterized by one imaginary frequency, corresponding 
to a negative force constant, which indicates that in one direction, in the 
Chapter 2: Experimental Section 
92 
nuclear configuration space, the energy has a maximum, while in all the 
other directions the energy has a minimum. Furthermore, transition states 
have been carefully checked to be properly connected to the correct 
minima by IRC (intrinsic reaction coordinate) analysis.31,32  
The Tomasi’s implicit Polarizable Continuum Model (PCM)33,34 as 
implemented in Gaussian 09 has been used to include the effects arising 
from the presence of the solvent and the UFF set of radii has been used 
to build-up the cavity in which the solute molecules are accommodated. 
Solvation Gibbs free energies have been calculated performing single-
point calculations for all in vacuum stationary points structures in implicit 
water (ε = 78.4) at the same level of theory. Enthalpies and Gibbs free 
energies have been obtained using standard statistical procedures35 at 298 
K and 1 atm from total energies, including zero-point, thermal and 
solvent corrections. As the free energy corrections in the Gaussian’s 
default standard state corresponds to an ideal gas at a standard pressure 
of 1 atm, the computed free energies have been converted36 to yield Gibbs 
energies with a solution phase standard state of 1 mol L-1 for all the 
species, except the water solvent. For water molecules a standard state of 
55.5 M has been used. That is, to the free energy of each species, as 
computed in Gaussian, a free energy correction term equal to RT ln(Vmolar 
gas/Vmolar solution), (R = gas constant, T = absolute temperature) has been 
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added, where Vmolar gas is the volume occupied by one mole of ideal gas 
at the considered temperature, and Vmolar solution is the volume occupied by 
one mole of species in a standard solution of concentration 1 mol L-1 .  
 
2.3.8. Cell Seed and Passage 
Cells were generally seeded by Dr. Isolda Romero-Canelón (The 
University of Warwick) in T-75 or T-175 culture flasks as adherent 
monolayers and passaged 2-3 times per week whenever confluence 
reached 80-90%, using 0.25% trypsin for A2780 digestion or 0.25% 
trypsin/EDTA for all other cell line digestions. The environment for cell 
growth was in an incubator pre-set at 310 K with a 5% CO2 humidified 
atmosphere. The cell culture media were composed of Dulbecco's 
Modified Eagle Medium (DMEM), phosphate buffered saline, L-
glutamine, penicillin / streptomycin, fetal bovine serum. 
 
2.3.9. In vitro growth inhibition assay  
The cells used in experiments were normally between 5 and 25 numbers 
of passages. Approximately 5000 cancer cells was seeded per well in 96-
well plates, and grown at 310 K for 24 h, after which cell media 
containing various gradient concentrations of osmium complexes was 
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used to replace the drug-free media in each well, and cells were exposed 
to complexes for a period of 24 h at 310 K. Then the supernatant in each 
well was removed and the survival cell was washed by phosphate-
buffered saline (PBS) and recovered for 72 h at 310 K. The cell viability 
was determined by SRB (Sulforhodamine B) assay,37 in which 
absorbance measurements of the solubilised dye (BioRad iMark 
microplate reader, 470 nm filter) allowed the determination of viable 
treated cells and which were then compared to untreated controls. IC50 
values (the concentration of complexes required to cause 50% cell death) 
were determined as triplicates of duplicates for each complex. ICP-OES 
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The serendipitous discovery and success of cisplatin greatly stimulated 
the development of metal-based anticancer drugs. In recent years, many 
anticancer metallodrugs, such as Ru(III), Ru(II), Ir(II), Os(II) complexes, 
have been reported to display high potency with novel mechanism of 
action.1-5 Half-sandwich osmium (II) arene complexes, following [Os(η6-
p-cymene)(2-(phenylazo)pyridine)Cl/I]PF6
 (1-Cl/I•PF6) as the basic 
template, have been developed (Figure 3.1),6 and the lead complex       
[Os (η6-p-cymene)(4-(2-pyridylazo)-N,N-dimethylaniline)I]PF6 (2-I•PF6, 
also known as FY26) exhibits a 49-fold higher cytotoxicity than cisplatin 
itself towards 809 cancer cell lines.7 More promisingly, [2-I]+ still 
maintains cytotoxicity to cisplatin-resistant cancer cells and significantly 
delays the growth of HCT116 human colon cancer xenografts in mice.8 
In a previous study, [2-I]+ was radio-labelled with the β-/γ emitter, 131I 
(t1/2 8.02 d), and cellular accumulation of the tracer complex, [2-
131I]+, in 
MCF-7 breast cancer cells was explored in vitro. The tracer complex is 
stable in cell culture media,  but once taken up by MCF-7 cells, 99% of 
[2-131I]+ lost the  radio-iodide ligand after 24 h, which was observed in 
the supernatents in the form of free iodide.9 Free thiols, such as GSH and 
cysteine, were found to play crucial roles in this process and activate the 
hydrolysis of [2-I]+.9 Based on these interesting findings, the mechanism 




of action of [2-I]+, especially the reaction of [2-I]+ with GSH, is be 
explored in this thesis.  
In this Chapter 3, several key complexes (Figure 3.1) related to the 
reaction of [2-I]+ with GSH were synthesised, including the lead complex 
2-I•PF6, the chlorido analogue 2-Cl•PF6, the nitrate analogue 2-NO3•PF6, 
the hydroxido analogue [2-OH]+ (solution), the glutathione adduct 2-SG 
and the N-acetyl cysteine adduct 2-NAC. Meanwhile, the non-substituted 
basic template complex 1-Cl•PF6, imino analogue 2-impy-I•PF6, 2-
impy-Cl•PF6 were also prepared for comparison with lead complex 2-
I•PF6.  These osmium complexes were characterized by 1H NMR, high 
resolution mass spectrometry (HRMS) and CHN elemental analysis.  
The pKa value of [2-OH2]
2+ was determined to understand which species 
([2-OH]+ or [2-OH2]2+) predominates under physiological conditions due 
to Henderson–Hasselbalch equation. The cytotoxicity of [2-OH]+, 2-SG 
and 2-NAC towards cancer cells was tested for comparing with lead 
complex [2-I]+. The UV-vis spectra of these osmium complexes in 
aqueous solution were acquired and their extinction coefficients were 
determined using accurate concentrations of osmium obtained from 
inductively coupled plasma-optical emission spectrometry (ICP-OES). 
Time-dependent density functional theory calculations (TD-DFT) for 
these complexes were carried out by Prof. Emilia Sicilia (Università della 




Calabria, Italy) to assist with assignment of electronic absorption bands. 
Moreover, the HPLC retention times on high performance liquid 
chromatography (HPLC), and high resolution mass spectrometry (HRMS) 
identification of complexes 2-I•PF6, 2-Cl•PF6, 2-impy-Cl•PF6, 2-impy-
I•PF6, [2-OH]+, 2-SG, 2-NAC were standardised. HPLC and LC-MS are 
very powerful tools to explore reactions and widely used in this thesis. 
However, it is difficult to quantify each species observed by HPLC 
considering the difference of extinction coefficients for different 
molecules. In order to solve this problem and quantitatively analyse 
reactions of osmium complexes, a simple but very sensitive method was 
applied combining HPLC peak area integration and ICP-OES 
determination. The proportionality between peak area on HPLC trace and 
concentrations of these osmium complexes was established.  
Overall, the work in this Chapter 3 includes synthesis of key complexes, 
pKa measurements, electronic spectra acquisition, extinction coefficient 
determination, HPLC retention times and mass spectrometry 
identification, HPLC peak area and concentration quantitation. These 
experimental results provide the basis for quantitative studies of osmium 
complexes in reactions with GSH in the following Chapter 4, and 
contribute to the overall aim of exploring the mechanism of action of 
anticancer osmium complexes in this thesis. 

















3.2. Experimental Section 
3.2.1. Materials 
Osmium dimers ([Os(η6-p-cym)X2]2, where X = Cl or I) were prepared 
using reported procedures 10 as described in Chapter 2. Reduced 
glutathione (GSH), N-acetyl-L-cysteine (NAC) and silver nitrate were 
purchased from Sigma Aldrich. Pyridine-2-azo-p-dimethylaniline 
(AZPY-NMe2) was purchased from Alfa Aesar. The non-substituted 
ligand pyridine-2- phenyldiazenyl (AZPY) and imino ligand pyridine-2-
imino-p-dimethylaniline, (IMPY-NMe2) were synthesized using 
reported procedures.11,12 Sodium hydroxide, sodium chloride, sodium 
phosphate dibasic (Na2HPO4), sodium phosphate monobasic 
(H2NaPO4·2H2O) and trifluoroacetic acid were purchased from Fisher 
Scientific. All other solvents and reagents for synthesis and analysis were 
purchased from commercial suppliers and used as received. 
 
3.2.2. Instrumentation 
The instrumentation used in this chapter including UV-vis, NMR, HPLC, 
LC-MS, CHN elemental analysis, ICP-OES, HRMS, microwave reactor, 
flash chromatography product purification instrument are fully described 
in Chapter 2.  




3.2.3. Synthesis of Complexes  
[Os(η6-p-cymene)( AZPY-NMe2)Cl]PF6 (2-Cl•PF6) 
 
Following a previously reported protocol,6 to a stirred solution of [Os(η6-
p-cymene) Cl2]2 (158.7 mg, 0.2 mmol) in methanol (10 mL), AZPY-
NMe2 (90.4 mg, 0.4 mmol) in methanol (5 mL) was added drop wise and 
the colour changed from orange to dark blue immediately. The solution 
was stirred at ambient temperature for a period of 24 h. Ammonium 
hexafluorophosphate (326.7 mg, 2.0 mmol) was then added. The volume 
was reduced to ~5 mL, then was placed in a freezer (ca. 268 K) overnight. 
A deep-blue coloured precipitate was collected via vacuum filtration and 
washed with ice-cold ethanol (2 × 1 mL), diethyl ether (2 × 5 mL), and 
dried overnight in a vacuum desiccator. Yield: 260.3 mg (94.3 %). 
HMRS calculated for [2-Cl]+ (C23H28ClN4Os
+) m/z 587.1602, found m/z 
587.1594. 1H NMR (CD3OD) with 400 MHz: δ = 9.06 (d, 1H, J = 5.9 
Hz), 8.58 (d, 1H, J = 8.0 Hz), 8.30-8.24 (m, 3H), 7.71 (m, 3H), 6.59 (d, 
1H, J = 6.1 Hz), 6.32-6.26 (m, 3H), 2.80 (s, 6H), 2.48-2.46 (m, 1H), 2.45 
(s, 3H), 0.98 (d, 3H, J = 6.9 Hz), 0.94 ppm(d, 3H, J = 6.9 Hz). 






Following a previously reported protocol,6 to a stirred solution of [Os(η6-
p-cymene) I2]2 (232.6 mg, 0.2 mmol) in methanol (10 mL), AZPY-NMe2 
(90.4 mg, 0.4 mmol) in methanol (5 mL) was added drop wise and the 
colour of the solution changed from orange to dark blue. The solution 
was stirred at ambient temperature for 24 h, then ammonium 
hexafluorophosphate (326.7 mg, 2.0 mmol) was added. The volume was 
then reduced to ~5 mL with rotary evaporator and then the solution was 
placed in a freezer (ca. 268 K) overnight. A deep-blue precipitate was 
collected via vacuum filtration and washed with ice-cold ethanol (2 × 1 
mL), diethyl ether (2 × 5 mL), and dried overnight in a vacuum desiccator. 
Yield: 282.6 mg (85.8 %). HMRS calculated for [2-I]+ (C23H28IN4Os
+) 
m/z 679.0969, found m/z 679.0952. 1H NMR (CD3OD) with 400 MHz: 
δ = 9.43 (d, 1H, J = 6.0 Hz), 8.64 (d, 1H, J = 8.0 Hz), 8.30-8.22 (m, 3H), 
7.65 (m, 1 H), 6.96 (d, 2H, J = 8.9 Hz), 6.59 (d, 1H, J = 6 Hz), 6.29 (m, 
3H), 3.41 (s, 3H), 2.80 (s, 6H), 2.62-2.56 (m, 1H), 1.03 (d, 3H, J = 6.9 
Hz), 0.98 (d, 3H, J = 6.9 Hz). 




[Os(η6-p-cymene) (AZPY) Cl]PF6 (1-Cl•PF6) 
 
Following a previously reported protocol,6 to a stirred solution of [Os(η6-
p-cymene) Cl2]2 (158.7 mg, 0.2 mmol) in 10 mL methanol, AZPY (73.3 
mg, 0.4 mmol) in methanol (5 mL) was added drop wise, and the colour 
changed from orange to brown. The solution was stirred at ambient 
temperature for 24 h, then ammonium hexafluorophosphate (326.7 mg, 
2.0 mmol) was added. The volume was reduced to 5 mL using rotary 
evaporator and then the solution was placed in a freezer (ca. 268 K) 
overnight. A dark-coloured precipitate was collected via vacuum 
filtration and washed with ice-cold ethanol (2 × 1 mL), diethyl ether (2 × 
5 mL), and dried overnight in vacuo. Yield: 198.1 mg (81.2 %). HMRS 
calculated for [1-Cl]+ (C21H23ClN3Os
+) m/z 544.1195, found m/z 
544.1198. 1H NMR (CD3OD) with 400 MHz: δ = 9.65 (d, 1H, J = 5.9 
Hz), 9.01 (d, 1H, J = 8.9 Hz), 8.50-8.48 (m, 1H), 8.16 (d, 2H, J = 8.0 Hz), 
8.01-7.99 (m, 1H), 7.77 (m, 3H), 6.79 (d, 1H, J = 6.1 Hz), 6.39 (d, 1H, J 
= 5.9 Hz), 6.32 (m, 2H), 2.54 (m, 1H), 2.44 (s, 3H), 1.01 (d, 3H, J = 6.9 
Hz), 0.96 ppm (d, 3H, J = 6.9 Hz). 




 [Os(η6-p-cymene)( IMPY-NMe2)Cl]PF6 (2-Impy-Cl•PF6) 
 
Following a previously reported protocol,5 to a stirred solution of [Os(η6-
p-cymene) Cl2]2 (158.7 mg, 0.2 mmol) in methanol (10 mL), IMPY-
NMe2 (90.4 mg, 0.4 mmol) in methanol (5 mL) was added drop wise. 
The colour changed from orange to red. The solution was stirred at 
ambient temperature for 24 h, then ammonium hexafluorophosphate 
(326.7 mg, 2.0 mmol) was added. The volume was reduced to 5 mL using 
rotary evaporator, the solution was left in a freezer (ca. 268 K) for 
overnight. A red precipitate was collected via vacuum filtration and 
washed with ice-cold ethanol (2 × 1 mL), diethyl ether (2 × 5 mL), and 
dried overnight in a vacuum desiccator. Yield 223.4 mg (80.5 %). HMRS 
calculated for [2-Impy-Cl]+ (C24H29ClN3Os
+) m/z 586.1649, found 
586.1633. 1H NMR(CD3OD) with 400 MHz: δ = 9.56 (d, 1H, J = 4.9 Hz), 
9.20 (s, 1 H), 8.46 (d, 1H, J = 6.9 Hz), 8.32 (t, 1H, J = 7.2 Hz), 7.82 (t, 
1H, J = 6.0 Hz), 7.76 (d, 2H, J = 9.0 Hz), 6.91 (d, 2H, J = 9.1 Hz), 6.44 
(d, 1H, J = 6.1 Hz), 6.04 (d, 1H, J = 5.9 Hz), 5.97 (d, 1H, J = 6.1 Hz), 
5.85 (d, 1H, J = 6.2 Hz), 3.16 (s, 6H), 2.42 (s, 3H), 2.22-2.11 (m, 1H), 
1.10 (d, 3H, J = 7.2 Hz), 1.07 ppm (d, 3H, J = 7.1 Hz). 




 [Os(η6-p-cymene)( IMPY-NMe2)I]PF6 (2-Impy-I•PF6) 
  
Following a previously reported protocol,5 to a stirred solution of [Os(η6-
p-cymene) I2]2 (232.6 mg, 0.2 mmol) in methanol (10 mL), IMPY-NMe2 
(90.4 mg, 0.4 mmol) in methanol (5 mL) was added drop wise. The 
colour of the solution changed from orange to red. The solution was 
stirred at ambient temperature for 24 h. Ammonium hexafluorophosphate 
(326.7 mg, 2.0 mmol) was added. The volume was reduced to ~5 mL, 
then was placed in a freezer (ca. 268 K) overnight. A red precipitate was 
collected via vacuum filtration and washed with ice-cold ethanol (2 × 1 
mL), diethyl ether (2 × 5 mL), and dried overnight in a vacuum desiccator. 
Yield 255.4 mg (77.6 %). HMRS calculated for [2-Impy-I]+ 
(C24H29IN3Os
+) m/z 678.1016, found 678.1028. 1H NMR(CD3OD) with 
400 MHz: δ =  9.54 (d, 1H, J = 5.2 Hz), 9.13 (s, 1 H), 8.46 (d, 1H, J = 7.1 
Hz), 8.25 (t, 1H, J = 7.3 Hz), 7.83 (d, 2H, J = 9.1 Hz), 7.74 (t, 1H, J = 4.9 
Hz), 6.89 (d, 2H, J = 8.9 Hz), 6.38 (d, 1H, J = 6.0 Hz), 6.04 (d, 1H, J = 
6.1 Hz), 5.92-5.87 (m, 2H), 3.15 (s, 6H), 2.65 (s, 3H), 2.21-2.13 (m, 1H), 
1.09 (d, 3H, J = 5.9 Hz) 1.07 ppm (d, 3H, J = 6.1 Hz). 






To a stirred solution of [Os(η6-p-cymene) Cl2]2 (158 mg, 0.2 mmol) in 
methanol (10 mL), AgNO3 (136 mg, 0.8 mmol) in water (10 mL) was 
added. Then the solution was stirred 310 K for 2 h and generated white 
precipitate which was removed by filter. Then a solution of pyridine-2-
azo-p-dimethylaniline (90.4 mg, 0.4 mmol) in methanol (5 mL) was 
added. The mixture was stirred for 18 h at ambient temperature. The 
volume of the solution was reduced to ~2 mL under reduced pressure and 
then ammonium hexafluorophosphate (326 mg, 2 mmol) was added, 
using ultrasonic to promote dissolution. The solution was left in a freezer 
(ca. 268 K) for overnight and a deep-blue precipitate was collected via 
vacuum filtration, washed with ice-cold ethanol (2×1 mL), diethyl ether 
(2 × 5 mL), and then dried overnight in a vacuum desiccator. Yield: 96 
mg (40%). From HRMS, 1H NMR and C H N analysis, the product was 
2-NO3•PF6. HRMS calculated for [2-NO3]+ (C23H28N5O3Os
+) m/z 
614.1802, found: 614.1809. 1H NMR (CD3OD) with 400 MHz: δ = 9.45 
(d, 1H, J = 5.2 Hz), 8.39 (d, 1H, J = 8.0 Hz), 8.30-8.24 (m, 3H), 7.60 (t, 




1H, J = 7.1 Hz), 7.03 (d, 2H, J = 9.5 Hz), 6.59 (d, 1H, J = 5.9 Hz), 6.35 
(d, 1H, J = 5.8 Hz), 6.20-6.00 (m, 2H), 3.43 (s, 6H), 2.39 (s, 3H), 2.30-
2.20 (m, 1H), 0.95-0.82 (dd, 6H, J = 6.9 Hz). CHN analysis: calculated 
for C23H28F6N5O3OsP (2-NO3•PF6): C, 36.46%; H, 3.72%; N, 9.24%. 
Found: C, 36.52%; H, 3.69%; N, 9.17%. 
 
[Os(η6-p-cymene)( AZPY-NMe2)OH]+ ([2-OH]+) 
 
 
2-NO3•PF6 was dissolved into water and stirred for 24 h at ambient 
temperature. [2-OH]+ solution with NO3
- was acquired. HRMS 
calculated for [2-OH]+(C23H29N4OOs
+): m/z 569.1951. Found: 569.1941. 
1H NMR(D2O) with 400 MHz: δ = 9.23 (d, 1H, J = 5.7 Hz), 8.35 (d, 1H, 
J = 8.4 Hz), 8.14-8.21 (m, 3H), 7.60 (t, 1H, J = 6.6 Hz), 6.99 (d, 2H, J = 
9.5 Hz), 6.38 (d, 1H, J = 5.7 Hz), 6.18-6.24 (m, 2H), 6.14 (d, 1H, J = 5.6 
Hz), 3.39 (s, 6H), 2.35 (s, 3H), 2.20-2.12 (m, 1H), 0.85-0.70 (dd, 6H, J = 
6.9 Hz).     
 




Os (η6-p-cymene) (AZPY-NMe2) N-acetyl-L-cysteine (2-NAC) 
 
 
[Os (η6-p-cymene) (4-(2-pyridylazo)-N,N-dimethylaniline) Cl]PF6 (2-
Cl•PF6) (146.2 mg, 0.2 mmol), MeONa (43.2 mg, 0.8 mmol) and N-
acetyl-L-cysteine (65.2 mg, 0.4 mmol) was placed to 25 mL flask. The 
air in the flask was removed by fulfilling with dinitrogen. Dry methanol 
(10 mL) was injected into the flask and the solution was stirred at ambient 
temperature for 24 h with the protection of dinitrogen. Then the reaction 
mixture was filtered and the solvent was removed under reduced pressure. 
Flash chromatography was used to purify the product and a deep-blue 
solid was recovered and then dried in a vacuum desiccator. Yield 86.67 
mg (50.9%). HRMS calculated for [2-NAC + H+]+ (C28H36N5O3SOs
+): 
m/z 714.2147. Found: 714.2149. 1H NMR (CD3OD) with 400 MHz: δ = 
9.15 (d, 1H, J = 5.7 Hz), 8.50 (d, 1H, J = 8.1 Hz), 8.12-7.94 (m, 3H), 7.5 
(t, 1H, J = 6.6 Hz), 6.88 (d, 2H, J = 8.3 Hz), 6.33-6.29 (dd, 1H, J = 5.8 
Hz), 6.10-6.04 (dd, 1H, J = 7.8 Hz), 5.90-5.82 (m, 2H), 4.02-3.95 (m, 
1H), 3.28 (s, 6H), 2.49 (d, 3H, 5.6), 2.32-2.22 (m, 1H), 2.03-1.70 (m, 5H), 




0.81-0.75 (m, 6H). CHN analysis: calculated for C29H40ClN5Na2O5OsS 
(2-NAC + CH3OH + NaCl + NaOH): C, 42.17%; H, 4.72%; N, 8.20. 
Found: C, 42.31%; H, 4.65%; N, 8.28. 
 
Figure 3.2. 400 MHz 1HNMR spectrum of 2-NAC in CD3OD (The two sets of 











Os (η6-p-cymene) (AZPY-NMe2) glutathione (2-SG)  
 
 
[Os (η6-p-cymene) (4-(2-pyridylazo)-N,N-dimethylaniline) Cl] PF6 (2-
Cl•PF6) (146.2 mg, 0.2 mmol), MeONa (324 mg, 6 mmol) and 
glutathione (γ-L-Glu-L-Cys-Gly) (614.4 mg, 2 mmol) were placed to a 
25 mL flask. The air in the flask was removed by filling with dinitrogen. 
Dry methanol (10 mL) was then injected into the flask and the solution 
was stirred at ambient temperature for 24 h with the protection of 
dinitrogen. Then the reaction mixture was filtered and the solvent was 
removed under reduced pressure. Flash chromatography was then 
employed to purify the product and the deep-blue product was isolated 
and dried in a vacuum desiccator. Yield 106.56 mg (53.28%). HRMS 
calculated for [2-SG + H+] (C33H44N7O6OsS
+): m/z 858.2682. Found: 
858.2693. 1H NMR (CD3OD): δ = 9.20 (dd, 1H, J = 5.3 Hz), 8.52 (d, 1H, 
J = 8.9 Hz), 8.13-8.05 (m, 3H), 7.54 (t, 1H, 6.3 Hz), 6.94-6.88 (m, 2H), 
6.29-6.26 (m, 1H), 6.05-6.03 (m, 1H), 5.90-5.86 (m, 2H), 3.85-3.50 (m, 
4H), 3.36 (s, 2H), 3.31 (s, 6H), 2.46 (d, 3H, J = 3.6 Hz), 2.40-2.17 (m, 
3H), 2.15-1.49 (m, 5H), 0.82-0.68 (m, 6H).  CHN analysis: calculated for 




C34H44Cl2N7NaO6OsS (2-SG - H
+ + Na+ + CH2Cl2): C, 42.41%; H, 
4.61%; N, 10.18%. Found: C, 42.36%; H, 4.67%; N, 10.23%. 
 
 











3.2.4. pKa of [2-OH]+ 
A solution of [2-OH]+ (2 mM) was prepared in D2O, and dioxane (4 mM) 
was added as NMR standard reference (δ 3.75 ppm).13 The solution was 
aliquoted into 8 samples of 600 µL and the pH* values (read from pH 
meter without correction for the effect of deuterium on the glass electrode) 
were adjusted sequentially by adding 1-10 µL of either KOD or DNO3 
(0.01, 0.1, 1, 2, 3, 4, 6, 8 or 10 M) in D2O. The pH
* values were measured 
over a range of 1.5 - 13.5. Changes in the chemical shifts of protons in 
complex [2-OH]+ were followed by 1H NMR, and pH* values were 
corrected via the equation: pH = 0.929pH* + 0.412.14 Data were fitted to 
the Henderson-Hasselbalch equation using Origin 8.5. 
 
3.2.5. Anti-proliferative Activity 
The IC50 (half maximal inhibitory concentration) values of [2-OH]
+, 2-
NAC, 2-SG to A2780 ovarian cancer and A549 alveolar cancer cell lines 
were determined by Dr. Isolda Romero-Canelón (University of Warwick). 








3.2.6. TD-DFT Calculations 
The time-dependent DFT calculations of [2-I]+, [2-Cl]+, [2-OH]+, 2-SG, 
2-NAC were carried out by Prof. Emilia Sicilia (Università della Calabria, 
Italy). The Gaussian 09 program was employed to carry out all 
calculations in the framework of the density functional theory using the 
hybrid Becke three-parameter exchange functional15 and the Lee–Yang–
Parr correlation functional, B3LYP.16 Dispersion corrections for non-
bonding interactions have been included through the Grimme approach 
using atom pair-wise additive schemes,17 DFT-D3 method. LANL2DZ 
effective core potential has been used for the Os atom,18 along with the 
split valence basis set. The standard triple-ζ quality 6-311+G** basis sets 
of Pople and coworkers have been used for the atoms directly 
participating in the process, whereas in order to reduce the computational 
effort, the 6-31G* basis sets have been employed for peripheral atoms. 
More details of DFT calculations are described in Chapter 2.   
 
3.2.7. Extinction Coefficient 
Aqueous solutions of osmium complexes 2-I•PF6, 2-Cl•PF6, [2-OH]+, 2-
SG, 2-NAC were prepared at ca. 25 μM. The UV-vis spectra of these 
osmium complexes aqueous solution were acquired with a Cary 300 UV-
Vis recording spectrophotometer and the accurate concentrations of these 




osmium solutions were determined with ICP-OES. The extinction 
coefficients of these complexes were calculated using the Beer–Lambert 
law based on the UV-vis spectra, and concentrations of osmium from 
ICP-OES and the cuvette path length (1 cm).19 More details regarding 
UV-Vis spectroscopy and ICP-OES are available in Chapter 2. 
 
 
3.2.8. HPLC and LC-MS 
Table 3.1. The solvent B (acetonitrile) gradient used in HPLC/LC-MS for analysing 
osmium azo and imino complexes. 
Time (min) 
% (B) for 
azo complexes 
% (B) for 
imino complexes 
0 10 20 
30 80 60 
40 80 60 
41 10 20 
55 10 20 
 
The solutions of 2-I•PF6, 2-Cl•PF6, [2-OH]+, 2-SG, 2-NAC, 2-impy-
Cl•PF6, 2-impy-I•PF6 in phosphate buffer (75 mM, pH = 7.4) were 
prepared with at ~100 μM and analysed by HPLC and LC-MS. The 
details of the HPLC, LC-MS instrument, the column information are 
described in Chapter 2. The mobile phases used in the experiments were 
solvent A (H2O with 0.1% TFA) and solvent B (MeCN with 0.1% TFA). 




Osmium imino complexes were analysed at a detection wavelength of 
254 nm with reference wavelengths set to 360 nm and 510 nm, whilst 
osmium azo complexes were analysed at 610 nm with a reference 
wavelength set to 360 nm. 
 
3.2.9. HRMS 
The solutions of 1-Cl•PF6, 2-I•PF6, 2-Cl•PF6, [2-OH]+, 2-SG, 2-NAC, 
2-impy-Cl•PF6, 2-impy-I•PF6 in ammonium acetate buffer (5 mM, pH 
= 7.2) were prepared with a concentration of ca. 20 μM and these 
solutions were analysed with HRMS. More details regarding the HMRS 
instrument are provided in Chapter 2. 
 
3.2.10. The Proportionality between HPLC Peak and Concentration 
The solutions of 2-I•PF6, 2-Cl•PF6, [2-OH]+, 2-SG, 2-NAC in phosphate 
buffer (75 mM, pH = 7.4) were prepared with a concentration of ca. 100 
μM. Then each solution was diluted 1×, 2× or 4× times and analysed by 
HPLC. The concentrations of the stock solutions were measured by ICP-
OES. The linear proportionality between concentrations of solutions 
versus their integrated peak area on HPLC traces at 610 nm was plotted. 
 





In this Chapter 3, several osmium complexes related to FY26 (2-I•PF6) 
were synthesised. Although 1-Cl•PF6, 2-I•PF6, 2-Cl•PF6, 2-impy-I•PF6, 
2-impy-Cl•PF6 were reported before,5,6 herein they are prepared with 
yield-improved methods. Complexes 2-NO3•PF6, [2-OH]+ (solution), 2-
NAC, 2-SG are obtained and characterized here for the first time. After 
acquiring these osmium complexes, their properties were studied, 
including the pKa value of [2-OH2]
2+ (Section 3.3.1), anti-proliferative 
activity studies (Section 3.3.2), TD-DFT calculations for their electronic 
spectra (Section 3.3.3), extinction coefficients (Section 3.3.4), retention 
times and mass spectrometry identification (Section 3.3.5), and the 
proportionality between HPLC peak and concentration for quantification 
purposes (Section 3.3.6). 
 
3.3.1. pKa of [2-OH]+ 
The pKa value of [2-OH2]
2+ deprotonating to [2-OH]+ (Scheme 3.1.) was 
determined using 1H NMR through observing the change in chemical 
shift of an aromatic p-cym proton as the pH* in D2O solution was varied 
(pH* corresponds to the pH reading of a D2O solution using a H2O 
calibrated pH-meter). The pH* values were corrected to pH values with 
pH = 0.929pH* + 0.412,14 and the data was fitted to Henderson-




Hasselbalch equation. From the data, the pKa of [2-OH]
+ is 5.20 ± 0.02 
and the error was obtained as a computer fitting error using Origin 8.5. 
 
 
Scheme 3.1. Protonation of [2-OH]+ and deprotonation of [2-OH2]2+ with dissociation 




Figure 3.4. Variation of the chemical shift of an aromatic p-cym proton of [2-OH]+ 
with pH. The red line represents a computer best fit to the Henderson-Hasselbalch 
equation. 
pKa=5.20 0.02























3.3.2. Anti-proliferative Activity 
The IC50 values of novel complexes [2-OH]
+, 2-NAC, 2-SG against 
A2780 and A549 cancer cells were determined using the protocol 
described in Chapter 2. From these data (Table 3.2), all these three 
complexes are inactive to A549 cancer cells. For A2780 cancer cells, [2-
OH]+ exhibited IC50 = 9.1± 0.7 μM, while 2-NAC and 2-SG were 
inactive (IC50 > 100 μM). The cell culture media were composed of 
Dulbecco's Modified Eagle Medium (DMEM), phosphate buffered saline, 
L-glutamine, penicillin / streptomycin, fetal bovine serum. 
Table 3.2. The anti-proliferative activity of [2-OH]+, 2-NAC, 2-SG against A2780 
and A549 cancer cells. 
Complexes IC50 (A2780) (μM) IC50 (A549) (μM) 
[2-OH]+ 9.1± 0.7a > 100 
2-NAC > 100 > 100 
2-SG > 100 > 100 
Means ± standard deviation from three independent repeats 
 
3.3.3. Electronic Spectra from TD-DFT Calculations 
Time-dependent DFT calculations were carried out by Prof. Emilia 
Sicilia (Università della Calabria, Italy) for complexes [2-I]+, [2-OH]+, 
[2-OH]2+ and 2-SG and their electronic absorption spectra were 




predicted. From the results (Figure 3.5 – 3.8), all these complexes had a 
similar maximum absorbance at 550-610 nm (553 nm for [2-I]+, 573 nm 
for [2-OH]+, 611 nm for [2-OH]2+, 566 nm for 2-SG) and this 
predominantly arose from the excitation from highest occupied 
molecular orbital (HOMO) to lowest unoccupied molecular orbital 
(LUMO). From the model of HOMO to LUMO (Figure 3.5-3.8), it was 
clearly a charge transfer band arising from the metal centre to the ligands. 
Thus the maximum absorbance band at 550-610 nm can be assigned to  
metal-ligand charge transfer (MLCT), which was from the filled Os 5d6 
orbitals of Os(II) to the empty π* ligand orbitals (5d6 Os π→π*). Apart 
from MLCT, intra-ligand transitions (IL π→π*) also contribute to the 
absorbance from 200-400 nm. The absorbance of intraligand transitions 
was relatively lower than metal-ligand charge transfer, and mainly 
contributed by the excitation from HOMO-8 to LUMO for [2-I]+, 
HOMO-1 to LUMO+1 for [2-OH]+, HOMO to LUMO+2 for [2-OH]2+ 
and HOMO-9 to LUMO for 2-SG, respectively. 





Figure 3.5. The HOMO and LUMO models, electronic spectrum (blue line) and 




Figure 3.6. The HOMO and LUMO models, electronic spectrum (blue line) and 
assignments for [2-OH]+ from the TD-DFT calculations. 





Figure 3.7. The HOMO and LUMO models, electronic spectrum (blue line) and 
assignments for [2-OH2]2+ from the TD-DFT calculations. 
 
 
Figure 3.8. The HOMO and LUMO models, electronic spectrum (blue line) and 
assignments for 2-SG from the TD-DFT calculations. 
 




3.3.4. Extinction Coefficients 
The UV-vis spectra of complexes [2-Cl]+, [2-I]+, 2-NAC, 2-SG, [2-OH]+ 
in fresh aqueous solutions in 75 mM phosphate buffer (pH 7.4) were 
acquired. These complexes possessed very similar UV-vis absorbance 
spectra and have three maxima at 610 nm, 475 nm and 290 nm, of which 
the absorbance at 610 nm is the highest for all complexes. The spectra 
(Figure 3.9) are consistent with the electronic spectra predicted from TD-
DFT calculations. 
Then concentrations of osmium in these stock solutions were determined 
using ICP-OES as 26.45 ±0.13 μΜ for [2-Cl]+, 17.02±0.09 μΜ for [2-I]+, 
34.34±0.24 μΜ for 2-NAC, 20.92±0.35 μΜ for 2-SG and 22.32±0.19 
μΜ for [2-OH]+. The extinction coefficients for each osmium complex 
at the above maxima were calculated based on the Beer–Lambert law.19 
The results are summarized at Table 3.3. Notably, complex [2-I]+ 
exhibits a higher extinction coefficient (40000 M-1 cm-1 at 611 nm) than 
the other osmium complexes [2-Cl]+ (25000 M-1 cm-1 at 608 nm), 2-NAC 
(20000 M-1 cm-1 at 607 nm), 2-SG (26000 M-1 cm-1 at 613 nm), and [2-








Table 3.3. Wavelengths of mmaximum aabsorbance, extinction coefficients, and 
assignments for osmium complexes [2-Cl]+, [2-I]+, 2-NAC, 2-SG, [2-OH]+. 
Complexes λ max (nm) ε (M-1 cm-1) Assignment 
[2-Cl]+ 










506 15225±81 IL π→π*   






467 5990±42 IL π→π* 






462 5872±98 IL π→π* 




475 8243±70 IL π→π* 
293 8032±68 IL π→π* 
a (sh) = shoulder. b(IL) = Intraligand. 
 





Figure 3.9. The UV-Vis spectrum for aqueous solutions of [2-Cl]+ (26.45 μΜ), [2-
I]+ (17.02 μΜ), 2-NAC aqueous solution (34.34 μΜ), 2-SG (20.92 μΜ), [2-OH]+ 
aqueous solution (22.32 μΜ), pH 7.4. 
 
 
3.3.5. HPLC Retention Times and Mass Spectrometric Analysis for 
Osmium Species 
Fresh aqueous solutions of osmium complexes 2-I•PF6, 2-Cl•PF6, 2-
impy-Cl•PF6, 2-impy-I•PF6, 2-NO3•PF6, [2-OH]+, 2-SG, 2-NAC were 
prepared in phosphate buffer (75 mM, pH = 7.4) and analysed by HPLC 
and LC-MS to give their corresponding retention times and m/z of 
positive ions. HRMS was used to confirm the m/z values observed by 




LC-MS for each species. The results are summarized in Table 3.4. The 
HPLC retention times for [2-I]+, [2-Cl]+, [2-impy-Cl]+, [2-impy-I]+, [2-
NO3]+, [2-OH]+, 2-SG, 2-NAC were 23.02, 19.67, 26.43, 41.42, 18.62, 
15.68, 12.53, 13.29 (min), respectively and corresponding HRMS m/z 
values were 679.0952, 587.1594, 586.1633, 678.1028, 614.1809, 
714.2149, 569.1941 and 858.2693, respectively. 
 
Table 3.4. Species identified by HPLC/LC-MS/HRMS, their molecular formula, 















+ 679.0969 679.02 679.0952 23.02 
[2-Cl]+ C23H28ClN4Os








+ 678.1016 678.17 678.1028 41.42* 
[2-NO3]+ C23H28N5O3Os




+ 714.2147 714.16 714.2149 15.68 
[2-OH]+ C23H29N4OOs




+ 858.2682 858.19 858.2693 13.29 
* The HPLC methods for imino complexes and azo complexes are different, see Table 3.1. 
 
 





Figure 3.10. HPLC chromatography retention times for osmium azo complexes in 
aqueous solution with concentration of ca. 100 μM. 
 
 
Figure 3.11. HPLC chromatography retention times for osmium imino complexes in 
aqueous solution with concentration of ca. 100 μM. 





Figure 3.12. HRMS spectra for 2-I. Molecular formula: C23H28IN4Os
+, calculated 




Figure 3.13. HRMS spectra for 2-Cl. Molecular formula: C23H28ClN4Os
+, calculated 
m/z: 587.1602, observed m/z: 587.1594, (error: 1.4 ppm). 
 
 





Figure 3.14. HRMS spectra for 2-NO3. Molecular formula: C23H28N5O3Os
+, 




Figure 3.15. HRMS spectra for 2-OH. Molecular formula: C23H29N4OOs
+, calculated 
m/z: 569.1951, observed m/z: 569.1941, (error: 1.8 ppm). 
 
 





Figure 3.16. HRMS spectra for 2-SG + H+. Molecular formula: C33H44N7O6OsS
+, 
calculated m/z: 858.2682, observed m/z: 858.2693, (error: 1.3 ppm). 
 
 
Figure 3.17. HRMS spectra for 2-NAC + H+. Molecular formula: C28H36N5O3OsS
+, 
calculated m/z: 714.2147, observed m/z: 714.2149, (error: 0.3 ppm). 
 
 





Figure 3.18. HRMS spectra for 2-impy-Cl. Molecular formula: C24H29ClN3Os
+, 




Figure 3.19. HRMS spectra for 2-impy-I. Molecular formula: C24H29IN3Os
+, 
calculated m/z: 678.1016, observed m/z: 678.1028, (error: 1.8 ppm).  
 
 




3.3.6. The Proportionality of HPLC Peak Areas with Concentrations 
Fresh aqueous solutions of 2-I•PF6, 2-Cl•PF6, [2-OH]+, 2-SG in 
phosphate buffer (75 mM, pH = 7.4) were prepared with a concentration 
of ca.100 μM and diluted 1×, 2× or 4× times. All these samples were 
analysed on HPLC at a wavelength of 610 nm and their corresponding 
integrated peak areas were recorded. Subsequently, ICP-OES was used 
to determine the concentration of osmium for each stock solution. The 
results are summarized in Table 3.5 and the linear relationship between 
the peak area in HPLC traces and concentration of osmium complexes 
were obtained for [2-Cl]+ is y = (81.47±0.11)x – (4.38±6.33); for [2-I]+ 
is y = (103.00±0.85)x – (126.09±16.61); for [2-OH]+ is y = (81.95±0.68)x 
– (28.86±34.96); for 2-SG is y = (84.63±0. 0.48)x – (81.96±32.96). 
Table 3.5. The HPLC peak area of osmium complexes at 610 nm and corresponding 
osmium concentrations. 

















a mean±sd from three independent determinations by ICP-OES; b mean±sd from three independent 
injections. 





Figure 3.20. Linear relationship between HPLC peak area (610 nm) and 
concentration of [2-Cl]+. 
 
 
Figure 3.21. Linear relationship between HPLC peak area (610 nm) and 
concentration of [2-I]+. 
 





Figure 3.22. Linear relationship between HPLC peak area (610 nm) and 
concentration of [2-OH]+. 
 
 
Figure 3.23. Linear relationship between HPLC peak area (610 nm) and 
concentration of 2-SG. 





The half-sandwich osmium azo complex [Os (η6-p-cymene) (4-(2-
pyridylazo)-N,N-dimethylaniline)I]PF6
  FY26 (termed 2-I•PF6 in this 
thesis) has been reported as a very promising anticancer drug candidate. 
This thesis is aimed to explore the mechanism of action of 2-I•PF6, 
especially studying the reactions between 2-I•PF6 with intracellular 
biomolecule GSH. Contributions towards the aim for the whole thesis, 
the work in this Chapter 3 includes the synthesis and characterization of 
2-I•PF6 and its analogue complexes including chloride analogue 2-
Cl•PF6, non-substitutes template complex 1-Cl•PF6, imino analogue 
complexes 2-impy-I•PF6 and 2-impy-Cl•PF6, hydrolysis product 
complex [2-OH]+ (solution), N-acetyl-cysteine adduct 2-NAC, 
glutathione adduct 2-SG.  
Figure 3.24. Structures of the complexes synthesised and studied in this chapter. 




After obtaining these complexes, some of their properties were studied, 
such as the pKa value of the aqua complex, electronic absorption spectra, 
extinction coefficients, liquid chromatography and mass spectrometry 
identification, proportionality between HPLC peak areas and 
concentrations. [2-I]+ has been found to lose the monodentate iodido 
ligand significantly once uptaken by cancer cells9 and its hydrolysis 
product [2-OH]+ appears to be the key active species to the anticancer 
cytotoxicity. The measurement of the pKa value of [2-OH2]
2+ helps to 
uncover which form hydroxido [2-OH]+ or aqua [2-OH2]2+ predominates 
under the physiological condition (pH = 7.4). The result of pKa = 5.20 ± 
0.02 demonstrates that [2-OH]+ predominates in cells and its low pKa 
value is consistent with its Ru analogue  [Ru (η6-p-cymene) (4-(1H-
pyrazol-3-ylazo)-NMe2)OH]
+ (pKa = 4.60). The azo ligand bearing in [2-
OH]+ is a strong π-acceptor ligand that draws electron density away from 
the metal centre rendering it more electropositive and making the H2O 
ligand more acidic (lower pKa).
20 In contrast, anionic ligands such as 
acetylacetonate and picolinate produce an opposite effect of making the 
H2O ligand less acidic through placing more electron density around the 
metal centre.21,22 In general, Os(II) aqua adducts tend to have a lower pKa 
than the Ru(II) analogue.23 The pKa value is a crucial factor to the 
stability and reactivity of metal aqua complexes because pKa value 
determined aqua (M-OH2) or hydroxido analogue (M-OH) predominates 





Figure 3.25. Comparison of pKa values for Os(II) and Ru(II) arene aqua species with 
different bidentate ligands.11,21-27 
 
under physiological conditions and  M-OH is generally more stable than 
M-OH2 to various intracellular molecules.
28-30 For example, cisplatin 
aqua analogue [cis-Pt(OH2)2(NH3)2]
2+ is more reactive than hydroxido 
analogue [cis-Pt(OH)2(NH3)2] on reacting with glycine to form [cis-
Pt(NH3)2(glyH-O)(H2O)]
2+.31 In the ion exchange reaction with solvent, 
[(NH3)5CoOH2]
3+ exhibits 40 times faster exchange rate than hydroxido 
analogue [(NH3)5CoOH]
2+ and [Co(cyclen)(NH3)OH2]
3+ is two          
orders of magnitude faster than its hydroxido analogue 
[Co(cyclen)(NH3)OH]
2+.28,32,33  
Continued to the cytotoxicity of complexes [1-Cl]+, [2-Cl]+, [2-I]+ that 
have been measured and reported,6,34 the novel thiolate complexes 2-
NAC and 2-SG are inactive, similar to the corresponding Pt(II) and Ir(III) 




thiolate adducts.35,36 These thiol adducts may be too inert to react targets 
in the cancer cell and GS-X pump in cell membrane might lead low 
accumulation of thiol adducts into cancer cells.37-39 Complex [2-OH]+ 
(IC50 = 9.1± 0.7) was less cytotoxicity than [2-Cl]
+ (IC50 = 1.4 μM) and 
[2-I]+ (IC50 = 0.14 μM),
6 although [2-OH]+ was considered as the active 
species of [2-I]+ in the cancer cell line.9 This could be attributed to the 
too high reactivity of [2-OH]+ and its reactions with intracellular targets 
and non-target species. The hydroxido analogue of cisplatin is able to 
react with many intracellular species, including DNA bases, amino acids 
and even phosphate buffer.29,40,41 This may lead to drug inactivation, and 
minimise the amount of active species reaching its cellular targets.   
In terms of the UV-vis spectra and extinction coefficients of osmium 
complexes [2-Cl]+, [2-I]+, 2-NAC, 2-SG, and [2-OH]+, maximum 
absorbance bands at around 610,  475 and 290 nm were observed while 
the maximum absorbance of the free ligand (Azpy-NMe2) are 432 nm 
and 272 nm.11 Thus the bands at 610 nm for these osmium complexes can 
be assigned to metal-ligand charge transfer (MLCT) Os(5d6)→π* and the 
absorbance bands at 475 nm, 290 nm can be assigned to intra-ligand 
transitions. The TD-DFT calculations for the electronic spectra of these 
osmium complexes (Section 3.3.) suggest that the highest absorbance is 
mostly due to the excitation from HOMO to LUMO. Comparing the 




electron density in the HOMO and LUMO models, it is clear to that 
charge transfer from the osmium(II) centre to the ligands, which also 
supports to assignment of most intense bands at 610 nm to metal-ligand 
charge transfer. Moreover, the TD-DFT calculations show that the 
MLCT of [2-I]+ (excitation from HOMO to LUMO) involves phenyl and 
iodide ligands. However, the MLCT of other osmium complexes 
involves only the phenyl ligand. This difference might explain why the 
extinction coefficient of [2-I]+ is higher than other osmium complexes 
studied.  
The reversed-phase HPLC retention times of these osmium complexes 
reflect their hydrophobicities. The sequence of retention times is [2-OH]+ 
< 2-SG < 2-NAC < [2-Cl]+ < [2-I]+ (Figure 3.10). The column used for 
HPLC was a C18 reverse column. Thus the hydrophobicity trend might 
be [2-OH]+ > 2-SG > 2-NAC > [2-Cl]+ > [2-I]+. Together with retention 
times, the mass spectrometry identification of these osmium complexes 
provides the basis of using HPLC/LC-MS to study the behaviour of these 
osmium complexes. In order to quantify the reactions by HPLC, 
proportionality between HPLC peak areas and concentrations of osmium 
complexes was established by combining with ICP-OES determinations. 
 
 





In this chapter, 2-I•PF6 and its chloride analogue 2-Cl•PF6, non-
substituted template complex 1-Cl•PF6, imino analogue complexes 2-
impy-I•PF6 and 2-impy-Cl•PF6, hydrolysis product complex [2-OH]+ 
(solution), N-acetyl-cysteine adduct 2-NAC, and glutathione adduct 2-
SG were synthesized and characterized. The pKa value of [2-OH2]
2+ was 
determined as 5.20 ± 0.02 which indicates that under physiological 
conditions the more stable species [2-OH]+predominates. The IC50 value 
of [2-OH]+ towards A2780 ovarian cancer cells is 9.1 μM, less cytotoxic 
than [2-Cl]+ and [2-I]+. The thiol adducts 2-NAC and 2-SG are 
completely inactive to cancer cells. The comparison between their 
cytotoxicity highlights the importance of halogen ligands. The 
acquisition of the electronic spectra and extinction coefficients for these 
osmium complexes presents the basis for further study of their reactions 
by UV-vis analysis. Their maximum absorbance at around 610 nm 
provides a useful detection wavelength in HPLC studies. The retention 
time and mass spectrometry identification of these osmium complexes 
renders it possible to analyse the reactions by HPLC/LC-MS. Moreover, 
the establishment of proportionality between HPLC peak area and 
concentrations provides a simple but sensitive method to quantitatively 
analyse the reactions of these osmium complexes in following chapters.   





(1) Sava, G.; Zorzet, S.; Turrin, C.; Vita, F.; Soranzo, M.; Zabucchi, 
G.; Cocchietto, M.; Bergamo, A.; DiGiovine, S.; Pezzoni, G. Clin. 
Cancer. Res. 2003, 9, 1898. 
(2) Kapitza, S.; Jakupec, M. A.; Uhl, M.; Keppler, B. K.; Marian, B. 
Cancer Lett. 2005, 226, 115. 
(3) Dougan, S. J.; Habtemariam, A.; McHale, S. E.; Parsons, S.; Sadler, 
P. J. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 11628. 
(4) Liu, Z.; Romero‐Canelón, I.; Qamar, B.; Hearn, J. M.; 
Habtemariam, A.; Barry, N. P.; Pizarro, A. M.; Clarkson, G. J.; 
Sadler, P. J. Angew. Chem. Int. Ed. 2014, 53, 3941. 
(5) Fu, Y.; Romero, M. J.; Habtemariam, A.; Snowden, M. E.; Song, 
L.; Clarkson, G. J.; Qamar, B.; Pizarro, A. M.; Unwin, P. R.; Sadler, 
P. J. Chem. Sci. 2012, 3, 2485. 
(6) Fu, Y.; Habtemariam, A.; Pizarro, A. M.; van Rijt, S. H.; Healey, 
D. J.; Cooper, P. A.; Shnyder, S. D.; Clarkson, G. J.; Sadler, P. J. 
J. Med. Chem. 2010, 53, 8192. 
(7) Hearn, J. M.; Romero-Canelón, I.; Munro, A. F.; Fu, Y.; Pizarro, 
A. M.; Garnett, M. J.; McDermott, U.; Carragher, N. O.; Sadler, P. 
J. Proc. Natl. Acad. Sci. U.S.A. 2015, 112, E3800. 




(8) Shnyder, S. D.; Fu, Y.; Habtemariam, A.; van Rijt, S. H.; Cooper, 
P. A.; Loadman, P. M.; Sadler, P. J. MedChemComm 2011, 2, 666. 
(9) Needham, R. J.; Sanchez-Cano, C.; Zhang, X.; Romero-Canelón, 
I.; Habtemariam, A.; Cooper, M. S.; Meszaros, L.; Clarkson, G. J.; 
Blower, P. J.; Sadler, P. J. Angew. Chem. Int. Ed. 2017, 56, 1017. 
(10) Arthur, T.; Stephenson, T. A. J. Organomet. Chem. 1981, 208, 369. 
(11) Dougan, S. J.; Melchart, M.; Habtemariam, A.; Parsons, S.; Sadler, 
P. J. lnorg. Chem. 2006, 45, 10882. 
(12) Hindo, S. S.; Mancino, A. M.; Braymer, J. J.; Liu, Y.; 
Vivekanandan, S.; Ramamoorthy, A.; Lim, M. H. J. Am. Chem. 
Soc. 2009, 131, 16663. 
(13) Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. J. Org. Chem. 1997, 62, 
7512. 
(14) Krȩżel, A.; Bal, W. J. Inorg. Biochem. 2004, 98, 161. 
(15) Becke, A. D. J. Chem. Phys. 1993, 98, 5648. 
(16) Lee, C.; Yang, W.; Parr, R. G. Phys. Rev. B 1988, 37, 785. 
(17) Grimme, S.; Antony, J.; Ehrlich, S.; Krieg, H. J. Chem. Phys. 2010, 
132, 154104. 
(18) Dunning, T. H.; Hay, P. J. In Modern theoretical chemistry; 
Plenum Press: New York, NY, 1977; Vol. 3, p 1. 
(19) Swinehart, D. F. J. Chem. Educ. 1962, 39, 333. 




(20) Pizarro, A. M.; Habtemariam, A.; Sadler, P. J. In Medicinal 
Organometallic Chemistry. Topics in Organometallic Chemistry; 
Jaouen, G., Metzler-Nolte, N., Eds.; Springer: Berlin, Heidelberg, 
2010; Vol. 32, p 21. 
(21) Fernández, R.; Melchart, M.; Habtemariam, A.; Parsons, S.; Sadler, 
P. J. Chem. Eur. J. 2004, 10, 5173. 
(22) Peacock, A. F. A.; Parsons, S.; Sadler, P. J. J. Am. Chem. Soc. 2007, 
129, 3348. 
(23) Peacock, A. F. A.; Melchart, M.; Deeth, R. J.; Habtemariam, A.; 
Parsons, S.; Sadler, P. J. Chem. Eur. J. 2007, 13, 2601. 
(24) Chen, H.; Parkinson, J. A.; Morris, R. E.; Sadler, P. J. J. Am. Chem. 
Soc. 2003, 125, 173. 
(25) Peacock, A. F. A.; Habtemariam, A.; Fernández, R.; Walland, V.; 
Fabbiani, F. P. A.; Parsons, S.; Aird, R. E.; Jodrell, D. I.; Sadler, 
P. J. J. Am. Chem. Soc. 2006, 128, 1739. 
(26) Peacock, A. F. A.; Habtemariam, A.; Moggach, S. A.; Prescimone, 
A.; Parsons, S.; Sadler, P. J. lnorg. Chem. 2007, 46, 4049. 
(27) Wang, F.; Chen, H.; Parsons, S.; Oswald, I. D. H.; Davidson, J. E.; 
Sadler, P. J. Chem. Eur. J. 2003, 9, 5810. 
(28) Helm, L.; Merbach, A. E. Chem. Rev. 2005, 105, 1923. 




(29) Berners-Price, S. J.; Appleton, T. G. In Platinum-based drugs in 
cancer therapy; Farrell, N. P., Kelland, L. R., Eds.; Humana Press 
Inc: Totawa, NJ, 2000, p 3. 
(30) Koelle, U. Coord. Chem. Rev. 1994, 135, 623. 
(31) Appleton, T. G.; Hall, J. R.; Ralph, S. F. lnorg. Chem. 1985, 24, 
673. 
(32) Hunt, H. R.; Taube, H. J. Am. Chem. Soc. 1958, 80, 2642. 
(33) Buckingham, D. A.; Clark, C. R.; Rogers, A. J.; Simpson, J. lnorg. 
Chem. 1998, 37, 3497. 
(34) Fu, Y.; Habtemariam, A.; Basri, A. M.; Braddick, D.; Clarkson, G. 
J.; Sadler, P. J. Dalton Trans. 2011, 40, 10553. 
(35) Kasherman, Y.; Sturup, S.; Gibson, D. J. Med. Chem. 2009, 52, 
4319. 
(36) Liu, Z.; Sadler, P. J. lnorg. Chem. Front. 2014, 1, 668. 
(37) Akimaru, K.; Kuo, M. T.; Furuta, K.; Suzuki, M.; Noyori, R.; 
Ishikawa, T. Cytotechnology 1996, 19, 221. 
(38) Senna, S. M.; Vidor, A. C.; Miyasaka, C. K.; Curi, R.; Williams, J. 
F. Biochem. Mol. Biol. Int. 1998, 45, 1243. 
(39) Ishikawa, T.; Akimaru, K.; Nakanishi, M.; Tomokiyo, K.; Furuta, 
K.; Suzuki, M.; Noyori, R. Biochem. J. 1998, 336, 569. 
(40) Heudi, O.; Cailleux, A.; Allain, P. J. Inorg. Biochem. 1998, 71, 61. 









Hydrolysis Studies on 








Chapter 4: Hydrolysis Studies on Azopyridine Osmium Arene Complexes 
149 
4.1. Introduction 
Half-sandwich organo-osmium complex [Os(η6-p-cym)(4-(2-
pyridylazo)-N,N-dimethylaniline)I]PF6 (2-I•PF6, also known as FY26, 
Figure 4.2) has been reported to exhibit 49× times higher potency than 
cisplatin in >800 cancer cell lines whilst still retaining cytotoxicity to 
cisplatin-resistant cancer cells.1-3 Thus, 2-I•PF6 is considered as a very 
promising anticancer drug candidate to overcome the drug-resistance 
induced by platinum drugs. Understanding the mechanism of action of 2-
I•PF6, an aim of this thesis, is a key process to contribute to its 
advancement to clinical application and ultimately lead the development 
of new analogues with improved performance. 
For many anticancer metallodrugs, the hydrolysis process should not be 
ignored when considering their reactions with intracellular targets and 
exploration of anticancer mechanism. Cisplatin is known to undergo 
hydrolysis before binding to DNA.4-6  In the mechanism of action of 
cisplatin, H2O attacks the Pt centre and replaces the chlorido ligand to 
form aquated products. This class of aquated product is a potent 
electrophile that can react with nucleophiles like nitrogen donor atoms 
on DNA base residues and then cause DNA damage.6 A similar 
mechanism action involving hydrolysis also has been observed for Ru(II) 
RAPTAs anticancer complexes (Figure 4.1). The liable Ru-Cl bonds in 
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the complex can be attacked by H2O to form aquated Ru(II) adducts 
which can pH-dependently bind to DNA.7,8  
 
Figure 4.1. The molecular structures of anticancer complexes with their hydrolysis-
mediated mechanism of action. 
 
Moreover, the hydrolysis rate and reactivity of aquated adducts are 
crucial to the cytotoxicity of anticancer complexes. Inappropriate 
hydrolysis rates and reactivites of such hydrolysis products might limit 
their anticancer applications. The clinical trials of anticancer candidate 
drug titanocene dichloride were terminated at phase II in view of 
hydrolytic instability.9,10 During the development of organo-osmium 
anticancer complexes, N,N-chelators (e.g. ethylenediamine) and O,O-
chelators (e.g. acetylacetone) were introduced. However, both these two 
series of osmium complexes are inactive towards cancer cells in view of 
their the excessive stability towards hydrolysis for N,N-chelating 
complexes or because of the excessive stability towards hydrolysis for 
O,O-chelating complexes.11,12 Finally, N,O-chelating osmium complexes 
(e.g. [Os(ŋ6-biphenyl)(picolinate)Cl]) provide a balanced compromise 
for facile hydrolysis and acquiring activity comparable to that of 
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cisplatin.13,14 Overall, many examples can be given to highlight the 
importance of the hydrolysis process in the mechanism of action of 
metal-based anticancer complexes. The aim of this thesis is to explore the 
mechanism action of 2-I•PF6, and its hydrolysis is studied in this Chapter. 
Before these studies, Dr. Russell Needham (University of Warwick) 
found that [2-I]+ is stable under physiological conditions. But once taken 
up by cancer cells, 99% of [2-I]+ rapidly loses its iodide ligand.15 The 
intracellular tripeptide glutathione (γ-L-Glu-L-Cys-Gly, GSH) was 
indicated to be involved in this process and promoted the hydrolysis of 
[2-I]+. GSH is well known as the most abundant low molecular weight 
thiol with a concentration range 0.1-10 mM in cells and a key molecule 
in the redox system in cells (further introduction to GSH is in Section 1.5 
of Chapter 1).16,17  
Hence in this Chapter 4, the hydrolysis of [2-I]+ in presence of GSH is 
studied in detail by techniques HPLC and LC-MS, including reactions of 
[2-I]+ with various concentrations of GSH, and time- and pH-dependent 
reactions of [2-I]+ with GSH. Based on the proportionality between the 
HPLC peak area and concentration of osmium species (Section 3.3.6 of 
Chapter 3), these reactions were quantitatively analysed. Reactions of 
osmium complexes [2-I]+ with GSH were also studied by NMR 
spectroscopy under an N2 atmosphere to avoid the auto-oxidation of GSH 
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to GSSG in the air. In addition to GSH, the reactions of other free thiols 
such as N-acetyl-L-cysteine (NAC) and 1,4-dithiothreitol (DTT) were 
also with [2-I]+ were also studied.  In order to better understand the 
hydrolysis of [2-I]+ in presence of GSH, reactions of GSH with analogues 
of [2-I]+ including chlorido analogue [2-Cl]+, hydroxido analogue [2-
OH]+ (hydrolysis product of [2-I]+), glutathione adduct 2-SG, imino 
analogue [2-impy-I]+ were also investigated. After analysing the 
experimental results and investigating related literature, three possible 
mechanistic pathways for the hydrolysis of [2-I]+ in presence of GSH 
were proposed and then probed using a computational approach based on 
density functional theory (DFT). 
 
Figure 4.2. Molecular structures of the compounds studied in this chapter. 
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4.2. Experimental Section 
4.2.1. Materials 
The osmium complexes 2-I•PF6, 2-Cl•PF6, 2-impy-I•PF6, [2-OH]+ 
(solution), 2-SG, 2-NAC were synthesised and characterized by 
procedures described in Section 3.2.3 of Chapter 3. The more soluble 
complex 2-I•Cl was provided by Dr. Russell Needham (University of 
Warwick) for NMR experiments. In aqueous solution, both 2-I•PF6 and 
2-I•Cl dissociate to [2-I]+. Phosphate buffer solutions (including 
deuterated phosphate buffer solution) were prepared as described in 
Chapter 2, Section 2.12. Reduced glutathione (GSH), N-acetyl-L-
cysteine (NAC), and 1,4-dithiothreitol (DTT) were purchased from 
Sigma Aldrich. Sodium hydroxide, sodium chloride, sodium phosphate 
dibasic (Na2HPO4), sodium phosphate monobasic dehydrate 
(H2NaPO4·2H2O), and trifluoroacetic acid were purchased from Fisher 
Scientific. Solvents used for high performance liquid chromatography 
(HPLC) and liquid chromatography-mass spectrometry (LC-MS) were 
purchased from Fisher Scientific. Analysis grade doubly deionised water 
(18 M Ω cm-1) was obtained from either a Millipore Simplicity UV, or an 
USF Elga UHQ PS purification system. All other solvents and reagents 
for synthesis and analysis were purchased from commercial suppliers and 
used as received. 
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4.2.2. General Samples Preparation for HPLC Analysis 
The osmium complexes was generally dissolved in doubly deionised 
water to prepare solutions of osmium complexes (100 μM). GSH or other 
thiols (NAC, DTT) were dissolved in phosphate (300 mM) with sodium 
chloride (100 mM) buffer solution (pH = 7.40) with GSH concentrations 
of 0.3 mM - 30 mM. Then 3 mL osmium complex solution (100 μM in 
H2O) was mixed with 1 mL GSH solution (required concentration of 
GSH in 300 mM phosphate with 100 mM NaCl buffer solution) to give 
the experimental samples (75 μM osmium complex with increasing 
concentrations of GSH in 75 mM phosphate buffer and 25 mM NaCl, pH 
= 7.40 solution). The experimental samples were incubated at 310 K for 
the required time. 
4.2.3. pH-Dependent Reaction Studies by HPLC 
The experimental solutions containing [2-I]+ (100 μM) with GSH (200 
μM) in phosphate buffer (1 mM) at various pH values 2.43, 6.86 and 
10.05. All the solutions were incubated at 310 K for the required time (3 
h or 6 h). Due to the effect of different pH values on the performance of 
HPLC, each experimental solution (3 mL) was mixed with a high 
concentration phosphate buffer (1 mL, 300 mM phosphate buffer, pH = 
7.40) to modify the pH value to 7.40 prior to injection onto the HPLC 
instrument. 
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4.2.4. HPLC Analysis Methods 
An Agilent HPLC instrument with an Agilent ZORBAX Eclipse Plus 
C18 250 × 4.6 mm column was used to analyse the samples and reactions 
in this thesis. Mobile phases consisted of: (A) H2O with 0.1 % TFA, and 
(B) MeCN with 0.1 % TFA at 1 mL/min. In view of the different polarity 
of organo-osmium bearing azo ligands and imino ligands, the solvent 
gradient methods are different for these two kinds of complexes. Osmium 
imino complexes were analysed at a detection wavelength of 254 nm with 
reference wavelengths set to 360 nm and 510 nm while osmium azo 
complexes were analysed at 610 nm with a reference wavelength set to 
360 nm. 
Table 4.1. The solvent B (acetonitrile) gradient used in HPLC for analysing 
osmium azo and imino complexes. 
Time (min) 
% (B) for 
azo complexes 
% (B) for 
imino complexes 
0 10 20 
30 80 60 
40 80 60 
41 10 20 
55 10 20 
 
4.2.5. Quantitative Analysis of HPLC Traces 
After acquiring the HPLC traces (detection wavelength is 610 nm and 
reference wavelength is 360 nm) for each samples, the peak areas on 
HPLC were integrated. The proportionality between HPLC peak area (y) 
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and concentrations of osmium complexes (x) was analysed in Section 
3.3.6 of Chapter 3. These proportions were: 
for [2-Cl]+ is y = (81.47±0.11)x – (4.38±6.33);  
for [2-I]+ is y = (103.00±0.85)x – (126.09±16.61);  
for [2-OH]+ is y = (81.95±0.68)x – (28.86±34.96);  
for 2-SG is y = (84.63±0. 0.48)x – (81.96±32.96). 
Based on the proportionality for each complexes, concentrations of each 
osmium species were calculated from integrated peak areas and the 
percentage of each osmium species was then determined. The results 
were presented with error bar which was calculated from the uncertainty 
of equations.    
4.2.6. Reactions under N2 Atmosphere Studied by NMR 
The reactions of [2-I]+ with GSH were studied by 1H NMR analysis under 
N2 with to avoid its auto-oxidation of GSH by atmospheric O2. The N2-
protected NMR experiments was carried out with a specific NMR tube 
with a screw cap. The osmium complex 2-I•Cl (in aqueous solution, both 
2-I•PF6 and 2-I•Cl dissociate to [2-I]+) for experiments were transferred 
into the NMR tube first, which was then placed in a long two-neck glass 
flask. A vacuum pump was used to remove the air from both NMR tube 
and long glass flask, then refilled with N2. After repeating three times, 
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the NMR solvent was added and NMR tube cap was screwed while the 
N2 was kept flowing. In this reaction, samples containing [2-I]
+ (2 mM) 
with GSH (200 μΜ) in deuterated phosphate buffer solution (pH 7.40) 
were analysed in NMR experiments. The pH value of deuterated 
phosphate buffer solution was recorded as a pH meter reading pH* and 
corrected to pH using the equation pH = 0.929pH* + 0.418 due to effect 
of deuterium on the glass pH electrode. 
 
Figure 4.3. (a) The specific NMR tube, and (b) long two-neck flask for N2-protection 
in NMR experiments (from Chapter 2). 
 
4.2.7. DFT Calculations 
All the computational calculations were carried out by Prof. Emilia 
Sicilia (Università della Calabria, Italy).  The Gaussian 09 program was 
employed to carry out all calculations in the framework of the density 
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functional theory using the hybrid Becke three-parameter exchange 
functional19 and the Lee–Yang–Parr correlation functional, B3LYP.20 
Dispersion corrections for nonbonding interactions have been included 
through the Grimme approach using atom pair-wise additive schemes,21 
DFT-D3 method. 
LANL2DZ effective core potential has been used for the Os atom,22 along 
with the split valence basis set. The standard triple-ζ quality 6-311+G** 
basis sets of Pople and coworkers have been used for the atoms directly 
participating in the process, whereas in order to reduce the computational 
effort, the 6-31G* basis sets have been employed for peripheral atoms. 
Vibrational frequencies at the same level of theory have been calculated 
for both establishing the nature of intercepted stationary points as minima 
and transition states and calculating zero-point energy (ZPE) and Gibbs 
free energy corrections. The intercepted transition states are first order 
saddle points on a potential energy surface (PES) and their vibrational 
spectrum is characterized by one imaginary frequency, corresponding to 
a negative force constant, which means that in one direction, in the 
nuclear configuration space, the energy has a maximum, while in all the 
other directions the energy has a minimum. Furthermore, transition states 
have been carefully checked to be properly connected to the correct 
minima by IRC (intrinsic reaction coordinate) analysis.23,24  
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The Tomasi’s implicit Polarizable Continuum Model (PCM)25,26 as 
implemented in Gaussian 09 has been used to include the effects due to 
the presence of the solvent and the UFF set of radii has been used to 
build-up the cavity in which the solute molecules are accommodated. 
Solvation Gibbs free energies have been calculated performing single-
point calculations for all in vacuum stationary points structures in implicit 
water (ε=78.4) at the same level of theory. Enthalpies and Gibbs free 
energies have been obtained using standard statistical procedures27 at 298 
K and 1 atm from total energies, including zero-point, thermal and 
solvent corrections. As the free energy corrections in the Gaussian’s 
default standard state corresponds to an ideal gas at a standard pressure 
of 1 atm, the computed free energies have been converted28 to yield Gibbs 
energies with a solution phase standard state of 1 mol L-1 for all the 
species except water solvent. For water molecules a standard state of 55.5 
M has been used. That is, to the free energy of each species, as computed 
in Gaussian, a free energy correction term equal to RT ln(Vmolar gas/Vmolar 
solution), (R = gas constant, T = absolute temperature) has been added, 
where Vmolar gas is the volume occupied by one mole of ideal gas at the 
considered temperature, and Vmolar solution is the volume occupied by one 
mole of species in a standard solution of concentration of 1 mol L-1 . 
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4.3. Results 
In this section, the results of quantitatively studying the hydrolysis of [2-
I]+ in presence of GSH under various conditions (different reagent ratios, 
reaction time, pH values) are presented. However, the influence of other 
free thiols (N-acetyl-L-cysteine and 1,4-dithiothreitol) on the hydrolysis 
of [2-I]+ were explored. For comparison with [2-I]+, the behaviours of 
chlorido analogue [2-Cl]+, imino analogue [2-impy-I]+, hydroxido 
analogue [2-OH]+ and thiolato analogue 2-SG with GSH are also studied. 
Finally, three possible pathways for the hydrolysis of [2-I]+ in presence 
of GSH are probed by DFT calculations.  
 
4.3.1. Reactions of [2-I]+ with GSH 
 
Reactions of [2-I]+ with various concentrations GSH. The [Os (η6-p-
cymene) (4-(2-pyridylazo)-N,N-dimethylaniline)I]+ ([2-I]+) (75 μM) was 
incubated with various concentrations of GSH in phosphate (75 mM), 
NaCl (25 mM) buffer solution (pH = 7.40) for 24 h at 310 K. The 
concentrations of GSH are 0 mM, 0.08 mM, 0.38 mM, 0.75 mM, 0.94 
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mM, 1.88 mM, 3.75 mM, and 7.50 mM. As shown in Figure 4.4, several 
peaks were observed in the HPLC traces of the experimental samples and 
these peaks were identified based on their retention times, m/z values of 
LC-MS and HRMS. The characterisation data for each osmium species 
are summarized in Table 4.2. The HPLC peaks for each osmium species 
were integrated and quantified based on the proportionality between 
HPLC peak area and concentrations of osmium complexes (Section 
4.2.5). The quantitative analysis results are shown in Figure 4.5. 
From these results, it was shown that [2-I]+ was very stable under 
physiological conditions and that less than 1% of [2-I]+ was hydrolysed 
in absence of GSH, which indicated that [2-I]+ was inert towards H2O, 
phosphate and NaCl present. However, mixing with GSH dramatically 
decreased the percentage of [2-I]+. 83% [2-I]+ was left with 1 molar 
equivalent of GSH and only 22% [2-I]+ was left with 5 molar equivalent 
GSH. However, an increase of [2-OH]+ was observed with more added 
GSH. 15% [2-OH]+ with 1 mole equiv GSH and the percentage of [2-
OH]+ was up to 80 % with 10 mole equiv GSH. Surprisingly, when 25 
mole equiv GSH was added, the percentage of [2-OH]+ decreased to 35% 
and no [2-OH]+ was detected with neither 50 nor 100 mole equiv GSH.  
The decrease of [2-OH]+ was mainly due to the increase of the thiolato 
adduct 2-SG when co-incubated with higher concentrations of GSH. 35 % 
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2-SG was observed with 25 mole equiv GSH, and more than 95% 2-SG 
predominated when adding 50 or 100 mole equiv GSH. Besides, other 
osmium species like chlorido analogue [2-Cl]+ (due to presence of 25 
mM NaCl mimicking cytoplasmic physiological conditions) and 
formation of the sulfenate analogue 2-SOG was also observed.  
 
Figure 4.4. HPLC traces for reactions of complex [2-I]+ (75 µM) with various 
concentrations of GSH (0 - 7.5 mM) after incubation for 24 h at 310 K in phosphate 
buffer (75 mM, pH 7.40) with NaCl (25 mM). 




GSH (mM)  
Percentage of Osmium Species (%)a 
[2-I]+ [2-OH]+ [2-Cl]+ 2-SG 2-SOG 
0 98.65±3.45 1.65±0.05 0 0 0 
0.08 80.64±2.82 17.15±0.54 2.21±0.08 0 0 
0.38 21.68±0.76 73.6±2.31 4.72±0.17 0 0 
0.75 13.34±0.47 80.18±2.52 4.65±0.16 0.97±0.04 0.86±0.04 
0.94 13.08±0.46 80.24±2.52 4.26±0.16 0.99±0.04 1.43±0.06 
1.88 2.1±0.07 31.51±0.99 2.91±0.11 35.31±1.59 28.17±1.27 
3.75 0 0.23±0.07 0 96.17±4.33 3.60±0.15 
7.50 0 0.13±0.04 0 98.67±4.44 1.20±0.05 
a mean±sd from uncertainty of the equations (Section 4.2.5)  
Figure 4.5. Bar chart (top) and table (bottom) showing the percentage (%) of osmium 
species ([2-I]+, [2-Cl]+, [2-OH]+, 2-SG and 2-SOG) observed in reactions of [2-I]+ 
(75 µM) with various concentrations of GSH (0 - 7.5 mM) after incubation for 24 h 
at 310 K in in phosphate buffer (75 mM, pH 7.40) with NaCl (25 mM). 
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Table 4.2. Species identified by HPLC/LC-S/HRMS, their molecular formulae, calculated and observed m/z values, and HPLC retention times (RT). 
Species Formula Calculated m/z Observed m/z (LCMS) Observed m/z (HRMS) HPLC RT (min) 
[2-I]+ C23H28IN4Os
+ 679.0969 679.02 679.0952 23.02 
[2-Cl]+ C23H28ClN4Os
+ 587.1602 587.21 587.1594 19.67 
[2-impy-Cl]+ C24H29ClN3Os
+ 586.1649 586.23 586.1633 26.43* 
[2-impy-I]+ C24H29IN3Os
+ 678.1016 678.17 678.1028 41.42* 
[2-NO3]+ C23H28N5O3Os
+ 614.1802 614.11 614.1809 18.62 
[2-NAC + H+]+ C28H36N5O3SOs
+ 714.2147 714.16 714.2149 15.68 
[2-OH]+ C23H29N4OOs
+ 569.1951 569.17 569.1941 12.53 
[2-impy-OH]+ C24H30N3OOs
+ 568.1999 568.23 568.1999 11.30* 
[2-SG + H+]+ C33H44N7O6OsS
+ 858.2682 858.19 858.2693 13.29 
[2-impy-SG + H+]+ C34H45N6O6OsS
+ 857.2730 857.11 857.2738 12.44* 
[2-SOG + H+]+ C33H44N7O7OsS
+ 874.2632 874.15 874.2634 11.54 
*The method applied in HPLC separations for imino complexes is different from that for azo complexes (Section 4.2.4).   
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Time-dependent reactions of [2-I]+ with GSH.  [2-I]+ (75 μM) was 
incubated with 25 mole equiv GSH (1.88 mM) in phosphate (75 mM), 
NaCl (25 mM) buffer solution (pH 7.40) at 310 K and this reaction was 
analysed at different time points (5 min, 1 h, 3 h, 6 h, 18 h and 24 h). The 
reaction started with 100% [2-I]+, but after 1 h incubation periods, the 
percentage of [2-I]+ dramatically decreased to 83% with 16% hydrolysis 
product [2-OH]+ together with 1% of the chlorido analogue [2-Cl]+ 
(Figure 4.6). With increasing reaction time, 16% of the glutathione 
adduct 2-SG was observed after 6 h incubation. The sulfenate adduct 2-
SOG was the last osmium species to appear after a 18 h incubation period.  
Figure 4.6. HPLC traces for kinetic reactions of [2-I]+ (75 µM) with GSH (1.88 mM) 
at 310 K in in phosphate buffer (75 mM, pH 7.40) with NaCl (25 mM). 




Percentage of Osmium Species (%)a 
[2-I]+ [2-Cl]+ [2-OH]+ 2-SG 2-SOG 
5 min 100.00±3.50 0 0 0 0 
1 h 83.09±2.91 0.88±0.03 16.03±0.59 0 0 
3 h 50.45±1.77 3.58±0.11 30.38±1.12 15.59±0.70 0 
6 h 26.22±0.92 4.08±0.13 33.63±1.24 36.07±1.62 0 
18 h 5.62±0.20 1.69±0.05 18.47±0.68 70.47±3.17 3.75±0.17 
24 h 4.23±0.19 1.35±0.04 16.54±0.61 68.23±3.07 9.65±0.43 
a mean±sd from uncertainty of the equations (Section 4.2.5)  
Figure 4.7. Bar chart (top) and table (bottom) showing the percentage (%) of osmium 
species ([2-I]+, [2-Cl]+, [2-OH]+, 2-SG and 2-SOG) observed in the reaction of [2-
I]+ (75 μM) with GSH (1.88 mM) after 5 min, 1 h, 3 h, 6 h, 18 h, 24 h incubation at 
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pH-dependent reactions of [2-I]+ with GSH. [2-I]+ (100 μM) was 
incubated with 2 mol equiv of GSH (200 μM) under various pH values 
(pH = 2.43, 6.86 and 10.05) at 310 K and analysed with HPLC after 3 h 
or 6 h incubation. Less than 1% of the hydrolysis product [2-OH]+ was 
observed at pH 2.43 after either 3 h or 6 h incubation. However, 14% of 
[2-OH]+ was observed at a pH 6.86, and 45% [2-OH]+ at pH 10.05 after 
3 h incubation (Figure 4.10). It seems that acidic conditions inhibited the 
hydrolysis of [2-I]+ by reaction with GSH while basic conditions 
promoted the reaction. In control experiments of [2-I]+ incubated at pH 
10.05 without GSH, little hydrolysis was observed after 24 h (Figure 4.9). 
 
Figure 4.8. HPLC traces for the reactions of [2-I]+ (100 μM) with GSH (200 μM) at 
various pH values (2.43, 6.86, 10.05) in phosphate buffer (1 mM) after 3 h or 6 h 
incubation at 310 K. 
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Figure 4.9. HPLC traces for complex [2-I]+ (100 µM) after 5 min or 24 h incubation 
at 310 K for in basic phosphate buffer (1 mM, pH 10.05) solution. 
 
Time pH value 
Percentage of Osmium Species (%)a 
[2-I]+ [2-OH]+ 2-SG 
3 h 
2.43 99.40±3.48 0.60±0.02 0 
6.86 86.22±3.02 13.78±0.51 0 
10.05 55.39±1.94 44.61±1.65 0 
6 h 
2.43 99.26±3.47 0.74±0.03 0 
6.86 72.83±2.55 23.87±0.88 3.30±0.15 
10.05 24.24±0.85 72.85±2.70 2.91±0.13 
a mean±sd from uncertainty of the equations (Section 4.2.5)  
Figure 4.10. Bar chart (top) and table (bottom) showing percentage (%) of osmium 
species ([2-I]+, [2-OH]+ and 2-SG) observed in the reaction of [2-I]+ (100 μM) with 
GSH (200 μM) under different pH (2.43, 6.86 and 10.05) in phosphate buffer (1 mM) 
after 3 h or 6 h incubation at 310 K. 
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NMR studies of reactions of [2-I]+ with GSH under N2. The reaction 
of [2-I]+ (2 mM) with 0.1 mole equiv GSH (0.2 mM) in deuterated 
phosphate buffer (75 mM, pH 7.40) with NaCl (25 mM) was studied 
under an N2 atmosphere. Each spectrum for the reaction was recorded 
every 5 min on a AV-400 spectrometer at 298 K for 2 h. The spectra show 
significant level of [2-OH]+ (525 μM) was generated while little GSH 
was consumed. This suggests that the thiol might be regenerated during 
the reaction, playing a catalytic role in the hydrolytic process with a turn 
over frequency number of 1.97 h-1 (200 μM GSH catalyses 525 μM [2-
I]+ to hydrolyse in 90 min). 
 
Figure 4.11. The change in concentrations of GSH, [2-I]+ and [2-OH]+ throght a 2 h 
for the reaction of [2-I]+ (2 mM) with GSH (200 μM, 10% mole equiv) in phosphate 
buffer (75 mM, pH 7.40) at 298 K under N2 (mean±sd is based on three independently 
NMR peak integration). 




Figure 4.12. The NMR spectra and assignment for the reactions of [2-I]+ (2 mM) 
with GSH (200 μM, 10% mole equiv) in phosphate buffer (75 mM, pH 7.40) after 
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4.3.2. Reactions of [2-I]+ with Various Thiols 
 
The reactions of [2-I]+ (75 μM) with 10 mole equiv GSH, NAC or DTT 
(0.75 mM) in phosphate buffer (75 mM, pH 7.40) with NaCl (25 mM) 
were studied after 24 h incubation at 310 K. Significant amounts of the 
hydrolysis product [2-OH]+ were observed in all the reactions with free 
thiols GSH, NAC and DTT, which indicated that the thiol group (-SH) is 
the key functional group in reactions with [2-I]+.  
 
Figure 4.13. HPLC traces for the reactions of [2-I]+ (75 μM) with the thiols NAC, 
GSH or DTT (0.75 mM) in phosphate buffer (75 mM, pH 7.4) with NaCl (25 mM) 
after 24 h incubation at 310 K. 





Percentage of Osmium Species (%)a 
[2-I]+ [2-Cl]+ [2-OH]+ 2-SG 2-NAC 
Buffer 99.87±3.50 0 0.13±0.01 0 0 
GSH 16.07±0.56 4.15±0.13 78.80±2.92 0.98±0.04 0 
DTT 34.57±1.21 0 65.53±2.42 0 0 
NAC 10.13±0.35 3.32±0.11 57.04±2.11 0 29.51±1.33 
a mean±sd from uncertainty of the equations (Section 4.2.5)  
Figure 4.14. Bar chart (top) and table (bottom) showing percentage (%) of osmium 
species ([2-I]+, [2-Cl]+, [2-OH]+, 2-SG and 2-NAC) observed in the reaction of [2-
I]+ (75 μM) with thiols GSH, NAC or DTT (0.75 mM) in phosphate buffer (75 mM, 
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4.3.3. Reactions of Chlorido Complex [2-Cl]+ with GSH 
 
Reaction of [2-Cl]+ with various concentrations of GSH. [Os (η6-p-
cymene) (4-(2-pyridylazo)-N,N-dimethylaniline)Cl]+ ([2-Cl]+) (75 μM) 
was incubated with various concentrations of GSH in phosphate (75 mM), 
NaCl (25 mM) buffer solution (pH = 7.40) for 24 h at 310 K. The 
concentrations of GSH were 0, 0.08, 0.38, 0.75, 0.94, 1.88, 3.75, and 7.50 
mM. All these reactions were quantitatively analysed based on the 
proportionality between HPLC peak area and concentrations of osmium 
complexes (Section 4.2.5). The identification of each peak observed in 
HPLC traces is summarized in Table 4.2. 
Similar to the behaviour of [2-I]+ in reactions with GSH observed in 
Section 4.3.1, [2-Cl]+ was stable under physiological conditions but GSH 
significantly induced the hydrolysis of [2-Cl]+. Co-incubation with 1 
mole equiv GSH dramatically induced 91% [2-Cl]+ to hydrolyse. With 
addition of more GSH, the thiolate adduct 2-SG and sulfenate adduct 2-
SOG started to be observed. The highest percentage of 2-SOG (27%) 
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appeared when [2-Cl]+ was incubated with 25 mole equiv GSH and 2-
SG predominated when [2-Cl]+ reacted with 50 or 100 mole equiv GSH. 
 
Figure 4.15. HPLC traces for reactions of complex [2-Cl]+ (75 µM) with various 
concentrations of GSH (0 - 7.5 mM) in phosphate buffer (75 mM, pH 7.40) with NaCl 
(25 mM) after 24 h incubation at 310 K. 
 
 




Percentage of Osmium Species (%)a 
[2-Cl]+ [2-OH]+ 2-SG 2-SOG 
0 92.55±2.91 7.45±0.28 0 0 
0.08 9.36±0.29 90.64±3.35 0 0 
0.38 3.12±0.10 96.23±3.56 0.65±0.03 0 
0.75 8.11±0.25 72.23±2.67 16.68±0.75 2.98±0.13 
0.94 8.16±0.26 56.83±2.10 25.47±1.15 9.54±0.43 
1.88 0.45±0.01 1.64±0.06 70.72±3.18 27.19±1.22 
3.75 0 0.36±0.01 92.70±4.17 6.94±0.31 
7.50 0 0 95.64±4.30 4.36±0.20 
a mean±sd from uncertainty of the equations (Section 4.2.5)  
Figure 4.16. Bar chart (top) and table (bottom) showing percentage (%) of osmium 
species ([2-Cl]+, [2-OH]+, 2-SG and 2-SOG) observed in the reaction of [2-Cl]+ (75 
µM) with various concentrations of GSH (0 - 7.5 mM) in phosphate buffer (75 mM, 
pH 7.40) with NaCl (25 mM) after 24 h incubation at 310 K.  
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Time-dependent reactions of [2-Cl]+ with GSH. [2-Cl]+ (75 μM) was 
incubated with 12.5 mole equivalent GSH (0.94 mM) in phosphate (75 
mM), NaCl (25 mM) buffer solution (pH 7.40) at 310 K and this reaction 
was analysed at different time points (5 min, 1 h, 3 h, 6 h, 18 h and 24 h) 
by HPLC. After 1 h incubation more than 80% [2-Cl]+ underwent 
hydrolysis to generate [2-OH]+ and after 3 h incubation 14% 2-SG 
formed. The sulfenate complex 2-SOG was the last specie to appear after 
18 h incubation and there was still 28% 2-SOG present after 24 h 
incubation (Figure 4.17 and Figure 4.18). 
 
Figure 4.17. HPLC traces for kinetic reaction of [2-Cl]+ (75 µM) with GSH (0.94 
mM) at 310 K in in phosphate buffer (75 mM, pH 7.40) with NaCl (25 mM). 





Percentage of Osmium Species (%)a 
[2-Cl]+ [2-OH]+ 2-SG 2-SOG 
5 min 97.17±3.05 2.83±0.11 0 0 
1 h 16.21±0.51 83.79±3.10 0 0 
3 h 8.70±0.27 77.09±2.85 14.21±0.64 0 
6 h 6.34±0.20 68.10±2.52 25.56±1.15 0 
18 h 2.87±0.09 41.01±1.52 36.92±1.66 19.20±0.86 
24 h 1.96±0.06 36.81±1.36 33.25±1.50 27.98±1.26 
a mean±sd from uncertainty of the equations (Section 4.2.5)  
Figure 4.18. Bar chart (top) and table (bottom) showing the percentages (%) of 
osmium species ([2-Cl]+, [2-OH]+, 2-SG and 2-SOG) observed in the reaction of [2-
Cl]+ (75 μM) with GSH (0.94 mM) after 5 min, 1 h, 3 h, 6 h, 18 h, 24 h incubation at 
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4.3.4. Reactions of Imino Analogue [2-impy-I]+ with GSH 
 
[2-impy-I]+ (75 μM) was incubated with 1 or 2 mole equiv GSH (75 μM 
or 150 μM) in phosphate (75 mM), NaCl (25 mM) buffer solution (pH 
7.40) at 310 K and these reactions were analysed at different time points 
(5 min, 3 h, 24 h) by HPLC analysis. In view of the different chemical 
properties of imino analogue, the method applied for HPLC analysis of 
these reactions was different from the method for analysing reactions of 
azo complexes ([2-I]+, [2-Cl]+) (Section 4.2.4). The peaks observed in 
the HPLC traces were identified and assigned based on the retention time 
and HRMS spectrometry which have been summarized at Table 4.2. 
The imino analogue [2-impy-I]+ showed a completely different 
behaviour to the azo complex [2-I]+ during its hydrolysis and reactions 
with GSH. Firsly, [2-impy-I]+ is not as stable as [2-I]+ under 
physiological conditions. After 3 h incubation in absence of GSH, almost 
half [2-impy-I]+ hydrolysed to [2-impy-OH]+. More surprisingly, co-
incubation with GSH did not increase the extent of hydrolysis of [2-
impy-I]+ after either 3 h or 24 h. However, the extent of formation of the 
thiolate adduct 2-impy-SG dramatically increased even with 1 mole 
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equiv GSH. In presence of 2 mole equiv GSH, thiolate adduct 2-impy-
SG completely predominated in the reactions while similar 
predomination of 2-SG needed 50 mole equiv GSH to react with [2-I]+. 
Besides, no glutathione sulfenate adduct could be detected in the reaction 
of [2-impy-I]+ with GSH. 
 
Figure 4.19. HPLC traces for the reaction of [2-impy-I]+ (75 µM) with GSH (0 mM, 
0.08 mM, 0.15 mM) after (a) 3 h and (b) 24 h incubation at 310 K in phosphate buffer 
(75 mM, pH 7.40) with NaCl (25 mM). 
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4.3.5. Reactions of Hydroxido Complex [2-OH]+ with GSH 
 
In the reactions of GSH with [2-I]+ or [2-Cl]+, the hydrolysis product [2-
OH]+ was normally observed. Therefore the behaviour of [2-OH]+ was 
also explored in reactions with GSH. Thus the reactions of [2-OH]+ (75 
μM) with various concentration GSH (0, 0.08, 0.38, 0.75, 0.94, 1.88, 3.75, 
7.5 mM) in phosphate (75 mM), NaCl (25 mM) buffer solution(pH 7.40) 
were analysed after 24 h incubation at 310 K. All the peaks observed in 
HPLC traces were identified and assigned based on retention times and 
mass spectrometry (Table 4.2). Complex [2-Cl]+ was observed when [2-
OH]+ was incubated in NaCl (25 mM) solution without GSH, which 
demonstrated that [2-OH]+ could react with Cl- to generate [2-Cl]+. Then 
[2-OH]+ was incubated in KI (25 mM) in phosphate (75 mM) buffer 
solution (pH 7.40) and [2-I]+ was observed after 24 h incubation at 310 
K. In presence of more than 10 mole equiv GSH, thiolate adduct 2-SG 
and sulfenate adduct 2-SOG were observed during the reactions (Figure 
4.20), similar to the reaction of [2-I]+ with GSH. 
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Figure 4.20. HPLC traces for reactions of complex [2-OH]+ (75 µM) with KI (25 
mM), NaCl (25 mM) or various concentrations of GSH (0 - 7.5 mM) with NaCl (25 
mM) after incubation for 24 h at 310 K in phosphate buffer (75 mM, pH 7.40). 
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4.3.6. Reactions of the Glutathione Adduct 2-SG with GSH 
 
Reactions of 2-SG with GSH in phosphate (75 mM), NaCl (25 mM) 
buffer solution (pH 7.40) were analysed after 24 h incubation at 310 K. 
All the peaks observed were identified and assigned based on retention 
times and mass spectrometry (Table 4.2). Complex 2-SG is quite stable 
in absence of GSH under physiological relevant conditions, but when 
mixed with GSH, the sulfenate analogue 2-SOG was observed, which 
might cause by the oxidative species from the reaction of GSH with 
dioxygen in the air. However, it was surprising that the hydroxido adduct 
[2-OH]+ was also observed during this reaction with GSH (Figure 4.21). 
 
Figure 4.21. HPLC traces for  the reactions of [2-SG]+ (75 µM) with GSH (0 mM, 
0.08 mM, 0.38 mM, 0.75 mM) after 24 h incubation at 310 K in phosphate buffer (75 
mM, pH 7.40) with NaCl (25 mM). 
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4.3.7. Hydrolysis Mechanism and DFT Calculations 
The hydrolysis of [2-I]+ in presence of GSH was probed using a 
computational approach based on DFT calculations carried out by Prof. 
Emilia Sicilia (Università della Calabria, Italy). Three different possible 
reaction mechanisms were analysed. These were chosen since they have 
been previously reported to occur in molecules related to [2-I]+, and 
included: 
1) Direct hydrolysis of the Os-I bond in presence of water, which 
occurs at normal physiological conditions for several 
organometallic complexes of the type [M (arene) (L-L’) X]+ 
(where M is, Os, Ru, Rh or Ir; arene, a polyhapto arene; L-L’, a 
chelating ligand; and X an halide);13,29-32 
2) Direct interaction of the metal ion centre with GSH, For example, 
[Ru (arene) (ethylenediammine) Cl] PF6 and its analogues form 
Ru-SG adducts through direct interaction with GSH, displacing the 
coordinated halide in the process. Thiolate adducts can then be 
oxidised in presence of O2, forming unstable Ru-SOG species that 
are easily hydrolysed.33 
3) Hydrolysis through redox mediation by the azo group, as organic 
diazenes structurally similar to the chelating ligand present in [2-
I]+ are known to catalyse the oxidation of GSH in presence of O2, 
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generating hydrazines and H2O2 during the process.
34,35 This 
reaction has also been observed when diazenes are coordinated to 
Ru(II) or Ir(III).36-38 
 
 
Figure 4.22. DFT analysis of the different reaction pathways for [2-I]+ with GSH 
(GS2- is deprotonated form of GSH). 
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Results obtained from DFT calculations showed differences in the energy 
barriers obtained for the three pathways proposed for the reaction (Figure 
4.22). Direct hydrolysis the in presence of water and interaction with 
GSH had relatively high energy barriers (25.4 and 23.2 kcal/mol, 
respectively). Moreover, direct interaction of GSH with Os(II) led to 
stable Os-SG adducts, and a possible hydrolysis of those species 
presented a much higher energy barrier (30.3 kcal/mol). On the contrary, 
the hydrolysis pathway considering the redox interaction between GSH 
and the azo ligand present in [2-I]+ showed the lowest initial energy 
barrier (19.4 kcal/mol). This allowed formation of a direct bond between 
GSH and the -N=N- bond present in [2-I]+, generating an area of high 
electronic density close to the Os centre which appared to destabilise the 
Os-I bond, and therefore facilitate hydrolysis (modelled as a second step 
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4.4. Discussion 
The organo-osmium anticancer complex [Os(η6-p-cym)(4-(2-
pyridylazo)-N,N-dimethylaniline)I]PF6 (2-I•PF6, also known as FY26) 
has been reported as a very promising next generation anticancer drug in 
view of its high potency in vitro and in vivo.2,3  [2-I]+ was relatively inert 
in solution under physiological conditions, but surprisingly released the  
iodido monodentate ligand very fast once uptaken into cancer cells.15 The 
intracellular tripeptide glutathione (GSH) was thought to be involved 
into this process and activate the prodrug [2-I]+ to the more reactive 
hydroxido adduct [2-OH]+.15 As part of the aim of exploring the 
mechanism of action of [2-I]+ in this thesis, hydrolysis studies of [2-I]+ 
in presence of GSH were studied in this Chapter, combining 
experimental (HPLC, NMR) and theoretical (DFT calculation) 
approaches. Based on the fundamental work in Chapter 3 of synthesis 
and characterization of the osmium complexes ([2-I]+, [2-Cl]+, [2-OH]+, 
2-SG) related to the reaction of [2-I]+ with GSH and build-up the   
proportionality between the HPLC peak area versus concentration of 
osmium species, the hydrolysis of [2-I]+ in presence of GSH was 
systematically studied and quantitatively analysed. On the basis of 
previous studies of the hydrolysis of metal complexes, three different 
hydrolysis modes were proposed for [2-I]+ and then these three possible 
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pathways were probed and analysed based on DFT calculations. Finally, 
the energy barriers of each pathway from the DFT calculations and the 
results of experiments were combined to present a reasonable mechanism 




The first pathway proposed for the hydrolysis of [2-I]+ involved the direct 
attack on the Os-I bond by H2O (Pathway 1), which occurs in many 
coordination complexes, such as cisplatin,39,40 and  several 
organometallic complexes of the type [M (arene) (L-L’) X]+ (where M is, 
Os, Ru, or Ir; arene, a polyhapto arene or Cp*; L-L’, a chelating ligand; 
and X an halide).29,32 The DFT calculations demonstrated that this 
pathway was thermodynamically possible with an energy barrier of 25.4 
kcal/mol. Meanwhile, the experimental results obtained for [2-I]+ and its 
chlorido analogue [2-Cl]+ in the absence of GSH were consistent with the 
DFT calculations performed. After 24 h incubation under physiological 
conditions, there was 0.13% (Figure 4.5) and 7.45% (Figure 4.16) 
hydrolysis of [2-I]+ and [2-Cl]+, respectively. However, the degree of 
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hydrolysis is quite low, and the energy barrier for this pathway seems 
relatively too high to contribute the whole hydrolysis of [2-I]+ withn cells. 
Especially in comparison with the dramatically increased hydrolysis in 
presence of GSH, there should be other more feasible pathways which 




The second pathway proposed for the hydrolysis of [2-I]+ with GSH 
present involves GS2- (deprotonated GSH) attacking the Os-I bond to 
from thiolate adduct 2-SG and then the H2O attacking the Os-S bond to 
generate the hydrolysis product [2-OH]+ (Pathway 2). This pathway is 
inspired from reported studies on [Ru (arene) (ethylenediammine)Cl] PF6 
and its analogues which form Ru-SG adducts through its direct 
interaction with GSH, displacing the coordinated halide ligand in the 
process. Thiolato adducts can then be oxidised in presence of O2, forming 
unstable Ru-SOG species that are easily hydrolysed.33 The DFT 
calculations indicated that this pathway is thermodynamically possible 
with an energy barrier 23.2 kcal/mol for GS2- attacking Os-I bond and 
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30.3 kcal/mol for H2O attack on the Os-S bond. The experimental results 
appear to support this pathway. 2-SG was observed in the reaction of [2-
I]+ with GSH (Figure 4.5), which suggested that it was possible for GSH 
to attack the Os-I bond. The sulfenate analogue 2-SOG and hydrolysis 
product [2-OH]+  were observed as products from the co-incubation of 
2-SG with GSH (Figure 4.21), which was quite similar to reactions of a 
Ru arene  thiolate adduct33,41 and indicated that [2-I]+ can undergo 
hydrolysis through this pathway. However, the energy barrier for H2O 
attack on the Os-S bond in this pathway was even higher than that for 
H2O directly attacking Os-I in Pathway 1. Only a very small amount 
(less than 2%) hydrolysis product [2-OH]+ was observed from the 
reaction of 2-SG with or without GSH. The same problem was observed 
for Pathway 2 as with Pathway 1 with H2O directly attacking Os-I. Both 
these two pathways were thermodynamically possible, but quite a small 
percentage hydrolysis product would be generated from them due to their 
high energy barriers. In the kinetic reaction of [2-I]+ with GSH, [2-OH]+ 
was observed at the 5 min time point ahead of 2-SG which was observed 
at the 3 h time point. This result did not agree with Pathway 2 in which 
[2-OH]+ was generated from H2O attacking Os-S bond in 2-SG. Thus 
Pathway 2 was not the main contributor to [2-I]+ hydrolysis and a more 
novel mechanism of hydrolysis of  [2-I]+ to give [2-OH]+ in presence of 
GSH was expected. 




The third pathway proposed for the hydrolysis of [2-I]+ with GSH 
involved attack by GS2- (deprotonated GSH) on the -N=N- azo bond to 
form sulfenylhydrazide intermediates 2-GS/NN followed by attack of 
H2O to the Os
II centre to produce the hydrolysis product [2-OH]+ 
(Pathway 3). The reduction of the azo bond potentially affected the 
strength of Os-I bond and made it easier to be attacked by H2O. As the 
DFT calculations for Pathway 3 have shown, this pathway was 
thermodynamically possible with an energy barrier 19.0 kcal/mol for 
GS2- attacking the -N=N- azo bond and 13.9 kcal/mol for H2O attacking 
the Os-I bond in the sulfenylhydrazide intermediate 2-GS/NN to produce 
the hydrolysis product [2-OH]+. It was very clear that the energy barriers 
in Pathway 3 (19.0 kcal/mol, 13.9 kcal/mol) were much lower than those 
of Pathway 1 (25.4 kcal/mol) and Pathway 2 (23.2 kcal/mol, 30.3 
kcal/mol), which indicated the Pathway 3 was more likely for the 
reaction of [2-I]+ with GSH and mainly contribute to the hydrolysis of 
[2-I]+ in cells. Meanwhile, the proposed mechanism in Pathway 3 could 
also reasonably explain the behaviours observed in HPLC and NMR 
experiments. The key step in Pathway 3 is the thiol group in GSH 
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attacking the -N=N- azo bond. Other thiols like N-acetyl-cysteine (NAC) 
and dithiothreitol (DTT) also dramatically induce hydrolysis of [2-I]+ 
confirming the importance of thiol group in the reaction. For confirming 
the importance of -N=N- azo group, reactions of chlorido [2-Cl]+ and 
imino [2-impy-I]+ complexes with GSH were also studied to compare 
with [2-I]+. Indeed, [2-Cl]+ had a similar hydrolysis behaviour as [2-I]+. 
The difference between [2-Cl]+ and [2-I]+ was that the chlorido complex 
seemed to be more active in view of the different strength of the Os-
halide bond. On the contrary, co-incubation with GSH does not increase 
the degree of hydrolysis of imino complex [2-impy-I]+. The pH influence 
on the reaction of [2-I]+ with GSH demonstrated that little hydrolysis 
occurred at low pH (2.43) and an increase of pH to 6.86 or 10.05 can 
induce a higher extent of hydrolysis of [2-I]+ in reactions with GSH. The 
inhibition in acidic conditions might be related to the lack of 
deprotonation of GSH to GS2- which is a key species to react with [2-I]+ 
according to Pathway 3. The thiol group in GSH has a relatively high 
pKa value of 9.65
42,43 and little deprotonated GS2- (dissociation 
percentage is less than 10-6) would be present at pH 3 to attack [2-I]+ and 
induce hydrolysis. While at pH 6.86 (0.16 % deprotonated GS2-) and at 
pH 10.05 (71 % deprotonated GS2-), there are enough active deprotonated 
GS2- to attack azo bond to induce its hydrolysis. Moreover, the catalytic 
nature of GSH-induced hydrolysis of [2-I]+ proposed has been 
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demonstrated in the NMR experiments and the catalytic nature (TOF = 
1.97 h-1) of GSH inducing the hydrolysis of [2-I]+ was observed (Figure 
4.11), which is consistent with the mechanism of action proposed in 
Pathway 3.  
On considering the computational and experimental results, the Pathway 
3 of deprotonated GS2- attacking the azo bond in [2-I]+ seems more likely 
to mainly contribute the hydrolysis of [2-I]+. This pathway provides a 
novel mechanism of hydrolysis based on azo ligands in coordinated 
complexes. Azo compounds have a wide range of medical applications. 
For example,  phenazopyridine is used in conjunction with an antibiotic 
or other anti-infective medication at the beginning of treatment to help 
provide immediate symptomatic relief (more information regarding azo 
compounds can be found in Section 1.4.1 of Chapter 1).44 The 
phenomenon of thiols attacking -N=N- azo bonds has been observed for 
both organic and inorganic azo compounds.35,36,38 Through being 
attacked by thiols, diamide (CH3)2NCON=NCON(CH3)2 and azoester I 
were reported to rapidly oxidize GSH to GSSG within human red blood 
cells.45-47 Due to being attacked by the cysteine residue, the diamide 
(CH3)2NCON=NCON(CH3)2 was found to inactivate active transport in 
the E.coli membrane vesicle.48 Based on a similar behaviour of azo bond 
being attacked by thiols, azo group linked dinuclear Ir(III) and Ru(II) 
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complexes have been developed as intracellular thiol probes.36,49,50 Azo 
ligands bearing half-sandwich ruthenium arene complex [Ru(η6-p-
cym)(4-(2-pyridylazo)-N,N-dimethylaniline)I]+ catalyse the oxidation of 
GSH to increase the intracellular ROS level and exhibit a high level of 
cytotoxicity towards cancer cells. In the mechanism of action, GSH 
reduces the azo bond in the ruthenium complexes and is a key step for 
the catalysis process.38 Although many systems of thiols attacking azo 
bond were reported, the key sulfenylhydrazide intermediates were rarely 
detected, which may be ascribable to short half-life. It is not surprising 
that the sulfenylhydrazide intermediate 2-GS/NN for the reaction of [2-
I]+ with GSH studied in this chapter has not been detected by 
chromatographic and NMR experiments. However, advanced X-ray 
absorption spectroscopy will be used to probe 2-GS/NN to confirm the 
mechanism of action presented here and related work will be introduced 
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4.5. Conclusions 
The mechanism of hydrolysis of [2-I]+ in presence of GSH has been 
explored in this Chapter 4 based on the fundamental work in Chapter 
3.  The proposed pathway, in which deprotonated GSH, the thiolato form 
GS2- reduces -N=N- azo bond to form the sulfenylhydrazide intermediate 
2-GS/NN and then H2O attacks the Os-I bond in the intermediate 2-
GS/NN to induce hydrolysis, has the lowest energy barrier according to 
DFT calculations, and is consistent with all the experimental data. As in 
the proposed pathway, the experimental results show the importance of 
the thiolate group and involvement of -N=N- function in the reaction with 
GSH, activating the hydrolysis of [2-I]+, and consistent with the 
behaviour of different free thiols and analogues of [2-I]+. Meanwhile, 
acidic conditions inhibit the hydrolysis process for [2-I]+ induced by 
GSH and basic conditions promote this reaction because of the presence 
of GSH’s deprotonated form GS2-, which is a key factor for attack on [2-
I]+. Then GSH can be regenerated after attacking -N=N- and and plays a 
catalytic role to activate the hydrolysis of [2-I]+. Based on all the 
experimental and computational approaches, the pathway for GSH attack 
on the -N=N- bond seems more likely to be the main contributor to the 
hydrolysis of [2-I]+ in the cellular-systems.  
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5.1. Introduction  
DNA is the target of many anticancer metallodrugs, 1-7 for example 
cisplatin,8-11 but the non-selectivity of such drugs to normal cells causes 
many side effects.12,13 This intracellular redox system is considered to be 
a novel target of anticancer drugs with higher selectivity. All cells require 
a strict redox balance and reactive oxygen species (ROS) play important 
roles in the function of cell metabolism and signal transduction.14,15 The 
characterization of cancer cells that undergo increased metabolism for 
higher energy and nutritional requirements requires a higher level of 
oxidative stress compared to healthy cells.16,17 Oxidative therapy is a 
method to increase significantly intracellular ROS levels and push cancer 
cells above a cellular tolerability threshold, while normal cells at lower 





Figure 5.1. Intracellular redox system. 
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The intracellular redox balance is normally maintained through a cell 
redox system in which glutathione (GSH, γ-Glu-L-Cys-Gly) reacts with 
ROS (H2O2 in Figure 5.1) and itself is oxidized to GSSG. Then GSH 
reductase catalyses electron transfer from NAD(P)H to GSSG producing 
NAD(P)+ and GSH.21-23 GSH is a tripeptide with a gamma peptide 
linkage between the carboxyl group of the L-glutamate side chain and the 
amine group of L-cysteine (Figure. 5.2).
24 It is generally maintained at an 
approximately 5 mM concentration level in mammal ion cells.25 The thiol 
group of GSH is the major source of non-protein thiols in the cell and 
reacts with ROS and complexes metal ions (Chapter 1, Section 1.6).26 
[Os (η6-p-cymene)(4-(2-pyridylazo)-N,N-dimethylaniline)I] PF6 (FY26, 
also named 2-I•PF6, which is dissociated to [2-I]+ in aqueous solution) 
was found to be involved in intracellular redox modulation and induce 
the superoxide production to kill cancer cells.27,28 The modification of 
intracellular glutathione level was able to affect the potency of 2-I•PF6 29 
and so interactions between 2-I•PF6 and GSH have become of significant 
interest. Thus this thesis is mainly concerned with studies of reactions 
between GSH with 2-I•PF6 as well as its related compounds. In Chapter 
4, studies of GSH promoting the hydrolysis of 2-I•PF6 were conducted 
and it was concluded that GS- catalysed the hydrolysis of 2-I•PF6 through 
attacking the azo bond -N=N- to form azo bond reduced intermediates in 
which  the  monodentate  halide  ligand  was  more   readily  replaceable   




Figure 5.2. The structures of compounds studied in EPR experiments. 
 
by H2O. It was interesting that under N2 protection, little GSH is 
consumed during the 2-I•PF6 hydrolysis process, but when the reaction 
was exposed to air GSH consumption was much faster (Chapter 4), even 
faster than the auto-oxidation of GSH without the osmium complex. Such 
results suggested that dioxygen plays important roles in the reaction of 2-
I•PF6 with GSH and free radicals could be generated. Following from the 
work in Chapter 4, in this Chapter 5, reactions between GSH with 2-
I•PF6 as well as related compounds are studied by electron paramagnetic 
resonance (EPR) to detect the free radicals. A problem for these studies 
was the poor solubility of 2-I•PF6 in aqueous solution. In order to 
improve its solubility, the anion of 2-I•PF6 was exchanged with Cl- 
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through anion-exchange chromatography to produce 2-I•Cl to replace 2-
I•PF6 (in aqueous solution, both 2-I•Cl and 2-I•PF6 dissociate to [2-I]+). 
The reactions of GSH with the chlorido analogue 2-Cl•PF6, hydroxido 
analogue [2-OH]+, imino analogue 2-impy-Cl•PF6, glutathione adduct 
2-SG, non-substituted analogue 1-Cl•PF6 and free ligand AZPY-NMe2 
are also studied by EPR. Apart from free radicals, other proposed 
products such as oxidized glutathione (GSSG) and hydrogen peroxide are 
also detected. Then DFT calculations were used to probe the possible 
intermediates for the free radicals production and finally a potential 
mechanism of action is proposed.  
EPR, also called ESR (electron spin resonance), is widely applied in the 
studying chemical species with unpaired electrons. It was developed by 
Yevgeny Zavoisky at Kazan State University and Brebis Bleaney at the 
University of Oxford in 1944.30,31 The basic concepts of EPR are 
analogous to those of NMR (nuclear magnetic resonance), but EPR is 
concerned the interaction of the electron spin with the microwave 
magnetic vector whilst NMR studies the spin of atomic nuclei. Basically, 
EPR spectra are characterised with two parameters: hyperfine coupling 
constants and g values. The g value is equivalent to the chemical shift ( ) 
parameter in NMR spectroscopy. It is independent of the microwave 
frequency and determined from the equation below where h is Plank’s 
constant (6.626×10-34 J.s), υ is the frequency (MHz), β is the Bohr 
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Magneton constant (9.274×10-24 J.T-1) and B0 is the magnetic field (G). 
The g value is the centre of the EPR spectrum and normally close to the 
value of free electron gE = 2.0023. But every radical has its own g value 
that is considered as a radical “fingerprint”.  
 
Hyperfine coupling, which is equivalent to the J coupling in NMR, is 
caused by the coupling of an unpaired electron with a magnetically active 
nuclei with spin (I) greater than zero such as 1H (1/2), 15N (1) and 31P 
(1/2). The number of expected lines in an EPR spectrum can be deduced 
from 2nI+1, where n refers to the number of equivalent magnetically 
active nuclei. The standard free radical 4-hydroxy-2,2,6,6-tetramethyl-
piperidine-1-oxyl (Tempol) generates a triplet EPR spectrum, which is 
produced from the coupling of the unpaired electron with the nitroxidic 
nitrogen (14N) (Figure 5.3). 
 
Figure 5.3. Triplet EPR spectrum of the standard free radical Tempol, with hyperfine 
coupling to 14N indicated. 
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5.2. Experimental Section 
5.2.1. Materials 
Osmium complexes 2-I•PF6 (FY26), 2-Cl•PF6 (FY025), [2-OH]+, 2-
impy-Cl•PF6 and 1-Cl•PF6 were synthesized and and characterised as 
described in Chapter 3, Section 3.2. 2-I•Cl was provided by Dr. Russell 
Needham from the Sadler Group. AZPY-NMe2 (pyridine-2-azo-p-
dimethylaniline) was purchased from Alfa Aesar. L-glutathione (GSH), 
ammonium molybdate and bovine superoxide dismutase (SOD) were 
purchased from Sigma Aldrich (Gillingham, UK). Peroxide analytical 
test strips were purchased from Merck KGaA. The trapping agent 5-
(diethoxyphosphoryl)-5-methyl-1-pyrroline-N-oxide (DEPMPO) was 
purchased from Enzo Life Sicences. EPR tubes were purchased from 
Wilmad Labglass. Phosphate buffer solution contaning sodium chloride 
was prepared by dissolving disodium hydrogen phosphate (3.45 g, 24.3 
mmol), sodium dihydrogen phosphate dehydrate (0.89 g, 5.7 mmol) and 
sodium chloride (0.58 g, 10 mmol) (all purchased from Fisher Scientific) 
together in deionised water (100 mL). The pH of the phosphate buffer 
solution was measured using a bench top pH meter (Chapter 2) with 
glass electrode and read pH = 7.4(±0.1). If necessary, the pH of the buffer 
solution was adjusted by aqueous sodium hydroxide (100 mM) or nitric 
acid (3.6%) to pH = 10.8(±0.1) or pH = 3.8(±0.1), respectively. The 
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deuterated phosphate buffer solution for NMR experiments was prepared 
according to the description provided in Chapter 2.  Sodium hydroxide 
and nitric acid were purchased from Fisher Scientific. Metal trace basis 
salts including disodium hydrogen phosphate, sodium dihydrogen 
phosphate dehydrate and sodium chloride were purchased from Sigma-
Aldrich and the no-metal absolute buffer solution was prepared in the 
same manners as the general buffer solution.    
 




- trapped by DEPMPO. 
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5.2.2. Radical Trapping 
In all the free radical detection experiments described in this chapter, 
DEPMPO was used as spin trap.32-34 As shown in Scheme 5.1, DEPMPO 
is capable of trapping HO• radical yielding an 8-peak spectrum 
(DEPMPO-OH),32,35 O2
-• radical yielding a 12-peak spectrum 
(DEPMPO-OOH),35 H• radical yielding a 16-peak spectrum (DEPMPO-
H),35 GS• (DEPMPO-SG) radical yielding an 8-peak spectrum,36 (the 
structure of GSH is provided in Figure 5.2), •SO3
- (DEPMPO-SO3
-) 
radicals yielding a 12-peak spectrum36 and •CO2
- (DEPMPO-CO2
-) 
radicals yielding a 12-peak spectrum.34,36 
5.2.3. Sample Preparation 
The samples were generally prepared by mixing 3 mL of 1.33 mM 
osmium compounds (2-I•PF6, 2-I•Cl, 2-Cl•PF6, [2-OH]+, 2-impy-
Cl•PF6 and 1-Cl•PF6) in deionised water with 1 mL of a 4 mM GSH 
solution in stock phosphate buffer solution ( Chapter 5, Section 5.2.1). 
The solutions were heated at 310 K for 1 h (samples of 1-Cl•PF6 were 
incubated for 30 min since it is unstable in aqueous solution) and the air 
bubbling into the solution was achieved with a long needle during the 
incubation (Figure 5.4a).  When the samples needed to be protected by 
N2, a vacuum pump was used to remove all the air from the two-neck 
flask which was then refilled with N2. 
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Figure 5.4. a) Preparation of samples with bubbling air; b) Preparation of sample 
with N2 protection; c) The EPR tube filled with sample; d) The EPR instrument. 
 
The osmium complex and GSH solutions were bubbled with N2 
separately for more than 1 h to remove the dissolved air from the 
solutions. Under N2 flow, the degassed osmium complex solution and the 
degassed GSH solution were mixed in the N2-filled two-neck flask. 
Finally a closed one neck of the flask and the other neck were protected 
by a balloon which was filled with N2 (Figure 5.4b). Solutions were 
heated at 310 K for 1 h. Subsequently, the solution was transferred to the 
EPR lab and 1 mL solution was taken out with a syringe to mix with 
DEPMPO (4.72 mg, 20 μmol). Immediately, the solution with DEPMPO 
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was transferred to quartz capillary EPR tube (I.D. 1.0 mm; O.D. 1.2 mm; 
Wilmad Labglass; Figure 5.4c) for loading on the EPR instrument 
(Figure 5.4d). In the experiments involving reaction of 2-I•PF6, 2-
Cl•PF6 and AZPY-NMe2 with GSH, in view of their poor solubility in 
water, ultrasonic irradiation was used to promote dissolution of the 
compounds. If the compounds could not be dissolved completely, turbid 
2-I•PF6, 2-Cl•PF6 or AZPY-NMe2 solutions were mixed with GSH 
solution for EPR experiments. 
 
5.2.4. Spectrum Acquisition and Simulation 
Dr. Ben Breeze from Department of Physics of the University of 
Warwick provided much help and guidance with the operation of the EPR 
instrument. All EPR spectra were recorded on a 9.5 GHz X-band EPR 
spectrometer at ambient temperature (ca. 291 K). The sweep time for 
each scanning was 83.89 seconds and every 10 scans produced an 
average spectrum which was recorded. Thus in the kinetic EPR 
experiments, one spectrum took about 15 min to be recorded. More 
specific details are described in Chapter 2. All the spectra were analysed 
and simulated using the EASYSPIN software.37 Three independent 
experiments and simulations combining spectra resolution (2048 data 
points in 200 G) were used to calculated error bars. 
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Figure 5.5. a) The parameters for EPR spectrum acquisition; b) The command for 
EPR spectrum (DEPMPO-OH) simulation; c) The parameters for EPR spectrum 
simulation. 
 
5.2.5. Effect of Superoxide Dismutase on Radical Generation  
The buffer solution used in this experiment was phosphate (75 mM) 
buffer solution with sodium chloride (25 mM), pH 7.4. Bovine 
superoxide dismutase (SOD) was dissolved in the buffer solution and its 
concentration (60 μM) was calculated from UV-vis absorbance at 258 
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nm (εmM = 10.3) from with Beer–Lambert law.38 Then 2 mL of SOD 
solution (60 μM) was mixed with 1.5 mL of [2-OH]+ (2.66 mM) and 0.5 
mL GSH solution (8 mM) to prepare the experimental sample and the 
control sample was prepared by mixing 2 mL buffer solution with 1.5 mL 
[2-OH]+ (2.66 mM) and 0.5 mL GSH solution (8 mM). Samples were 
incubated at 310 K for 1 h; 1 mL of the solution was then mixed with 
DEPMPO (4.72 mg, 20 μmol), transferred to a quartz EPR tube, and then 
loaded into the EPR instrument (i.e., the same procedure as that described 
in Section 5.2.3).  
5.2.6. H2O2 Measurements 
5.2.6.1. H2O2 Test Strips 
The buffer solution used in this experiment was phosphate (75 mM) 
buffer solution with sodium chloride (25 mM), pH value 7.4. 2-I•PF6 
solution (200 μM) and GSH solution (600 μM) were prepared, and 5 mL 
of 2-I•PF6 solution (200 μM) and 5 mL GSH solution (600 μM) mixed 
to prepare the experimental sample. Then 5 mL 2-I•PF6 solution (200 μM) 
was mixed with 5 mL buffer solution, and 5 mL GSH solution (600 μM) 
with 5 mL buffer solution to prepare two control samples. These three 
samples were incubated at 310 K for 3 h and then peroxide test strips 
were left to soak in the samples for 15 s. The colours of the test strips 
were then compared to a standard chart.   
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5.2.6.2. Ammonium Molybdate Method 
The buffer solution used in this experiment is the phosphate (75 mM) 
buffer solution with sodium chloride (25 mM), pH 7.4. 2-I•PF6 solution 
(200 μM), GSH solution (600 μM) and ammonium molybdate solution 
(32.4 mM) were prepared. Then 5 mL 2-I•PF6 solution (200 μM) and 5 
mL GSH solution (600 μM) were mixed to prepare the experimental 
sample. To prepare the two control samples 5 mL 2-I•PF6 solution (200 
μM) was mixed with 5 mL buffer solution, and 5 mL GSH solution (200 
μM) with 5 mL buffer solution. Incubated These three sample were 
incubated at 310 K for 5 min, 1 h, 2 h, 3 h and 4 h, and then 0.5 mL 
sample was removed and mixed with 0.5 mL ammonium molybdate 
solution (32.4 mM), and scanned by UV-vis to determine the absorbance 
 
Figure 5.6. The procedure for using ammonium molybdate to detect the H2O2 
production during the reactions of 2-I•PF6 with GSH. 
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changes at 405 nm in order to determine the amount of H2O2 presented.
39 
The calibration curve for the relationship between concentration of H2O2 
(y AU) and the absorbance change at 405 nm (x μM) was y = 0.0123x + 
0.0305 (r = 0.9996, n = 11).40 The sample containing 2-I•PF6 and GSH 
but no ammonium molybdate solution were also scanned by UV-Vis as 
the control sample. This experimental procedure is summarized in 
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5.3. Results 
In this section, the results of free radicals detection using the spin-trap 
DEPMPO trapping radicals generated from the reactions of osmium 
complexes (as well as free ligands) with GSH under various conditions 
(different pHs, air or N2 atmosphere) is presented. The osmium 
complexes include 2-I•PF6, chloride-counterion form 2-I•Cl (Improved 
solubility), chlorido analogue 2-I•PF6, hydroxido analogue [2-OH]+, 
imino analogue 2-impy-Cl•PF6 and no-substituted analogue 1-Cl•PF6. 
Apart from free radicals, other proposed products such as oxidized 
glutathione (GSSG) and hydrogen peroxide were also detected, and 
finally a favourable mechanism for this reaction system is proposed.     
 
5.3.1. Reactions of 2-I•PF6 with GSH 
 
5.3.1.1 pH = 7.4  
A turbid solution of 2-I•PF6 (1 mM) with GSH (1 mM) in sodium 
chloride (25 mM) and  phosphate buffer (75 mM), pH 7.4, was prepared. 
This was incubated at 310 K for 1 h and then DEPMPO (20 mM) was 
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added as a spin trap. The sample was then scanned by EPR for 3 h at 298 
K, but no free radical spectrum was observed (Figure 5.7). 
Figure 5.7. Spectra after 15 min and 3 h EPR scanning for sample of 2-I•PF6 (1 mM) 
with GSH (1 mM) and DEPMPO (20 mM)  in sodium chloride (25 mM) and  
phosphate buffer (75 mM) at pH = 7.4. 
 
5.3.1.2 pH = 10.8  
A turbid solution of 2-I•PF6 (1 mM) with GSH (1 mM) in sodium 
chloride (25 mM) and  phosphate buffer (75 mM) at pH = 10.8 was 
prepared. Then the solution was incubated at 310 K for 1 h and DEPMPO 
(20 mM) was added as spin trap. The sample was scanned by EPR for 3 
h at 298 K, but no free radical spectrum was observed (Figure 5.8). 
 
Figure 5.8. Spectra after 15 min and 3 h EPR scanning for sample of 2-I•PF6 (1 mM) 
with GSH (1 mM) and DEPMPO (20 mM) in sodium chloride (25 mM) and  
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5.3.2. Reactions of 2-I•Cl with GSH 
 
 
5.3.2.1. pH = 3.8 
A solution of 2-I•Cl (1 mM) with GSH (1 mM) in sodium chloride (25 
mM) and phosphate buffer (75 mM) at pH = 3.8 was prepared and 
incubated at 310 K for 1 h before DEPMPO (20 mM) was added as a spin 
trap. The sample was then kinetically scanned on EPR for 3 h at 298 K 
but no free radical spectrum was observed (Figure 5.9) 
 
Figure 5.9.  Spectra after 15 min and 3 h  scanning for sample of 2-I•Cl (1 mM) with 
GSH (1 mM) and DEPMPO (20 mM)  in sodium chloride (25 mM) and phosphate 
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5.3.2.2. pH = 7.4 
A solution of 2-I•Cl (1 mM) with GSH (1 mM) in sodium chloride (25 
mM) and  phosphate buffer (75 mM) at pH = 7.4 was incubated at 310 K 
for 1 h and then DEPMPO (20 mM) was added as spin trap. The sample 
 
Figure 5.10.  EPR spectra for sample of 2-I•Cl (1 mM) with GSH (1 mM) and 
DEPMPO (20 mM)  in sodium chloride (25 mM) and  phosphate buffer (75 mM) at 
pH = 7.4 after 15 min, 1 h, 3 h, 6 h, 9 h and 12 h scanning at 298 K. The set of signal 
labelled with green  was assigned to DEPMPO-OH, the set of signal labelled with 
red  was assigned to DEPMPO-H and the set of signal labelled with purple  was 
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was scanned by EPR for 12 h at 298 K. An 8-peak spectrum was observed 
at the beginning (from 15 min to 3 h) and then an 18-peak spectrum 
started to be observed after 9 h scanning (Figure 5.10).From the 
simulation results (Section 5.3.9), the 8-peak spectrum was assigned to 
DEPMPO-OH (green ) and the 18-peak spectrum was assigned to 
mixture of DEPMPO-OH (green ), DEPMPO-H (red ) and DEPMPO-
OOH (purple ). 
 
 
5.3.2.3. pH = 10.8 
A solution of 2-I•Cl (1 mM) with GSH (1 mM) in sodium chloride (25 
mM) and  phosphate buffer (75 mM) at pH = 10.8 was incubated at 310 
K for 1 h and then DEPMPO (20 mM) was added as spin trap. The 
concentration of osmium complex was confirmed by ICP-OES (detection 
of Os) as 1.054 mM (more details of ICP-OES are provided in Chapter 
2). The sample had been scanned on EPR for 12 h at 298 K. During the 
scanning period, an 18-peak spectrum was continuously observed 
(Figure 5.11). From the simulation results (Section 5.3.9), the 18-peak 
spectrum was assigned to a mixture of DEPMPO-OH (green ), 
DEPMPO-H (red ) and DEPMPO-OOH (purple ). 
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Figure 5.11.  EPR spectra for sample of 2-I•Cl (1 mM) with GSH (1 mM) and 
DEPMPO (20 mM)  in sodium chloride (25 mM) and  phosphate buffer (75 mM) at 
pH = 10.8 after 15 min, 1 h, 3 h, 6 h, 9 h and 12 h scanning periods at 298 K. The set 
of signal labelled with green  was assigned to DEPMPO-OH, the set of signals 
labelled with red  was assigned to DEPMPO-H and the set of signals labelled with 
purple  was assigned to DEPMPO-OOH. 
 
 
5.3.2.4. Under N2 
Solutions of 2-I•Cl (1 mM) with GSH (1 mM) in sodium chloride (25 
mM) and  phosphate buffer (75 mM) at pH = 3.8, 7.4 and 10.8 were 
prepared separately under N2 protection and then incubated at 310 K for 
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1 h before DEPMPO (20 mM) was added as spin trap. The samples were 
scanned by EPR for 3 h at 298 K, but no free radical spectra were 
observed (Figure 5.12).  
 
Figure 5.12. EPR spectra for sample of 2-I•Cl (1 mM) with GSH (1 mM) and 
DEPMPO (20 mM)  in sodium chloride (25 mM) and phosphate buffer (75 mM) at 




Figure 5.13 EPR spectra samples of 2-I•Cl (1 mM) in absence of GSH or GSH (1 
mM) in absence of 2-I•Cl with DEPMPO (20 mM) in sodium chloride (25 mM) and 
phosphate buffer (75 mM) at pH = 10.83 after 3 h scanning at 298 K. 
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5.3.2.5 GSH Absence or 2-I•Cl Absence Controls 
A solution of 2-I•Cl (1 mM) without GSH (1 mM) in sodium chloride 
(25 mM) and phosphate buffer (75 mM) at pH = 10.8 and a solution of 
GSH (1 mM) without 2-I•Cl in sodium chloride (25 mM) and phosphate 
buffer (75 mM) at pH = 10.8 were incubated at 310 K for 1 h and then 
DEPMPO (20 mM) was added as spin trap. The sample was scanned by 





5.3.2.6. In Trace Metal Basis Buffer   
Metal ions especially Cu2+ are reported to catalyse the oxidation of GSH 
by dioxygen.41 In general phosphate buffer solution, there are residual 
trace metal ion which have the potential to affect the reactions of osmium 
complexes with GSH. To eliminate the interference of residual metal ions, 
a sample of 2-I•Cl (1 mM) with GSH (1 mM) in sodium chloride (25 mM) 
and phosphate trace metal basis buffer (75 mM) solution at pH = 10.8 
was incubated at 310 K for a 1 h duration and then DEPMPO (20 mM) 
was added as a spin trap. The sample was scanned by EPR for a period 
of 12 h at 298 K. The same result as for the corresponding sample in 
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general buffer solution with residual metal ions, an 18-peak spectrum, 
was continuously observed (Figure 5.14). From the simulation results 
(Section 5.3.9), this 18-peak spectrum was assigned to a mixture of 
DEPMPO-OH (green ), DEPMPO-H (red ) and DEPMPO-OOH 
(purple ). 
 
Figure 5.14. EPR spectra for sample of 2-I•Cl (1 mM) with GSH (1 mM) and 
DEPMPO (20 mM) in trace metal basis sodium chloride (25 mM) and phosphate 
buffer (75 mM) solution at pH = 10.83 after 15 min, 1 h, 3 h, 6 h, 9 h and 12 h  
scanning at 298 K. The set of signals labelled with green  was assigned to 
DEPMPO-OH, the set of signals labelled with red  was assigned to DEPMPO-H 

























Chapter 5: Free Radicals Detection 
224 
5.3.3. Reactions of 2-Cl•PF6 with GSH 
 
 
5.3.3.1. pH = 3.8 
A solution contatning 2-Cl•PF6 (1 mM) with GSH (1 mM) in sodium 
chloride (25 mM) and  phosphate buffer (75 mM) at pH = 3.8 was 
incubated at 310 K for 1 h and then DEPMPO (20 mM) was added as 
spin trap. The sample was scanned by EPR for 3 h at 298 K, but no free 
radical spectrum was observed (Figure 5.15). 
 
Figure 5.15.  EPR spectra of a sample of 2-Cl•PF6 (1 mM) with GSH (1 mM) and 
DEPMPO (20 mM)  in sodium chloride (25 mM) and  phosphate buffer (75 mM) 
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5.3.3.2. pH = 7.4 
A solution of 2-Cl•PF6 (1 mM) with GSH (1 mM) in sodium chloride (25 
mM) and  phosphate buffer (75 mM) at pH = 7.4 was incubated at 310 K 
for 1 h and then DEPMPO (20 mM) was added as spin trap. The sample 
scanned on EPR for 12 h at 298 K and an 8-peak spectrum was observed  
 
Figure 5.16. EPR spectra for sample of 2-Cl•PF6 (1 mM) with GSH (1 mM) and 
DEPMPO (20 mM)  in sodium chloride (25 mM) and phosphate buffer (75 mM) at 
pH = 7.40 after 15 min, 1 h, 3 h, 6 h, 9 h and 12 h scanning at 298 K. The set of signal 
labelled with green  was assigned to DEPMPO-OH, the set of signal labelled with 
red  was assigned to DEPMPO-H and the set of signal labelled with purple  was 
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from 15 min to 6 h scanning along with an 18-peak spectrum appearing 
after 9 h scanning (Figure 5.16). From the simulation results (Section 
5.3.9), the 8-peak spectrum was assigned to DEPMPO-OH (green ) and 
the 18-peak spectrum was assigned to mixture of DEPMPO-OH (green 
), DEPMPO-H (red ) and DEPMPO-OOH (purple ).  
 
5.3.3.3. pH = 10.8 
A solution of 2-Cl•PF6 (1 mM) with GSH (1 mM) in sodium chloride (25 
mM) and  phosphate buffer (75 mM) solutions at pH = 10.8 was 
incubated at 310 K for 1 h and then DEPMPO (20 mM) was added as 
spin trap. The sample was scanned by EPR for 12 h at 298 K. At the 
beginning, an 18-peak spectrum was observed but later some peaks (red
 and purple ) decreased in intensity whilst that of others (green ) 
increased. Finally, a 12-peak spectrum was observed (Figure 5.17). From 
the simulation (Section 5.3.9), the 18-peak spectrum was assigned to 
mixture of DEPMPO-OH (green ), DEPMPO-H (red ) and DEPMPO-
OOH (purple ball ) and the 12-peak spectrum was assigned to mixture 
DEPMPO-OH (green ball ) and DEPMPO-H (red ). 
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Figure 5.17.  EPR spectra for a sample of 2-Cl•PF6 (1 mM) with GSH (1 mM) and 
DEPMPO (20 mM)  in sodium chloride (25 mM) and phosphate buffer (75 mM) at 
pH = 10.8 after 15 min, 1 h, 3 h, 6 h, 9 h and 12 h scanning at 298 K. The set of signal 
labelled with green  was assigned to DEPMPO-OH, the set of signal labelled with 
red  was assigned to DEPMPO-H and the set of signal labelled with purple  was 
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5.3.3.4. Under N2 
Solutions of 2-Cl•PF6 (1 mM) with GSH (1 mM) in sodium chloride (25 
mM) and  phosphate buffer (75 mM) solution at pH values of 3.8, 7.4 and 
10.8 was prepared under N2 protection and incubated at 310 K for 1 h and 
then DEPMPO (20 mM) was added as spin trap. The sample was scanned 
by EPR for 3 h, but no free radical spectrum was observed (Figure 5.18). 
 
Figure 5.18.  EPR spectra for sample of 2-Cl•PF6 (1 mM) with GSH (1 mM) and 
DEPMPO (20 mM)  in sodium chloride (25 mM) and phosphate buffer (75 mM) 
solution at pH values of 3.8, 7.4 and 10.8 with the protection of N2 after 3 h scanning 
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5.3.4. Reactions of 2-impy-Cl•PF6 with GSH 
 
Solutions of 2-impy-Cl•PF6 (1 mM) with GSH (1 mM) in sodium 
chloride (25 mM) and  phosphate buffer (75 mM) at pH = 3.8, 7.4 and 
10.8 were incubated at 310 K for 1 h and then DEPMPO (20 mM) was 
added as spin trap. The sample was scanned by EPR for 3 h but no free 
radical spectrum was observed (Figure 5.19). 
 
Figure 5.19.  EPR spectra for sample of 2-impy-Cl•PF6 (1 mM) with GSH (1 mM) 
and DEPMPO (20 mM)  in sodium chloride (25 mM) and  phosphate buffer (75 mM) 
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5.3.5. Reactions of [2-OH]+ with GSH 
 
 
5.3.5.1. pH = 3.8 
A solution of [2-OH]+ (1 mM) with GSH (1 mM) in sodium chloride (25 
mM) and  phosphate buffer (75 mM) at pH = 3.8 was incubated at 310 K 
for 1 h and then DEPMPO (20 mM) was added as spin trap. The sample 
was scanned by EPR for 3 h at 298 K, but no free radical spectrum was 
observed (Figure 5.20). 
 
Figure 5.20.  EPR spectra for sample of [2-OH]+ (1 mM) with GSH (1 mM) and 
DEPMPO (20 mM)  in sodium chloride (25 mM) and  phosphate buffer (75 mM) at 
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5.3.5.2. pH = 7.4 
A solution of [2-OH]+ (1 mM) with GSH (1 mM) in sodium chloride (25 
mM) and  phosphate buffer (75 mM) solutions at pH = 7.4 was incubated 
at 310 K for 1 h. Then DEPMPO (20 mM) added as spin trap. 
 
Figure 5.21.  EPR spectra for sample of [2-OH]+ (1 mM) with GSH (1 mM) and 
DEPMPO (20 mM)  in sodium chloride (25 mM) and  phosphate buffer (75 mM) at 
pH = 7.4 after 15 min, 1 h, 3 h, 6 h, 9 h and 12 h  scanning at 298 K. The set of signal 
labelled with green  was assigned to DEPMPO-OH, the set of signal labelled with 
red  was assigned to DEPMPO-H and the set of signal labelled with purple  was 
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The sample was scanned by EPR for 12 h. An 18-peak spectrum was 
continuously observed (Figure 5.21) but as the reaction progressed one 
set of peaks (green ) increased in intensity whilst and the rest of the 
peaks decreased (red  and purple ). There was still an 18-peak 
spectrum even after 12 h. From the simulation results (Section 5.3.9), 
this 18-peak spectrum was assigned to mixture of DEPMPO-OH (green
), DEPMPO-H (red ) and DEPMPO-OOH (purple ). 
 
5.3.5.3. Effect of Superoxide Dismutase (SOD) 
A solution of [2-OH]+ (1 mM) with GSH (1 mM) in sodium chloride (25 
mM) and  phosphate buffer (75 mM) at pH = 7.4 was prepared and 
divided into two. To one portion, was added superoxide dismutase (30 
μM) and to the other, which served as a control, was added buffer. After 
incubation of these two samples at 310 K for 1 h was added DEPMPO 
(20 mM) as spin trap. These two samples were scanned by EPR. An 18-
peak spectrum was observed for the control sample and a 12-peak 
spectrum was observed for the sample containing superoxide dismutase 
(Figure 5.22). As the simulation results (Section 5.3.9) showed, the 18-
peak spectrum can be assigned to a mixture of DEPMPO-OH (green ), 
DEPMPO-H (red ) and DEPMPO-OOH (purple ) and the 12-peak 
spectrum observed for the sample containing SOD can be assigned to a 
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mixture of DEPMPO-OH (green ) and DEPMPO-H (red ), with an 
absence of peaks for  DEPMPO-OOH. This result supported the 
assignment of peaks labelled with purple  to DEPMPO-OOH. 
 
Figure 5.22.  Comparison of EPR spectra for samples of [2-OH]+ (1 mM) with GSH 
(1 mM) and DEPMPO (20 mM) in presence or absence of SOD (30 μM) in sodium 
chloride (25 mM) and phosphate buffer (75 mM) at pH = 7.4. 
 
 
Figure 5.23.  EPR spectra for samples of AZPY-NMe2 (1 mM) with GSH (1 mM) 
and DEPMPO (20 mM)  in sodium chloride (25 mM) and phosphate buffer (75 mM) 
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5.3.6. Reactions of AZPY-NMe2 with GSH 
 
Solutions of free ligand AZPY-NMe2 (1 mM) with GSH (1 mM) in 
sodium chloride (25 mM) and  phosphate buffer (75 mM) at pH = 3.8, 
7.4 and 10.8 were prepared and incubated at 310 K for 1 h and then 
DEPMPO (20 mM) was added as spin trap. The samples were scanned 
by EPR for 3 h, but no free radical species were observed (Figure 5.23). 
 
5.3.7. Reactions of 1-Cl•PF6 with GSH 
 
A solution of 1-Cl•PF6 (1 mM) with GSH (1 mM) in sodium chloride (25 
mM) and  phosphate buffer (75 mM) solutions at pH = 10.8 was prepared, 
incubated at 310 K for 30 min, and then DEPMPO (20 mM) was added 
as spin trap. The sample was scanned by EPR for 12 h. An 18-peak 
spectrum was observed after 15 min scanning at 310 K and then the 
spectrum decayed very rapidly (this may be ascribable the instability of 
1-Cl•PF6 in aqueous solution27). After a 9 h scanning period, only very 
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weak signals for radicals were observed (Figure 5.24). From the 
simulation results (Section 5.3.9), the 18-peak spectrum was assigned to 
the mixture of DEPMPO-OH (green ), DEPMPO-H (red ) and 
DEPMPO-OOH (purple ). 
 
Figure 5.24.  EPR spectra for sample of 1-Cl•PF6 (1 mM) with GSH (1 mM) and 
DEPMPO (20 mM)  in sodium chloride (25 mM) and  phosphate buffer (75 mM) at 
pH = 10.8 after 15 min, 1 h, 3 h, 6 h, 9 h and 12 h  scanning at 298 K. The set of 
signal labelled with green  was assigned to DEPMPO-OH, the set of signal labelled 
with red  was assigned to DEPMPO-H and the set of signal labelled with purple  
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5.3.8. Reactions of 2-SG with GSH 
 
Solutions of 2-SG (1 mM) with GSH (1 mM) in sodium chloride (25 mM) 
and  phosphate buffer (75 mM) at pH = 3.8, 7.4 and 10.8 were incubated 
at 310 K for 1 h and then DEPMPO (20 mM) was added as spin trap. The 
sample was scanned by EPR for 3 h but no free radical spectrum was 
observed (Figure 5.25). 
 
 
Figure 5.25.  EPR spectra for sample of 2-SG (1 mM) with GSH (1 mM) and 
DEPMPO (20 mM)  in sodium chloride (25 mM) and  phosphate buffer (75 mM) at 
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5.3.9. Simulation of EPR Spectra 
EPR experiments were conducted in this chapter to study reactions of the 
osmium complexes with GSH. An 8-peak spectrum was observed in the 
reactions of 2-I•Cl with GSH at pH = 7.4 (Section 5.3.2.2) and 2-Cl•PF6 
with GSH at pH = 7.4 (Section 5.3.3.2). An 18-peak spectrum was 
observed in the reactions of 2-I•Cl with GSH at pH = 7.4 (Section 5.3.2.2) 
and pH = 10.8 (Section 5.3.2.3), 2-Cl•PF6 with GSH at pH = 7.4 (Section 
5.3.3.2) and pH = 10.8 (Section 5.3.3.3), [2-OH]+ with GSH at pH = 7.4 
(Section 5.3.5.2). These spectra were analysed and simulated with the 
EASYSPIN.37 Three independent experiments and simulation combining 
spectral resolution (2048 data points at 200 G) were used to calculate 
error bars. 
 
5.3.9.1. 8-Peaks Spectrual Simulation 
The experimental spectrum for the reaction of 2-I•Cl (1 mM) with GSH 
(1 mM) at pH = 7.4 with spin trap DEPMPO (20 mM) after 1 h reaction 
time at 310 K  and a further 1 h EPR scanning at 298 K was used as a 
typical 8-peak spectrum for simulation. The spectrum was fitted with 
parameters αP=47.52 G, αN=14.02 G, αH=13.06 G, which can be assigned 
to DEPMPO-OH (Figure 5.26).35 
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Figure 5.26. The simulation result for the typical 8-peaks spectrum (green ) 
observed in the reaction of 2-I•Cl (1 mM) with GSH (1 mM) at pH = 7.4 in presence 
of DEPMPO (20 mM), which was assigned to DEPMPO-OH. 
 
 
5.3.9.2. Simulation of the 18-peak Spectrum  
The experimental spectrum of 2-Cl•PF6 (1 mM) on reaction with GSH 
(1 mM) at pH = 10.8 in presence of DEPMPO (20 mM) after 1 h reaction 
time at 310 K  and a further 6 h EPR scanning at 298 K was used as a 
typical 18-peak spectrum for simulation. It was fitted as a mixture of 
peaks for DEPMPO-OH, DEPMPO-H and DEPMPO-OOH (Figure 
5.27). The simulation result showed the experimental spectrum contained 
DEPMPO-OH (αP = 47.52, αN =14.02, αH =13.06), DEPMPO-H (αP = 
49.91, αH =15.12, αN =13.58, αH = 3.21, αH = 0.29) and DEPMPO-OOH 
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(Isomer I, 44%, αP = 47.3, αN =13.72, αH  = 12.26, αH = 0.93, αH = 0.42, 
αH = 0.43; Isomer II, 42%, αP = 47.52, αN = 13.72, αH = 10.18, αH = 0.92, 
αH = 1.02, αH = 0.48; Isomer III, 14%, αP = 37.13, αN = 15.14, αH = 9.8, 
αH=1.38).33,35 The ratio of DEPMPO-OH (green ), DEPMPO-H (red ) 
and DEPMPO-OOH (purple ) signal intensities was 3:2:2. 
 
Figure 5.27. The simulation result for the typical 18-peaks spectrum (mixture of red 
, green  and purple ) observed in the reaction of 2-Cl•PF6 (1 mM) with GSH (1 
mM) at pH = 10.8 in presence of DEPMPO (20 mM), which was assigned to a spectral 
mixture of DEPMPO-OH, DEPMPO-H and DEPMPO-OOH. The ratio of DEPMPO-
OH (green ) : DEPMPO-H (red ) : DEPMPO-OOH (purple ) signal intensities is 
3:2:2 based on simulation weight.  
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Table 5.1. The comparison between observed parameters fitted by simulation for the 
spectra for reaction of 2-I•Cl with GSH (Figure 5.27) and reported parameters35 of 
DEPMPO-OH, DEPMPO-H. 
 Reported (G)b Observed (G)a 
DEPMOP-H 
αP = 47.50 αP = 48.62±1.15 
αN = 14.00 αN = 13.93±0.36 
αHa = 15.00 αHa =15.09±0.18 
αHa = 3.00 αHa = 3.10±0.19 
αHb = 0.27 αHb = 0.27±0.11 
DEPMPO-OH 
αP = 46.70 αP = 46.77±0.66 
αN =13.90 αN = 13.99±0.17 
αHa = 13.50 αHa = 13.40±0.51 
a means ± the standard deviation of three independent experiments with parameters fitted by simulation. 
b from reference 35 
 
 
Figure 5.28.  The EPR spectra (top) and structures of DEPMPO-H and DEPMPO-
OH (bottom). The atoms H (I = 1/2), N (I = 1), P (I = 1/2), causing hyperfine coupling 
are shown in red. 
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Table 5.2. The comparison between parameters fitted by simulation for the spectra 
the reaction of 2-Cl•PF6 with GSH (Figure 5.27) and reported parameters35 of 
DEPMPO-OOH. 
 Reported (G)b Observed (G)a 
Isomer I 
αP = 50.15 αP = 49.97±2.06 
αN = 13.00 αN  = 13.25±0.43 
αHa = 11.30 αHa = 11.55±1.15 
αHb = 0.85 αHa = 0.86±0.16 
αHb = 0.35 αHb = 0.37±0.13 
αHb = 0.53 αHb = 0.49±0.15 
Isomer II 
αP = 48.68 αP = 47.54±1.39 
αN = 13.08 αN = 13.29±0.41 
αHa = 10.20 αHa = 10.27±0.33 
αHb = 0.88 αHa = 0.97±0.24 
αHb = 0.41 αHb = 0.62±0.32 
αHb = 0.34 αHb = 0.47±0.16 
Isomer III 
αP = 40.08 αP = 39.13±1.61 
αN = 13.30 αN = 14.24±0.78 
αHa = 10.00 αHa = 9.81±0.40 
αHb = 1.50 αHb = 1.27±0.30 
a mean ± the standard deviation of three independent experiments with parameters fitted by simulation.  
b from reference 35 
 
Figure 5.29. The structures of four possible diastereoisomers of DEPMPO-OOH 
(bottom) and assumed EPR spectrum contribution from three of these four 
diastereoisomers.42 The atoms H (I = 1/2), N (I = 1), P (I = 1/2), causing hyperfine 
coupling are shown in red. 
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5.3.10. H2O2 Detection 
5.3.10.1. H2O2 Test Strips 
Three samples of [2-I]+ (100 μM) alone, GSH (300 μM) alone and [2-I]
+
 
(100 μM) mixing with GSH (300 μM) in sodium chloride (25 mM) and 
phosphate buffer (75 mM) solution at pH = 7.4 were incubated at 310 K 
for 3 h and then left in contact with the H2O2 test strips for 15 s. The result 
showed that there was below 2 mg/L (50 μM) hydrogen peroxide 
generated in the reaction [2-I]+ with GSH. There was a faint blue colour 
in the H2O2 test strip for the solution [2-I]
+
 (100 μM), which could be 
caused by the blue colour of [2-I]+ itself (Figure 5.30). 
 
Figure 5.30. Colour change of H2O2 test strips for samples of [2-I]+ (100 μM), GSH 
(300 μM) and [2-I]+ (100 μM) reacting with GSH (300 μM) in sodium chloride (25 
mM) and phosphate buffer (75 mM) at pH = 7.4 after 3 h incubation at 310 K. 
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5.3.10.2. Ammonium Molybdate Method 
Three solutions containing 2-I•PF6 (100 μM), GSH (300 μM) and 2-
I•PF6 (100 μM) mixed with GSH (300 μM) were prepared in sodium 
chloride (25 mM) and phosphate buffer (75 mM) at pH = 7.4, and 
incubated at 310 K for 5 min, 1 h, 2 h, 3 h and 4 h. Then 0.5 mL of these 
three solutions was mixed with 0.5 mL ammonium molybdate solution 
(32.4 mM), and the reaction sample in absence of ammonium molybdate 
was also prepared as control.  
The concentration of hydrogen peroxide for these four samples was 
determined from the change in absorbance at 405 nm using the 
calibration equation y = 0.0123x + 0.0305 (y is the absorbance change 
and x is the concentration of hydrogen peroxide in μM). The absorbance 
at 405 nm for sample of 2-I•PF6 (100 μM) on reaction with GSH (300 
μM) changed by 0.28 after 2 h incubation and the concentration of 
hydrogen peroxide was therefore ca. 20 μM (Figure 5.31). 
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Figure 5.31. UV-vis spectra of samples a) mixture of [2-I]+ (100 μM) with 
ammonium molybdate (32.4 mM); b) mixture of [2-I]+ (100 μM) with GSH (300 μM) 
and ammonium molybdate (32.4 mM); c) mixture of [2-I]+ (100 μM) with GSH (300 
μM); d) mixture of GSH (300 μM) with ammonium molybdate (32.4 mM). All 
samples were prepared in sodium chloride (25 mM) and phosphate buffer (75 mM) 
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5.3.11. GSSG Detection 
The oxidation of GSH in the reaction with [2-I]+ was determined through 
1H NMR experiments. The result (Figure 5.32) showed that 60% GSH 
was oxidized to GSSG in the reaction of [2-I]+ (2 mM) with 1 mole equiv 
GSH (2 mM) while little GSSG was observed in the sample of GSH (2 
mM) without 2-I after 3 h incubation at 310 K in deuterated phosphate 
buffer (75 mM, pH 7.4). GSSG solution (6 mM) in deuterated phosphate 
buffer (75 mM, pH 7.4) was also scanned as references. This result 
demonstrated that GSH may represent a source of electrons for the 
production of superoxide from dioxygen.  
 
Figure 5.32. The 1H NMR spectra for GSH (2 mM), GSSG (4 mM) references 
without incubation as well as reactions of GSH (2 mM) exposed to air and GSH with 
[2-I]+ (2 mM)exposed to air after 3 h incubation at 310 K in deuterated phosphate 
buffer (75 mM, pH 7.4). 
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5.4. Discussion  
GSH (γ-Glu-L-Cys-Gly) is a tripeptide with a ca. 5 mM intracellular 
concentration providing free thiol and electrons for many reactions 
including cell signalling and metabolism, especially reactions with free 
radicals to maintain the cellular redox balance, and binding to heavy 
metal inos to reduce metal-induced stress in cells.22,23,26 When transition 
metal ions as including metallodrugs enter into the cells, they are likely 
to bind to GSH and form metal-SG adducts which can be pumped out of 
the cell through the glutathione S-conjugate export pump (GS-X 
pump).43-45 As a result, GSH exhibits a ‘double-edged sword’ function 
that protects healthy cells from the heavy metal toxicity as well as 
reducing the activity of metallodrugs in cancer cells. It is a challenge to 
take advantage of the properties of GSH in anticancer metallodrug 
development. There are several good examples that GSH promoting 
rather than blocking the activity of metallodrugs. The anticancer complex 
PtII(ethylenediamine)Cl2 was reported to react with GSH and form a 
glutathione-bridged diplatinum(II) macrochelate. This dinuclear 
intermediate may play a role in allowing platinum drug  to reach the 
nucleus and bind to DNA.46 GSH was also found to promote the binding 
of [(η6-bip)Ru(en)Cl]+ (bip = biphenyl, en = ethylenediamine) to DNA 
with a mechanism in which GSH firstly binds to Ru ions to form the 
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thiolato adduct which was then very easily oxidized to the ruthenium 
sulfenate complex. Compared to the original Ru(II) complex, the 
sulfenate complex had a stronger ability to bind to DNA.47    
[Os(η6-p-cymene)(4-(2-pyridylazo)-N,N-dimethylaniline)I]+ (FY26, [2-
I]+) is about 49 times more toxic to >800 cancer cell lines than cisplatin 
and retains potency towards cisplatin-resistant cancer cells with a novel 
mechanism of action. [2-I]+ dramatically increased the level of 
intracellular ROS especially superoxide.28 Further studies showed that 
GSH promotes the hydrolysis process of [2-I]+ and activates this osmium 
pro-drug.48 The mechanism of this activation process was explored in 
Chapter 4. Results aquired indicated that deprotonated GS- (the pKa of -
SH in GSH is 9.6549) attacked on the -N=N- bond in the osmium azo 
complex and formed an sulfenylhydrazide intermediate in which the 
monodentate iodide ligand is easily replaced by H2O to produce aqua 
analogue [2-OH]2+ and further hydroxido analogue [2-OH]+.   
In this Chapter 5, EPR experiments were conducted to detect free  
radicals  in  the  reactions  of  GSH  with  several  osmium  complexes 
including lead complex [2-I]+, chloride analogue [2-Cl]+, hydroxido 
analogue [2-OH]+, imino analogue [2-impy-Cl]+, no-substituted [1-Cl]+, 
thiolate adduct 2-SG and free ligand AZPY-NMe2. The reaction 
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conditions including dioxygen concentration and pHs were modified 
since such conditions affect the hydrolysis reactions (Chapter 4). 
Table 5.3. The summary of free radicals production in the reactions of compounds 




3.8 7.4  10.8 
[2-I]+ ✖ ✔  ✔✔ ✖ 
[2-Cl]+ ✖ ✔  ✔✔ ✖ 
[2-OH]+ ✖ ✔✔  ✔✔ ○ 
[1-Cl]+ ○ ○  ✔✔ ○ 
[2-impy-Cl]+ ✖ ✖  ✖ ○ 
2-SG ✖ ✖  ✖ ○ 
✖ no free radicals observed; ✔ only hydroxyl radical (•OH) observed; ✔✔ mixed 
free radicals superoxide (O2-), hydroxyl radical (•OH) and hydrogen atom (•H) 
observed; ○ not determined.     
 
pH effect 
 For 2-I•PF6 (FY26), no free radicals were observed in the reaction with 
GSH because of its poor solubility but in the reactions of the solubility-
improved complex 2-I•Cl (in aqueous solution, both 2-I•PF6 and 2-I•Cl 
dissociate to [2-I]+) with GSH, at pH = 10.8, an 18-peak spectrum was 
observed which can be assigned to a mixture of DEPMPO-OH, 
DEPMPO-OOH and DEPMPO-H, at pH = 7.4, only an 8-peak spectrum 
was observed which can be assigned to DEPMPO-OH, and at pH = 3.8, 
no radicals were detected The influence of pH on free radical generation 
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can be explained by the conclusion that in the reaction of GSH with [2-
I]+, GS- rather than GSH attacked the complexes (Chapter 4). The pKa 
value of thiol group in GSH is 9.6549 and the pH value of the reaction 
determined the ratio of GSH and GS-. When the pH = 3.8, there was too 
low level GS- (dissociation percentage is less than 10-6) to attack osmium 
complex and little free radicals were detected by EPR. However, when 
pH value was increased to pH = 7.4 (1 % deprotonated GS-) and pH = 
10.8 (94 % deprotonated GS-), more GS- is present to be involved in the 
reaction and free radicals were observed.  
Attacking site for GSH on osmium complex  
In terms of the reaction site, the DFT calculations (Chapter 4) suggested 
that GS- attacks the -N=N- azo bond and activate [2-I]+. In order to 
confirm the importance of -N=N- azo bond, the detection of free radicals 
from the reactions of [2-Cl]+, [2-OH]+, [2-impy-Cl]+ and [1-Cl]+ with 
GSH were explored. Similar to [2-I]+, all the osmium azo complexes [2-
Cl]+, [2-OH]+ and [1-Cl]+ gave rise to free radicals at neutral or alkaline 
pH values (7.4 or 10.8). However no radicals were trapped from the 
reaction of osmium imino complex [2-impy-Cl]+ with GSH no matter the 
pH value, 3.8, 7.4 or 10.8. Such results confirmed that -N=N- bond plays 
a critical role in the free radical generation and is likely to be the attack 
site for GSH as the DFT calculations suggested. The key 
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sulfenylhydrazide intermediate 2-GS/NN of GSH attacking azo bond in 
[2-I]+ was detected using X-ray absorption spectroscopy in Chapter 6. 
Similar attacking of GSH on the azo bond in metal coordinated 
complexes have been observed for Ru (II)50 and Ir (III) 51complexes.  
Special behaviour of [2-OH]+  
It is interesting to compare the different behaviours of [2-I]+, [2-Cl]+ and 
[2-OH]+ in the reaction with GSH at pH=7.4.  After the first 6 h of EPR 
scanning, [2-I]+/[2-Cl]+ induced only the 8-peak spectrum of DEPMPO-
OH, but [2-OH]+ was able to induce mixed radical species of DEPMPO-
OH, DEPMPO-OOH and DEPMPO-H. This result indicates that [2-
OH]+ was more active than [2-I]+/[2-Cl]+ in the reaction with GSH to 
induce free radicals, especially superoxide. After 6 h scanning time, the 
superoxide radical was observed in the samples of all osmium complexes 
[2-I]+, [2-Cl]+ and [2-OH]+ after reaction with GSH. This was resulted 
from the hydrolysis of [2-I]+/[2-Cl]+ to [2-OH]+ . Thus in the cell living 
under physiological conditions (pH = 7.4), osmium arene halide 
complexes [2-I]+ and [2-Cl]+ may not be able to induce significant 
amounts of superoxide radicals but GSH can activate the hydrolysis of 
[2-I]+ and [2-Cl]+ to generate more active [2-OH]+ first (Chapter 4) and 
then GSH again reacts with [2-OH]+ to produce superoxide. This 
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mechanism provides a reasonable explanation of how [2-I]+ (FY26) 
increases the intracellular superoxide level.28  
How are the free radicals produced? 
In control experiments, no free radicals were observed when neither GSH 
nor osmium complexes were absent. The metal trace basis buffer solution 
had no effect on the free radical generation which confirmed that no 
residual metal ions in the buffer are involved in the radical production. In 
the reactions with [2-I]+, 60% GSH was rapidly oxidized to GSSG within 
3 h. From GSH to GSSG, 2 electrons can be released with O2 accepting 
one of them to give superoxide which can be trapped by DEPMPO. But 
the formed DEPMPO-OOH adduct is very easily decomposed to the 
more stable DEPMPO-OH.52,53 As a consequence, only DEPMPO-OH 
spectrum was observed for the reaction of [2-I]+ with GSH at pH = 7.4. 
At pH = 10.8, the higher concentration of GS- increases the reaction rate 
and more O2 is converted to superoxide. Even with decomposition to 
DEPMPO-OH, enough DEPMPO-OOH was present to detect by EPR. 
The superoxide generation was also supported by the effect of superoxide 
dismutase. To explain DEPMPO-H production, the superoxide O2
- could 
also react with GSH and generate hydrogen peroxide H2O2
54,55 which is 
reported to react with organo-osmium azo complexes to produce •H and 
•OH radicals.48 To confirm hydrogen peroxide production, H2O2 test 
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strips and the ammonium molybdate test were used to measure the 
concentration of H2O2. The result showed about 20 μM hydrogen 
peroxide was produced by 100 μM [2-I]+ in the reaction with GSH.  
What role does O2 play in the reactions? 
It seems likely that the free radicals observed in the reactions of osmium 
azo complexes with GSH are generally produced through the process in 
which they promote the electron transfer from GSH to O2 and generates 
GSSG and O2
-. Then the generated O2
- can give rise to other free radicals, 
•H and •OH. GSH is also involved in attack as GS- on the -N=N- azo 
bond to donate its electrons to the system but the mechanism by which 
dioxygen accept an electron is still unknown. Literature investigations 
suggest two possible pathways, one in which dioxygen can directly 
accept an electron from negatively-charged azo anions which is the 
intermediate from GS- reduction of the azo bond.56,57 However, the free 
azo ligand AZPY-NMe2 and thiolate adduct 2-SG cannot induce free 
radicals. This result does not support that dioxygen accept electron from 
negatively-charged azo anions. Thus osmium metal centre is critical to 
free radicals production and dioxygen involvement. The other pathway 
is that dioxygen could bind to the osmium centre to form an osmium-η1-
superoxo complex ([2-O2]+) as a reaction intermediate. Similar 
intermediate complexes have been observed in the activation of dioxygen 
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by Fe(II), Cu(II), Cr (III), Mn(III) and Ni(III) complexes.58-61 DFT 
calculations indicated the plausibility of [2-O2]+ for superoxide 
production.  
Proposed Mechanism for Radical Generation  
Overall, from all the experimental studies, DFT calculations and 
literature reports, a mechanism for the reaction of organo-osmium azo 
complex [2-I]+ and [2-Cl]+ with GSH can be proposed (Scheme 5.2). 
Firstly, GSH is deprotonated to GS- in aqueous solution at an alkaline pH 
value and then GS- attacks the -N=N- bond in osmium azo complexes to 
form a sulfenylhydrazide intermediate (2-GS/NN) that has been probed 
by DFT calculations in Chapter 4 and detected by X-ray absorption 
spectroscopy in Chapter 6.  
 In this sulfenylhydrazide intermediate 2-GS/NN, the bond between the 
osmium centre and monodentate halide becomes labile because attacking 
of GS- changes the electron density in this region. In the whole reaction 
system, O2 is the most electrophilic group compared with OH
-, GS- and 
H2O to react with 2-GS/NN so that O2 attacks the liable bond between 
osmium centre and monodentate halide ligand to form an osmium-η1-
superoxo intermediate complex ([2-O2]+) with release of the halide 
ligand (I- or Cl-). Then [2-O2]+ is also very liable and another GS- can 
attack the -N-SG bond in [2-O2]+ to generate GSSG- which is reported to 
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transfer electron to O2 producing superoxide O2
- and GSSG.54,55 H2O can 
attack the osmium-dioxygen bond to release another superoxide O2
- 
forming aqua adduct [2-OH2]2+ which then was deprotonated to [2-OH]+ 
with pKa 5.20 (Chapter 3). 
 [2-OH]+ can react with halide anions Cl- and 
I- to reform [2-Cl]+ and [2-I]+ and the azo bond in [2-OH]+ can also be 
attacked by GS- to produce superoxide with a similar mechanism to that 
of [2-Cl/2-I]+. The superoxide can be trapped by DEPMPO to form 
DEPMPO-OOH which is very easily to be decomposed to DEPMPO-OH. 
If more superoxide is generated, the DEPMPO-OOH can be detected and 
superoxide can also react with GSH to produce H2O2. The osmium azo 
complexes can be attacked by H2O2 to induce •OH and •H,
48 both of 
which can be trapped by DEPMPO. 
 
Scheme 5.2. Proposed mechanism for free radicals generation induced by osmium 
azo complexes in reactions with GSH in the presence of O2.   
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5.5. Conclusions 
In this Chapter 5, the results show that recycling of osmium azo 
complexes [2-I]+, [2-Cl]+ and [2-OH]+ promotes electron transfer from 
GS- to O2 and produces GSSG and superoxide that can give rise to other 
free radicals, •H and •OH. For the whole reaction, the osmium azo 
complex catalyses the oxidation of GSH to GSSG and activation of O2 to 
superoxide which provides a plausible explanation of how the osmium 
azo complex increases the superoxide level and may alter the redox 
balance within cells, contributing to their toxicity to cancer cells. GSH is 
usually considered to be an antioxidant which consumes free radicals but 
herein it works with osmium azo complexes to induce free radicals 
production. Based on all the experimental results, DFT calculations and 
literature reports, a novel mechanism of action of osmium azo anticancer 
drugs catalysing the GSH oxidation and dioxygen activation is proposed, 
in which dioxygen chelated to the osmium arene complex is an 
intermediate. This mechanism provides a new view on research on 
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6.1. Introduction 
The half-sandwich organo-osmium complex [Os(η6-p-cym)(4-(2-
pyridylazo)-N,N-dimethylaniline)I]+ ([2-I]+ (FY26) is being developed  
as a promising anticancer drug candidate with 49 × times higher potency 
than cisplatin.1,2 Interestingly, [2-I]+ is inert under physiological 
conditions, but can be activated to release its iodido ligand once taken up 
by cancer cells.3 The abundant intracellular tripeptide glutathione (GSH, 
γ-L-Glu-L-Cys-Gly) appears to play a key role in the activation process 
of [2-I]+.3 Thus the aim of this thesis is to explore the mechanism of 
action of [2-I]+, especially to study the reaction [2-I]+ with GSH. From 
the work in Chapter 4, GSH can catalyse the hydrolysis of [2-I]+ to 
produce hydroxido analogue [2-OH]+ through a pathway of reducing the 
-N=N- azo bond in the complex (Figure 6.1). Similar behaviours of thiols 
reducing the azo bond has been observed to both organic diazenes4,5 and 
diazenes coordinated to Ru(II) or Ir(III).6-8 However, the 
sulfenylhydrazide intermediate 2-GS/NN in the reaction of GSH with [2-
I]+ has not been characterised even after much attempts using HPLC, 
NMR, UV-vis and Raman technology. The work in this Chapter 6 seeks 
to provide some experimental evidence for the 2-GS/NN intermediate 
from the X-ray absorption spectroscopy (XAS) studies of [2-I]+ in 
reactions with GSH. 
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Figure 6.1. The proposed pathway for GSH attack on the azo bond to promote the 
hydrolysis of [2-I]+ described in Chapter 4.  
 
X-ray absorption spectroscopy (XAS) has been developed since the 
1970s9,10 and is now widely used for determining the local geometric and 
electronic structures of matter, including organometallic complexes. The 
samples for XAS can be gases, solutions or solids, and the experiment is 
usually performed with synchrotron radiation facilities which provide 
intense and tunable X-ray beams. The XAS experiments in this Chapter 
6 were carried on BM23 beamline at the European Synchrotron Radiation 
Facility (ESRF) located in Grenoble, France.11 XAS data are obtained by 
tuning the photon energy (0.1-100 keV) to excite the core electrons using 
a crystalline monochromator. Corresponding to the quantum numbers (n 
= 1, 2, 3) of the excited electrons, the excitation edge is termed as a K-, 
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L- or M-edge. For example, excitation of a 1s electron occurs at the K-
edge, while excitation of a 2s or 2p electron occurs at an L-edge.12 
The spectrum generated from XAS data generally has two regions that 
are the X-ray absorption near-edge structure (XANES) and extended X-
ray absorption fine structure (EXAFS) (Figure 6.2). XANES is related 
to the measurement of transitions from core electronic states to the lowest 
unoccupied molecular orbital (LUMO), which can provide detailed 
information regarding the oxidation state and coordination environment 
of metal atoms.13,14 Moreover, at energies somewhat greater than the 
LUMO level, the absorption of an X-ray provides sufficient energy to 
cause the absorbing atom excitation and the excess energy is given as an 
ejected photo-electron from the absorbing atom. With other atoms nearby, 
the ejected photo-electron can scatter from one or multi neighbouring 
atoms and then return back to the absorbing atom. The interference effect 
of the outgoing photo-electron wave and back-scattered photo-electron 
wave results in the X-ray absorption fine structure (XAFS). But the 
energy range of the photoelectron scattering cross-section between multi 
neighbouring atoms is weak. Thus the scattering of the ejected 
photoelectron by neighbouring atoms can be approximated by single 
scattering events, which dominate the extended X-ray absorption fine 
structure (EXAFS).12,14 EXAFS mainly provides information about the 
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distance between the absorbing and back-scattering atoms within a 
distance of about 5 Å, as well as the identity and number of the 
backscattering atoms.14 
 
Figure 6.2. Two regions (XANES and EXAFS) in a XAS spectrum. 
 
The advantages and limitations of XAS can be summarized as follows.14-
16 
Advantages 
 XAS is element specific, so the focus can be on one element 
without interference from other elements present in the sample. 
 There is no limitation of sample states. Gas, solution or solid 
samples can be studied with XAS because it is sensitive only to the 
local metal site structure. 
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 XAS is never “silent” to the metal of interest. The system could be 
‘silent’ with respect to EPR, optical, or other spectroscopic 
methods, but the metal site structure can always be probed by XAS. 
 The radiation damage to the samples caused in the XAS 
experiments can be precisely monitored and controlled, thus 
allowing data collection from an intact sample. 
Limitations 
o A frequent problem of XAS is the inability to distinguish 
between scattering atoms with little difference in atomic 
number (C, N, O, or S, Cl, or Mn, Fe). 
o The presence of more than one metal centre limits the 
resolution of distance determinations to between 0.1 and 0.2 Å. 
It is difficult to determine whether a Fourier peak should be fit 
to one distance with a relatively large disorder parameter or to 
two distances, each having a small disorder parameter. 
o Determination of coordination numbers or number of 
backscatterers is fraught with difficulties. The Debye-Waller 
factor (DWF, description of the attenuation of X-ray scattering 
caused by thermal motion) is strongly correlated with the 
coordination number and there must be recourse to other 
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information to narrow the range that is possible from curve-
fitting analysis alone. 
With these advantages and limitations, XAS has been widely applied to 
study metal-containing system including metallo-proteins, coordinated 
complexes, and inorganic catalytic systems and provides an excellent 
opportunity to identify redox states of metal-centre, determine distances 
of the metal centre with neighbouring atoms and detect the intermediates 
of metal-containing system reactions. An example of the development of 
XAS is the structural research on photosynthetic oxygen-evolving 
complex (OEC) in photosystem II (PS II) and the XAS studies focused 
on Mn4Ca cluster in PS II which provide mechanistic information during 
the catalytic cycle.17-20 In terms of small molecule coordinated complexes, 
XAS studies has demonstrated the reduction behaviour of Ru(III) to 
Ru(II),21 Pt(IV) to Pt(II)22 in cancer cells and characterized Pt-thiosulfate 
complex to confirm the strategy of reducing the toxicity of cisplatin by 
co-administering sodium thiosulfate. Similar to Pt-S bonds,23 metal-
sulphur bonds in Hg(II)- , Ni(II)- , Cr(III)- , and Mo(V)-cysteine 
complexes24 and Au-cysteine bonds arising from the reaction of Au(III) 
complexes with a ‘zinc finger’ have been characterized by XAS.25 
Therefore, it appears attractive to use XAS to detect the intermediates in 
reactions of metal complexes with substrates. The key transient 7-
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coordinate RuV=O intermediate has been characterized with in situ 
EXFAS during the oxygen evolution reaction catalysed by Ru-bda type 
(bda is 2,2’-bipyridine-6,6’-dicarboxylate) complexes.26 In XAS studies 
on osmium, many osmium-containing clusters and complexes has been 
investigated to characterize the redox states of osmium as well as the Os-
Os, Os-Cu, Os-C, Os-O, Os-N bonds etc.27-29    
Overall, XAS is a powerful tool to investigate the behaviours of 
coordinated complexes and complementary to the studies in this thesis 
which aim to explore the chemical mechanism of action of the anticancer 
complex Os(η6-p-cym)(4-(2-pyridylazo)-N,N-dimethylaniline)I]+ ([2-
I]+). The redox state of [2-I]+ in cancer cells which may involve oxidation 
from Os(II) to Os(III) has been demonstrated by XANES30 and the 
localization of [2-I]+ to mitochondria in cancer cells has been studied 
with a synchrotron X-ray fluorescence nanoprobe (SXRFN).31 Using 
such X-ray studies of [2-I]+, the work in this Chapter 6 will focus on 
using XAS, especially EXAFS, to detect the sulfenylhydrazide 
intermediate 2-GS/NN (Figure 6.3) which is a key intermediate in the 
reaction of [2-I]+ with GSH in the mechanism proposed in Chapter 4. 
For probing the intermediate 2-GS/NN, references XAS spectra for 
complexes [2-I]+, [2-Cl]+, [2-OH]+, 2-SG were first obtained and then 
DFT calculations used to validate the models of [2-I]+, 2-SG against their 
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experimental EXFAS spectra, based on which the EXAFS signature 
corresponding to the DFT model of the intermediate 2-GS/NN will be 
simulated. Finally, the EXAFS spectra for kinetic reactions of [2-I]+ with 
GSH at pH 3, 5 and 7 (due to the pH influence to the reaction 
demonstrated at Section 4.3.1 of Chapter 4) are analysed using a linear 
combination fit model and the contribution of 2-GS/NN to the spectra is 
tracked. 
 
Figure 6.3. The molecular structures of compounds and intermediate (2-GS/NN) 
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6.2. Experimental Section 
6.2.1. Materials 
Osmium complexes 2-Cl•PF6, [2-OH]+ (in solution), 2-SG were 
synthesised and characterized as procedures described in Section 3.2.3 
of Chapter 3. A solid containing [2-OH]+ was prepared by freeze-drying 
to remove the solvent from the solution. The more soluble complex 2-
I•Cl (compared to the PF6 salt) was provided by Dr. Russell Needham 
(University of Warwick, UK). The phosphate buffer (200 mM, pH 7) and 
citrate-phosphate buffer (200 mM, pH 5 or 3) were prepared as the 
described in Section 2.1.2 of Chapter 2.  Reduced glutathione (GSH) 
was purchased from Sigma Aldrich. Sodium hydroxide, sodium chloride, 
sodium phosphate dibasic (Na2HPO4), sodium phosphate monobasic 
dehydrate (H2NaPO4·2H2O), and citric acid were purchased from Fisher 
Scientific. Analysis grade doubly deionised water (18 M Ω cm-1) was 
obtained from USF Elga UHQ PS purification system. All other solvents 
and reagents for synthesis and analysis were purchased from commercial 
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6.2.2. Methods 
XAS experimental setup and data collection strategies. X-ray 
absorption (XAS) experiments at the Os L3-edge (10871 eV) were 
performed at the BM23 beamline of the European Synchrotron Radiation 
Facility (ESRF, Grenoble, France).11 The data was collected with the aid 
of Dr. Elisa Borfecchia (Università degli Studi di Torino, Italy). XAS 
experiments were conducted in transmission mode, using a Si(111) 
double crystal monochromator to select the incident X-ray energy. The 
intensity of the incident beam I0 and the beam transmitted through the 
sample (I1) and a reference Hf metal foil (I2) was monitored by 30 cm 
ionization chambers. Such a setup allowed a precise energy calibration 
for each collected XAS spectrum. For static and in situ experiments in 
solution, a 4-mm thick EXAFS cell, specifically devoted to liquid 
samples, was filled with 30 mM solutions of [2-I]+ in pH 7.0 (200 mM 
phosphate buffer), pH 5.0 (200 mM citrate-phosphate buffer), or pH 3.0 
(200 mM citrate-phosphate buffer) buffers, resulting in edge-jumps Δµx~ 
0.3 for a total absorption after the edge µx ~ 2.2. Initiation of the reaction 
for in situ experiments was obtained by injecting GSH into the cell at 
Os:GSH molar ratios of 1:2 or 2:1, depending on the specific experiment. 
The solid-state structure of [2-I]+, as well as of the 2-SG, [2-Cl]+, [2-
OH]+ and OsCl3 model compounds, was also characterized with 
Chapter 6: X-ray Absorption Spectroscopy (XAS) Studies 
273 
transmission-mode XAS measurements, performed on self-supporting 
pellets of optimized mass. 
For studies on solid-state model compounds, we employed higher-quality 
scans in the 10639 ‒ 12107 eV range, requiring ca. 40 min of data 
collection per spectrum. The pre-edge region and XANES part of the 
spectra were acquired with a constant energy step of 5 and 0.5 eV, 
respectively, while the EXAFS part (up to 18 Å–1) was collected with a 
Δk = 0.035 Å–1, resulting in a variable sampling step in energy. The 
integration time was 1 s/point for the pre-edge region and XANES 
regions, and quadratically variable from 1 to 8 s/point in the EXAFS part 
of the spectrum. For in situ experiments during [2-I]+ hydrolysis reaction, 
we adopted shorter scans (20 min per spectrum) in the 10724 ‒ 11619 eV 
range. In this case, the integration time in the EXAFS region 
quadratically increased from 1 to 4 s/point, up to 14 Å–1, while the energy 
sampling parameters in the pre-edge and XANES region were the same 
as for the longer scans. Notably, the first accessible time point after GSH 
injection corresponded to 40 min, including ca. 20 min to safely set the 
measurement and 20 min to collect of the first scan. 
Energy calibration and alignment, normalization to the edge jump, and 
extraction of the (k) functions for all the collected spectra was 
performed using the Athena program.32 For static experiments, two or 
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three consecutive EXAFS spectra were collected for each sample, and 
the corresponding µx(E) curves were averaged, after checking the data 
reproducibility. 
EXAFS fitting model and simulation strategy. The high-quality 
EXAFS spectra collected for [2-I]+ and 2-SG in the solid state, as well as 
for that in solution at pH 7.0, 5.0, and 3.0 buffered solutions of [2-I]+, 
were fitted starting from the available DFT models. EXAFS fits were 
performed by Dr. Elisa Borfecchia (Università degli Studi di Torino, Italy) 
using the Arthemis software.32 The fits were performed in R-space in the 
ΔR = 1.2–5.0 Å range, Fourier transforming the k2χ(k) curves in the 2.0‒
15.5 Å-1 range, resulting in 42 independent points. Phase and amplitude 
functions of each path were calculated using as starting guess the 
geometry of [2-I]+ or 2-SG from computational analysis. To limit the 
number of optimized variables, the single scattering (SS) and multiple-
scattering (MS) paths included in the fitting model were optimized with 
the same amplitude factor (S0
2) and with the same energy shift (ΔE) 
parameter. 
For both the Os-complexes, the fitting model included SS (single 
scattering) contribution from N1 and C1 sub-shells, involving two N 
atoms from the pyridylazolate unit and 6 C atoms from the p-cymene unit, 
respectively. The SS contributions from the I ligand in [2-I]+ and for the 
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S ligand in 2-SG were also included. For each of these coordination shells, 
the corresponding SS paths have been parametrized employing the same 
Debye-Waller (DW) factors 2i and bond distances Ri from the Os 
absorber, with coordination number fixed to the DFT geometry. 
A lower-level parametrization strategy has been employed for the SS 
involving the distant C atoms of the pyridylazolate unit and the numerous 
MS paths falling in the 3.0–5.0 Å range from the Os center. These paths 
were parametrized by considering a common contraction/expansion 
factor αfar and a DW factor 
2
far increasing as the square root of the path 
length Reff. This approach, allowing a significant reduction of the number 
of free fit parameters, has already been successfully used in the EXAFS 
analysis of metal complexes in solution as well as hosted in microporous 
matrixes, for which an initial structural model was available either from 
XRD or from computational modelling.33-35  
The values of the optimized parameters obtained in these fits were 
employed to guide the simulation of the EXAFS signature for the 2-
GS/NN intermediate predicted by DFT. For the simulation, we calculated 
all the SS and MS paths resulting from the DFT geometry in the relevant 
R-space range 1.2‒5.0 Å. Then, we parametrized the paths as described 
before for the fits, and fixed the eight relevant parameters (S0





far) based on the best-fit values obtained for [2-I]
+ 
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and 2-SG. The simulation was hence obtained by summing all the 
parametrized paths.  
k-space Linear Combination Fit (LCF) analysis of in situ EXAFS. 
Linear combination fit (LCF) analysis of the k2-weighted time-dependent 
in situ EXAFS spectra was performed in k-space the 3.0–12.0 Å-1 interval, 
using the Athena software from the Demeter package.32 Each 
experimental scan, k2χEXP(k), was fitted as a linear combination of 
reference EXAFS spectra, k2χi
REF (k), i.e.: k2χi
LCF(k) = Σiwi k
2χi
REF (k), 
optimizing the weights wi for each reference spectrum. LCF was 
performed by setting the total sum of the weights to unity, Σiwi = 1 and 
contraining the weights in the [0 ; 1] interval (0 ≤ wi ≤ 1). For each 





2, where j denotes each experimental point 
in fitted k-range, 3.0–12.0 Å-1; R-factor = 0 corresponds to the ideal 
reproduction of the experimental curve: k2χEXP(k)  k2χLCF(k). Reference 
spectra were selected for each specific in situ experiment based on the 
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6.3. Results 
6.3.1. XAS Spectra of Reference Complexes 
The XAS spectra from the Os L3-edge of solid state standards of OsCl3, 
[2-I]+, [2-Cl]+, [2-OH]+, 2-SG, and an aqueous phase  (30 mM, pH 7) 
standard of [2-I]+ were acquired. The complexes ([2-I]+, [2-Cl]+, [2-
OH]+, 2-SG) have been observed in the reaction of [2-I]+ with GSH and 
their XAS (including XANES and EXAFS) spectra provide the 
references to study the reaction.  Initial assessment of the spectra 
indicated discrimination between [2-I]+ and other Os-containing moieties 
([2-Cl]+, [2-OH]+, 2-SG) could not rely on analysis of the XANES area 
due to the minor differences observed between the spectroscopic 
signatures of the different adducts. Nevertheless, EXAFS proved to be 
highly sensitive to the different ligands in the first coordination sphere of 
Os as shown in Figure 6.5. In particular, XAS spectra of [2-I]+ both in 
aqueous phase (pH 7 buffer) and in the solid state were virtually 
undistinguishable, whilst important differences in the EXAFS 
oscillations were noted for [2-I]+, especially when compared with [2-Cl]+, 
[2-OH]+ and 2-SG from k = 10 Å-1 upward. On the contrary, [2-Cl]+ 
showed very similar spectra to 2-SG (most likely attributable to 
similarities in size and weight between Cl and S).  
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Figure 6.4. Os L3-edge XANES spectra of reference compounds [2-I]+, 2-SG, [2-




Figure 6.5. Os L3-edge k
2-weighted k2χ(k) EXAFS spectra of reference compounds 
[2-I]+, 2-SG, [2-Cl]+, [2-OH]+, OsCl3 in the solid state and [2-I]+ in the solution phase 
(30 mM, pH 7). 
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6.3.2. FT-EXAFS Spectra of Reference Complexes 
Fourier-transformed (FT-) EXAFS was able to provide direct 
information on the characteristic scattering contributions stemming from 
the atoms in the proximity of Os centres of the different complexes 
studied ([2-I]+, [2-Cl]+, [2-OH]+ and 2-SG). From this, it was possible to 
determine that the low-R ranges of the spectra of [2-I]+, [2-Cl]+ and 2-
SG (up to ~1.8 Å in the phase-uncorrected spectra) were mainly 
dominated by contributions from low-Z scatterers (N atoms from 
pyridylazo ligand and C atoms from p-cym unit), resulting in a similar 
EXAFS signal. [2-OH]+ was instead characterised by a pronounced 
enhancement of the low-R ranges with respect to the other complexes. 
This was consistent with the presence of an Os–O single scattering (SS) 
contribution in addition to contributions from pyridylazolate N and p-
cym C atoms. At higher distances from the Os centre, a prominent peak 
for [2-I]+, centred at ~2.5 Å, arising from the Os–I single SS was 
observed. Smaller features at ~2.0 Å due to the presence of S or Cl atoms 
in the first coordination sphere of 2-SG/[2-Cl]+ complexes were also 
observed. Finally, the exclusive presence of low-Z scatterers in [2-OH]+ 
was also marked by a distinct shape of the FT-EXAFS signal in the 2-3 
Å range, which was clearly discernible from what is observed for [2-I]+ 
or 2-SG/[2-Cl]+. 
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Figure 6.6. Phase-uncorrected (a) magnitude and (b) imaginary part  of the Fourier 
Transformed (FT-) EXAFS functions for reference complexes [2-I]+, 2-SG, [2-Cl]+, 
[2-OH]+ (The part ranged 2.0-12.5 Å-1 from the EXAFS spectra in Figure 6.5 was 
selected for Fourier Transform for better comparison with in situ EXAFS spectra).  
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6.3.3. Validation of DFT Geometries against EXFAS Spectra 
Based on the available EXAFS spectra of reference complexes, their 
structural models were validated from DFT (density functional theory) 
calculations. Initially, the computational models of [2-I]+ and 2-SG were 
used as the starting hypothesis to fit EXAFS spectra collected from solid-
state standards, and results were assessed according to the quality and 
physical reliability of the optimised values of the structural parameters 
obtained. The best-fit curves shown in Figure 6.7 showcase the quality 
of fit, as they adequately reproduced all the experimental features in the 
R-space range considered in the analysis, resulting in fit R-factors < 2% 
(Table 6.1). Furthermore, the optimised bond distances obtained were in 
substantial agreement with the x-ray crystal structure of [2-I]+ and the 
DFT models for both complexes.3 However, EXAFS analysis revealed a 
slight elongation of the average Os–N1 bond length (up to 0.03 Å) 
paralleled by a slight contraction of the average Os–C1 distance (up to 
0.08 Å) with respect to theoretical predictions. Moreover, the Os–I 
distance in [2-I]+ was optimised at (2.708 ± 0.004) Å (in good agreement 
with x-ray crystal structure 3), whereas the S ligand in 2-SG was refined 
at (2.39 ± 0.01) Å (corroborating the qualitative interpretation of the R-
ranges between 2-2.5 Å of the FT-EXAFS proposed in Figure 6.6). 
Again, contractions in the order of 0.06 Å were noted in both cases with 
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respect to the respective DFT models. Nevertheless, all the other fitting 
parameters were optimised to physically reliable values, falling in their 
respective expectation intervals under the relevant experimental 
conditions. Finally, Debye-Waller (DW) factors for the N1 and C1 shells 
were higher for 2-SG (σ2N1 = 0.0024 ± 0.0006 Å
2; σ2C1 = 0.004 ± 0.001 
Å2) with respect to [2-I]+ (σ2N1 = 0.0011 ± 0.0008 Å
2; σ2C1 = 0.0015 ± 
0.0008 Å2), suggesting a higher degree of structural disorder for 2-SG.  
Based on these results, the EXAFS signature corresponding to the DFT 
model of 2-GS/NN was able to be simulated. Interestingly, the signal 
simulated for 2-GS/NN shows only small shifts to lower distances and a 
minor intensity enhancement at low-ranges R when compared to the 
experimental spectra of both [2-I]+ and 2-SG. Conversely, from 1.8 Å 
upward, the absence of scattering contribution from close high-Z atomic 
neighbours (in this case, S falls at ~ 4.5 Å from the Os centre), results 
into a distinct, unstructured, EXAFS signal. Such differences can also be 
clearly observed in the contrast in k-space EXAFS oscillations between 
the experimental spectra of [2-I]+ and 2-SG and the simulated spectrum 
of the synthetically inaccessible intermediate 2-GS/NN (Figure 6.7). 
More importantly, the calculations based on experimentally-validated 
models allowed attempts to probe the presence of 2-GS/NN when the 
reaction between [2-I]+ and GSH was followed in situ EXAFS. 
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Table 6.1. Optimized parameters from EXAFS fitting of [2-I]+ and 2-SG in the solid state, 
employing as starting guess the respective DFT geometries. The fit was performed in R-space 
in the range (1.2-5.0) Å, Fourier-transforming the k2χ(k) functions in the (2.0-15.5) Å-1 range. 
Selected DFT bond distances were also presented in bold, for comparison. The last column 
reports spectroscopic and structural parameters employed in the DFT-assisted simulation of 
the EXAFS spectrum for the intermediate 2-GS/NN. For each ith shell of scattering atoms, 
both the optimised (average) bond distances Ri and the corresponding radial shifts from DFT 
values [ΔRi] are presented.  
Parameters [2-I]+ 2-SG 2-GS/NN 
 DFT Solid state ref. DFT Solid state ref. DFT Sim. parameters 
S02 – 0.72 ± 0.03 – 0.74 ± 0.4 – 0.75 
ΔE (eV) – 9 ± 1 – 9 ± 1 – 9 
R-factor – 0.00964 – 0.01588 – – 
n° par./n° ind. – 10/42 – 10/42 – – 
Corr. > 0.8 – 
σ2N & σ2C → 
0.8175 




2.06 ± 0.03 
[+ 0.004] 
2.061 












2.22 ± 0.01 
[– 0.048] 
2.297 





σ2C1 (Å2) – 0.0015 ± 0.0008 – 0.004 ± 0.001 – 0.004(d) 
RS 
[ΔRS] (Å) 
– – 2.443 
2.39 ± 0.01 
[– 0.059] 
– – 







2.708 ± 0.004 
[– 0.057] 
– – – – 
σ2I (Å2) – 0.0022 ± 0.0003 – – – – 
αfar – – 0.009 ± 0.005 – 
− 0.022 ± 
0.006 
– − 0.015(c) 
σ2far(Å2) – 0.005 ± 0.002 – 0.006 ± 0.003 – 0.006(d) 
(a) Obtained as the average of the ΔRN1 best-fit values for the [2-I]+ and 2-SG solid-state references. 
(b) Obtained as the average of the ΔRC1 best-fit values for the [2-I]+ and 2-SG solid-state references. 
(c) Obtained as the average of the α best-fit values for the [2-I]+ and 2-SG solid-state references. 
(d) Fixed for each sub-shell to the maximum best-fit value obtained in the fits of [2-I]+ and 2-SG solid-state 
references. 
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Figure 6.7. Structural refinement from static EXAFS. (a, c) DFT-optimised structural models 
of the first coordination sphere of Os in (a) [2-I]+, (b) 2-SG and (c) 2-NN/SG intermediate 
predicted by theory. Atom colour code: Os, indigo; N, blue; C, grey; S, yellow; I, purple. 
Coloured halos and corresponding labels denote the different sub-shells of scattering atoms 
employed for EXAFS fitting and simulation. (c, d) Comparison between experimental and 
best fit FT-EXAFS spectra (magnitude and imaginary part in top and bottom panels, 
respectively) for the solid-state references (b) [2-I]+ and (d) 2-SG using the DFT models in 
parts (a) and (c), respectively, as initial input in the EXAFS fit. (f) Simulated EXAFS 
spectrum of the 2-GS/NN intermediate, obtained based on the DFT-optimised geometry in 
part (e) by exploiting the results of the EXAFS fits shown in parts (b, d) on reference 
compounds [2-I]+ and 2-SG. Parts (b, d, f) also report the principal contributions to the 
EXAFS signal, with the same colour code used to identify the different sub-shells of 
scattering atoms in parts (a, c, e). (g) Comparison between the experimental k2χ(k) functions 
of the [2-I]+ (purple) and 2-SG (red) solid-state references and the simulated k2χ(k) for the 2-
GS/NN intermediate (dark grey). The spectra were shown in the (3.0-12.0) Å-1 k-space range, 
which were also employed for the analysis in situ of the reaction between [2-I]+ and GSH 
using EXAFS. 
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6.3.4. Validation of Models of [2-I]+ in Aqueous Environments 
Based on the DFT models validated, valuable structural information was 
obtained from the EXAFS spectra of [2-I]+ standards in three different 
aqueous environments (pH = 3, 5 and 7). This was of great importance 
as those were the main conditions used during our XAS experiments to 
study the hydrolysis of [2-I]+ in presence of GSH. Data analysis indicated 
that, when [2-I]+ was in solution, the closest Os coordination 
environment was substantially similar to the solid-state configuration, 
and adequately predicted by the DFT model (fit R-factor < 3% in all 
cases). This was particularly true for the spectra at pH 5 and 7, at which 
all the optimised values obtained for structural parameters were 
equivalent with those found from the solid-state standards. However, at 
pH 3, a slight contraction of the Os–N1 bond length (2.02 ± 0.01 Å
 vs 
2.06 ± 0.03 Å for the solid-state standard) was observed. EXAFS also 
provided evidence for a higher degree of structural disorder for [2-I]+ 
standards in solution, reflected by a global increase in DWs and fitting 
uncertainties with respect to the solid-state standards (Table 6.2). 
However, a remarkably good fitting quality is still attained (Figure 6.8). 
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Table 6.2. Best-fit parameters optimized in the EXAFS fit of the k2-weighted spectra 
of 30 mM buffer solutions of [2-I]+ at pH 7, pH 5 and pH 3, employing as starting 
guess in the fitting procedure the DFT-optimized geometry. The fit was performed in 
R-space, in the range (1.2-5.0) Å, employing the k-range (2.0-15.5) Å-1 for the FT-






(30 mM, pH 7) 
[2-I]+ 
(30 mM, pH 5) 
[2-I]+ 
(30 mM, pH 3) 
S0
2 – 0.75 ± 0.07 0.81 ± 0.05 0.79 ± 0.05 
ΔE (eV) – 9 ± 1 9 ± 1 8 ± 1 
R-factor – 0.02960 0.01594 0.02586 
N° par./N° 
ind. 
– 10/42 10/42 10/42 






<RN1> (Å) 2.056 2.06 ± 0.03 2.06 ± 0.03 2.02 ± 0.01 
σ2N1(Å
2)  0.003 ± 0.001 0.003 ± 0.001 0.002 ± 0.001 
<RC1> (Å) 2.268 2.21 ± 0.01 2.21 ± 0.01 2.21 ± 0.01 
σ2C1 (Å
2)  0.003 ± 0.002 0.003 ± 0.001 0.002 ± 0.001 





0.0026 ± 0.0004 0.0018 ± 0.0004 
α  – 0.01 ± 0.01 – 0.010 ± 0.007 – 0.02 ± 0.01 
σ2 (Å2)  0.005 ± 0.004 0.006 ± 0.003 0.006 ± 0.004 
Relevant parameters (S02, ΔE, RN1, σ2N1, RC1, σ2C1, σ2I, RI , αfar, σ2far) were fixed based on best-fitting 
results including amplitude factor (S02), energy shift (ΔE), average length of Os-N/C/I bonds (RN1, RC1, 
RI) and maximum best-fit value with solid references (σ2N1, σ2C1, σ2I ), common contraction/expansion 
factor α and a DW factor 2. 
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Figure 6.8. Comparison between experimental (colored circles) and best fit (dark 
grey solid lines) FT-EXAFS spectra for 30 mM buffer solution of [2-I]+ at (a) pH 7, 
(b) pH 5 and (c) pH 3, using the DFT models as initial input in the EXAFS fit (see 
Table 6.2 for quantitative results of the fits). Magnitude and imaginary parts of the 
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6.3.5. 2-GS/NN Tracking in Reactions of [2-I]+ with GSH 
Experiments at pH 7. Initially, an in situ XAS experiment at pH 7, using 
a Os : GSH molar ratio of 1:2 was carried out. Under these experimental 
conditions (30 mM [2-I]+, 60 mM GSH, in 200 mM phosphate buffer pH 
7, 298 K), the hydrolysis of Os-I bond was much faster than in the HPLC 
experiments performed previously (Section 4.3.1 in Chapter 4), and the 
reaction was mostly finished after 40 min from GSH being injected. 
Further minor spectral modifications were observed between 40-80 min, 
but EXAFS features were mostly stable at longer reaction times (80-220 
min). A linear combination fit (LCF) analysis corroborated these 
observations, and indicated the dominant presence of 2-SG and [2-Cl]+ 
after 80 min from GSH injection (accounting for over 80-90% of all the 
Os species found in the reaction mixture), together with contributions of 
< 10% from [2-I]+ and [2-OH]+ (Table 6.3, Figure 6.9). LCF analysis 
could provide the percentage of the individual chlorido and thiolate 
adducts (Table 6.3). However, only the combined total percentage of the 
two species should be considered because [2-Cl]+ and 2-SG standards 
could not be easily discriminated by EXAFS analysis. Unfortunately, 
there no signal was tracked that could be assigned to the intermediate 2-
GS/NN, perhaps due to its high reactivity at pH 7 with Os : GSH molar 
ratio of 1:2. 
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Figure 6.9. Time-resolved in situ FT-EXAFS (solid line) for reaction between [2-I]+ 
(30 mM) and GSH (60 mM) at pH 7, Os : GSH = 1:2, compared with reference 
complexes (dashed lines).  
 
Table 6.3. Os speciation during in situ XAS experiment on the reaction of [2-I]+ (30 
mM) with GSH (60 mM) at pH 7 from LCF analysis of the EXAFS scan collected at 
representative time points. LCF performed on k2χ(k) curves, in the range (3.0-12.0) 
Å-1. Dominant contributions from 2-SG and [2-Cl]+ are highlighted in bold font. 
LCF results 
Concentration (% total Os) 
40 min 80 min 220 min 
[2-I]+ 9 ± 3 8 ± 3 7 ± 3 
2-SG 63 ± 5 54 ± 4 50 ± 5 
[2-Cl]+ 22 ± 5 33 ± 4 42 ± 5 
[2-OH]+ 6 ± 8 6 ± 7 2 ± 7 
R-factor 0.0148 0.0093 0.0114 
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Figure 6.10. Comparison between experimental in situ EXAFS spectrum (thick dark 
red line) collected after 220 min for reaction of [2-I]+ (30 mM) with GSH (60 mM) 
at pH 7 and the corresponding best fit curve (grey line), from LCF analysis in k-space. 
The scaled LCF contributions to the EXAFS signal related to [2-I]+, 2-SG, [2-Cl]+ 
and [2-OH]+ were also presented, vertically translated for the sake of clarity. 
 
Experiments at pH 3. An in situ XAS experiment under acidic 
conditions (30 mM [2-I]+, 60 mM GSH, pH 3) was carried out. In contrast 
to pH 7,   EXAFS spectra at pH 3 were almost identical to [2-I]+ standards, 
and remained unchanged over the whole duration of the study (220 min 
from GSH injection). This was in line with the finding from 
chromatographic experiments (Section 4.3.1 in Chapter 4). Furthermore, 
it meant that although no direct comparison could be made between the 
kinetics of the reactions studied by EXAFS and HPLC, they still followed 
the same trend as a function of pH. Intrinsically, this also suggested that 
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it may be possible to capture some dynamics related to the hydrolysis of 
[2-I]+ in presence of GSH by careful tuning of the reaction conditions (i.e. 
pH, Os:GSH molar ratio). 
 
Figure 6.11. Time-resolved in situ FT-EXAFS (solid line) for reaction between [2-
I]+ (30 mM) and GSH (60 mM) at pH 3, Os : GSH = 1:2, comparing with reference 
complexes FT-EXAFS (dash line).  
 
Experiments at pH 5. The reaction of [2-I]+ with GSH was further 
studied at pH = 5, and using a new Os : GSH ratio of 2:1 (30 mM and 15 
mM, respectively), in an attempt to moderate the reaction rate. 
Remarkably, EXAFS spectra collected in the 40-220 min time range from 
GSH injection under these conditions, showed the presence of an 
oscillatory behaviour within the reaction. It was observed that periodic 
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and opposite changes in the intensity of the peak at ca. 2.5 Å (Os-I SS 
contribution in [2-I]+), and the shoulder at ca. 2.0 Å (Os-S SS 
contribution in 2-SG) in the phase-uncorrected spectra. However, certain 
time points showed dampened contributions from Os-I SS (single 
scattering) without an increase in the characteristic Os-S SS (i.e. 200 min 
after GSH injection), suggesting the presence within the reaction mixture 
of additional unknown Os species. Furthermore, the cyclic behaviour 
may arise from alternated periods dominated by cleavage or formation of 
Os–I bonds. To check this, it Os-speciation was determined as a function 
of the reaction time by applying EXAFS LCF analysis in k-space.  
 
Figure 6.12. Time-resolved in situ FT-EXAFS for reaction between [2-I]+ (30 mM) 
and GSH (15 mM) at pH 5, Os:GSH = 2:1.  
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Figure 6.13. Comparison between experimental in situ EXAFS spectra (thick 
coloured lines) collected during reaction between [2-I]+ (30 mM) with GSH (15 mM) 
at pH 5, Os : GSH = 2:1 at selected reaction times and the corresponding best fit 
curves (grey lines), from LCF analysis in k-space. The three selected reaction time 
points 40 min (left panel), 120 min (middle panel), and 200 min (right panel), show 
the higher concentration of the 2-GS/NN intermediate in the reaction mixture. The 
scaled LCF contributions to the EXAFS signal related to [2-I]+, 2-SG and 2-GS/NN 
are also presented. 
 
Three different components were used to generate the LCF model: the 
experimental references for [2-I]+ and 2-SG and the simulated EXAFS 
signature for the 2-GS/NN intermediate predicted by theory. The model 
adopted yielded a good reproduction of the experimental signals (Figure 
6.13).  Inclusion in the LCF model of the 2-GS/NN component resulted 
in a significant improvement of the fitting quality in the time points with 
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high concentrations of such species (marked by coloured arrows in 
Figure 6.14) with respect to a two-component model solely including [2-
I]+ and 2-SG (Figure 6.14). Crucially, the maxima regarding the relative 
abundance of 2-GS/NN (from 16 to 24% total Os) systematically 
precluded increases in the concentration of 2-SG. This supported the 
presence of 2-GS/NN species as part of the reaction mechanism, and was 
in line with their intermediate character defined by DFT (Section 4.3.7 
of Chapter 4). 
 
Figure 6.14. Comparison between the LCF R-factors obtained at each time point for 
the three-component model (reactant [2-I]+; product 2-SG, intermediate 2-GS/NN) 
and for the two-component model (reactant [2-I]+; product 2-SG) reported in the top 
panel. The coloured arrows highlight the reaction times corresponding to the 
concentration of peaks for 2-GS/NN (in the 16-24% total Os range), corresponding 
to systematic improvement of the LCF quality (lower R-factor values) for the three-
component model. 
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LCF (linear combination fit) results highlighted the oscillating character 
of the reaction. [2-I]+ was cyclically converted into 2-SG (with a period 
of 60-80 min), which then was transformed again to [2-I]+. This could be 
related to fluctuations in the concentrations of free I- ions and free GSH 
as a result of the hydrolysis of Os-I bonds and the formation of new Os-
SG species. Indeed, our chromatographic experiments have shown 
previously that the presence of high concentrations of chloride ions in the 
medium can alter the amount of the Os species (increase in [2-Cl]+) found 
during the hydrolysis of [2-I]+ in presence of GSH (Section 4.3.1 in 
Chapter 4). Moreover, a more complex four-component LCF model 
(using experimental [2-I]+, 2-SG and [2-OH]+ and simulated 2-GS/NN 
references) suggested negligible quantities of [2-OH]+ in the reaction 
mixture (Figure 6.15). This might indicate the presence of high 
concentrations of free I- ions and free GSH in the reaction. By calculating 
the concentrations of free I- ions and free GSH (from amounts of [2-I]+ 
and 2-SG species indicated by LCF), an alternation between long periods 
of low I-/GSH ratios and short periods of I-/GSH ratios (every 60-80 min) 
is observed. Remarkably, the highest concentrations of free I- ions would 
always be found just before periods dominated by the formation of Os-I 
bonds (Figure 6.16), providing a possible explanation to the regeneration 
of [2-I]+. Finally, the presence of fluctuations in GSH, together with the 
fact that over 30 mM of Os-I bonds are hydrolysed (31.2 mM in total, 
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calculated from the amounts of [2-I]+ and 2-SG species indicated by LCF) 
by 15 mM of GSH also supports a possible catalytic nature of the reaction 
that has been observed in NMR experiments (Section 4.3.1 of Chapter 
4).  
 
Figure 6.15. Results from test LCF analysis of the time-resolved k2χ(k) curves during 
reaction between [2-I]+ (30 mM) with GSH (15 mM) at pH 5, Os : GSH = 2:1 
including in the fitting model also the [2-OH]+ model compound together with [2-I]+, 
2-SG, and the theoretical intermediate 2-GS/NN. The LCF R-factors (grey ×) were 
also presented (right ordinated axis). The fraction of [2-OH]+ was optimized at (0.0 
±0.1) over the whole investigated reaction time range, demonstrating that the [2-
OH]+ species was not detectable under the XAS experimental conditions. 
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Figure 6.16. Top panel: Comparison between the quantities of free I- ions and free 
GSH in the reaction environment with results of LCF analysis of the time-resolved 
k2χ(k) spectra collected during reaction between [2-I]+ (30 mM) with GSH (15 mM) 
at pH 5, Os:GSH = 2:1, using a three-component model (reactant [2-I]+ and product 
2-SG, and theoretical intermediate 2-GS/NN). Bottom panel: Comparison between 
the ratio of free I- ions/free GSH in the reaction environment with results of LCF 
analysis of the time-resolved k2χ(k) spectra collected during reaction between [2-I]+ 
(30 mM) with GSH (15 mM) at pH 5, Os : GSH = 2:1, using a three-component model 
(reactant [2-I]+ and product 2-SG, and theoretical intermediate 2-GS/NN). 
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6.4. Discussion 
Osmium-based anticancer candidate complex [2-I]+ has been reported to 
have a high potency.1,2 Surprisingly, [2-I]+ is highly inert under 
physiological conditions, but the intracellular tripeptide GSH can 
catalyse the hydrolysis of [2-I]+ to form the hydroxido adduct [2-OH]+ 
through attacking the -N=N- azo bond based on the combined theoretical-
experimental studies performed in Chapter 4. In the proposed 
mechanism of action, a sulfenylhydrazide intermediate 2-GS/NN is 
perceived to represent a key intermediate in the catalytic hydrolysis of 
[2-I]+ by GSH. As yet, this intermediate 2-GS/NN has not been detected. 
Detection of intermediates in the chemical reactions is always 
challenging. The attack of thiols on -N=N- has been widely observed for 
organic diazenes and diazenes coordinated to Ru(II) or Ir(III).4-8 However, 
the thiolated-hydrazine intermediate has never been detected, only the 
hydrazine reduction products were detected for some systems.4,7  
Contributing to the overall aim of exploring the mechanism of action of 
[2-I]+ in this thesis, efforts were made in this Chapter 6 to detect the 
intermediate 2-GS/NN in the reaction of [2-I]+ with GSH using XAS 
technology. Initially, the reference XAS spectra were acquired for the 
complexes [2-I]+, [2-Cl]+, [2-OH]+, 2-SG, which might be observed in 
the reaction of [2-I]+ with GSH.  This was performed in order to: 1) 
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determine if XAS methods could be used to discriminate between the 
different adducts; 2) validate the structural models of the different species 
involved in the reaction generated by DFT calculations; and 3) generate 
a valid simulation of the XAS spectra of the intermediate 2-GS/NN that 
could be used to study the reaction between [2-I]+ and GSH. The results 
showed that EXAFS was sensitive enough to distinguish between these 
osmium adducts. Important differences were observed for [2-I]+ in 
EXAFS spectra compared to other species ([2-Cl]+, [2-OH]+, 2-SG) 
although it was not readily possible to distinguish between [2-Cl]+ and 2-
SG because of the small difference in atomic number between S and Cl. 
Based on these reference EXAFS spectra, as well as the reported X-ray 
crystal structure of [2-I]+,3 the structural models of for [2-I]+, 2-SG and 
intermediate 2-GS/NN and their EXAFS spectra were validated. It is 
exciting to find that from computational 2-GS/NN exhibits a distinct 
EXFAS spectrum, the absence of scattering contribution from close high-
Z atomic neighbours (in this case, S is ~ 4.5 Å from Os), compared with 
[2-I]+ and 2-SG, which make it possible to attempt detect the presence of 
2-GS/NN when the reaction between [2-I]+ and GSH was followed in 
situ EXAFS. 
However, the initial attempts to detect the signal for 2-GS/NN from the 
reaction of [2-I]+ with GSH are disappointing. In the experiment with a 
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Os:GSH ratio of 1:2 at pH 7, the reaction was predominantly completed 
after 40 min, which was faster than HPLC experiments studied in 
Chapter 4 as expected due to the different concentrations of recants (30 
mM [2-I]+ for XAS experiments and 75 μM [2-I]+ for HPLC experiment). 
LCF analysis indicated that the EXAFS spectra for reaction was mainly 
contributed by 2-SG and [2-Cl]+ with no contribution assignable to 2-
GS/NN. On the contrary, in the experiment with as Os:GSH mol ratio of 
1:2 at pH 3, the EXAFS spectra for the reaction were almost identical to 
[2-I]+ standards, and remained unchanged over the whole duration of the 
study. The pH influence on the XAS experiment followed the same trends 
as the HPLC experiments, which demonstrated that acidic conditions 
inhibit the reaction of [2-I]+ with GSH. Intrinsically, this also suggested 
that it might be possible to capture some dynamics related to the 
hydrolysis of [2-I]+ in presence of GSH by carefully tuning the reaction 
conditions (i.e. pH, Os:GSH molar ratio) to reach an appropriate reaction 
rate. 
Thus further attempts to probe intermediate 2-GS/NN were made using 
the higher Os:GSH mol ratio of 2:1 and pH 5 for the in situ XAS 
experiment. Interestingly. the EXAFS spectra showed an oscillatory 
behaviour within the reaction and certain time points showed dampened 
contributions from the Os-I bond but without an increase in characteristic 
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Os-S features, suggesting the presence of additional unknown Os species. 
LCF analysis to the spectra was carried out employing three different 
models: two components ([2-I]+ and 2-SG), three components ([2-I]+, 2-
SG and 2-GS/NN) and four components (([2-I]+, 2-SG, 2-GS/NN and 
[2-OH]+). The three-component model ([2-I]+, 2-SG and 2-GS/NN) gave 
the best fitting quality and maxima in the relative abundance of 2-GS/NN 
from 16 to 24% total Os, and systematically precluded increases in the 
concentration of 2-SG (Figure 6.13). This supported the presence of 2-
GS/NN species in the reaction mechanism, as predicted by the DFT 
calculations (Section 4.3.7 of Chapter 4). Moreover, the oscillating 
behaviour of EXAFS spectra for the reaction indicated that ~30 mM Os-
I was cyclically hydrolysed by 15 mM GSH, which supported the 
catalytic nature of the  activation of [2-I]+ by GSH, a the result confirmed 
by NMR experiments (Section 4.3.1 of Chapter 4). As the pathway 
probed by DFT calculations in Chapter 4 (Section 4.3.7), this catalytic 
nature of GSH promoting Os-I is due to release of GSH from the 2-
GS/NN after the hydrolysis completing. 
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6.5. Conclusions 
Contributing to the overall aim of this thesis of exploring the chemical 
mechanism of action of [2-I]+, some experimental evidence is provided 
in this Chapter 6 to support the presence of the sulfenylhydrazide  
intermediate 2-GS/NN proposed from the DFT-predicted pathway for the 
reaction of [2-I]+ with GSH.  Based on the reference EXAFS spectra for 
the complexes [2-I]+, [2-Cl]+, [2-OH]+, and 2-SG observed in the 
reaction of [2-I]+ with GSH, the structure models and characteristic 
computational EXAFS spectra for the intermediate are validated. In situ 
XAS experiments at different pH values and reactant ratios were carried 
out and analysed by LCF. The results suggest there is maximum of ~20% 
abundance of sulfenylhydrazide intermediate 2-GS/NN in the reaction 
[2-I]+ with GSH. This experimental evidence confirms a pathway in 
which GSH promotes the hydrolysis of [2-I]+ through redox mediation 
by -N=N- azo group in the complexes. Moreover, the behaviour of acid 
inhibition and the catalytic nature of the reaction of [2-I]+ with GSH 
observed during in situ experiments in this Chapter 6 are line with the 
findings in Chapter 4 and Chapter 5, which indeed again provided 
evidence for the mechanism of action of [2-I]+ presented in this thesis.  
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7.1. Introduction  
The aim of this thesis was to explore the molecular mechanism of action 
of [Os(η6-p-cym)(4-(2-pyridylazo)-N,N-dimethylaniline)I]+ [2-I]+ that 
serves as a promising anticancer drug candidate. In this Chapter 7, the 
main conclusions from each previous chapter (Chapters 3 – 6) will be 
summarized. Based on these findings, further studies related to [2-I]+ will 
be suggested, including interactions between [2-I]+ and enzymes 
involved in glycolysis, as well as separation and evaluation of chiral 
isomers of [2-I]+ and its analogues, the effect on the concentrations of 
intracellular reduced cytochrome c, and vibrational spectroscopic studies 
of [2-I]+ interactions with GSH. 
 
7.2. Conclusions from Chapters 3 - 6 
Exploring the molecular level mechanism of action of anticancer drugs 
is always challenging but an important process in their medical 
application, and eventually this will promote the development of the next 
generation of anticancer drugs. The half-sandwich osmium complex 
[Os(η6-p-cym)(4-(2-pyridylazo)-N,N-dimethylaniline)I]+ [2-I]+ and its 
analogues were  first synthesised  ~10 years ago.1 Biological evaluations 
showed that [2-I]+ exhibits on average 49 × higher potency than the 
current first line anticancer drug cisplatin towards 809 cancer lines,2 and 
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promisingly, [2-I]+ still maintains high potency to cisplatin-resistant 
cancer cells and is active in vivo in a mouse model.3 Since [2-I]+ was first 
developed, many research studies about this anticancer drug candidate 
have been conducted. The results indicate that the cytotoxicity of [2-I]+ 
to cancer cells mainly arises from two routes: increasing the superoxide 
level in cancer cells and shunting the energy generation focus of cancer 
cells from glycolysis to oxidative phosphorylation.2 The intracellular 
tripeptide glutathione (γ-L-Glu-L-Cys-Gly, GSH) was found to play a 
crucial role in the potency of [2-I]+ and tuning an appropriate 
concentration of intracellular GSH can maximize the potential 
cytotoxicity of [2-I]+.4,5 The function of GSH towards [2-I]+ might 
involve activating the hydrolysis of [2-I]+ once uptaken by the cell.6 All 
these previous studies provided very important insight into the 
mechanism of action of [2-I]+ but an improved understanding of the 
molecular behaviour of [2-I]+, especially in reactions with GSH is still 
desired, which is an aim of this thesis. 
In Chapter 3, complexes related to the reaction of [2-I]+ with GSH (and 
other thiols) were synthesised and characterized including the lead 
complex [2-I]+, the chlorido analogue [2-Cl]+, the hydroxido analogue 
[2-OH]+, glutathione adduct 2-SG and the N-acetylcysteine adduct 2-
NAC (for structures see Figure 7.4). The chromatographic identification 
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(e.g. retention times, mass spectra) and electronic properties (e.g. 
extinction coefficients) of these complexes were determined. Moreover, 
by combining ICP-OES (inductively coupled plasma-optical emission 
spectrometry) and HPLC (high performance liquid chromatography) 
technologies, the proportional relationships between the concentration of 
these osmium complexes and HPLC peak areas were established. The 
work in Chapter 3 provided the basis to identify, analyse and quantify 
the reactions of [2-I]+ with GSH in the following chapters. 
In Chapter 4, the hydrolysis of [2-I]+ with GSH was systemically studied 
under various conditions. [2-I]+ was found to be very stable under 
physiological conditions, but the presence of GSH dramatically increased 
the extent of hydrolysis to form the hydroxido analogue [2-OH]+. With 
higher GSH : Os ratios, the thiolate adduct 2-SG and sulfenate adduct 2-
SOG were observed. Besides GSH, other free thiols such as N-acetyl 
cysteine and dithiothreitol displayed the same function to promote the 
hydrolysis of [2-I]+, which highlighted the importance of the thiol group 
in promoting this process. The pH influence of the hydrolysis of [2-I]+ 
by GSH was also explored and the results showed that acidic conditions 
inhibited the reaction. This suggests that the deprotonated GS- rather than 
GSH is a key species in the reaction with [2-I]+.  Moreover, the chlorido 
analogue [2-Cl]+ and imino analogue [2-impy-I]+ were compared with 
Chapter 7: Conclusions and Future Work 
311 
the lead complex [2-I]+. In the reaction with GSH, the azo group in 
complex [2-Cl]+ exhibited a similar behaviour to the azo group in 
complex [2-I]+ and GSH dramatically increased their hydrolysis. On the 
contrary, co-incubation with GSH did not increase the extent of 
hydrolysis of the imino complex [2-impy-I]+. Comparison between azo 
complexes ([2-I]+ and [2-Cl]+) with the imino complex ([2-impy-I]+) 
demonstrates the importance of the azo bond -N=N-. Based on these 
findings, pathways for the hydrolysis of [2-I]+ in presence of GSH were 
proposed and probed by DFT (density functional theory) calculations. As 
a consequence, the pathway of deprotonated GS- attacking the azo bond 
-N=N- in the ligand of [2-I]+ seems more likely to dominate its hydrolysis 
process. 
In Chapter 5, free radical signals were detected in the reactions of 
osmium azo complexes (lead complex [2-I]+, chlorido analogue [2-Cl]+, 
hydroxido analogue [2-OH]+) with GSH using EPR (electron 
paramagnetic resonance) spectroscopy. Under physiological conditions, 
[2-OH]+ induced a mixture of free radicals: superoxide (O2
-), hydroxyl 
radicals (•OH) and hydrogen atoms (•H) whilst [2-I]+ and [2-Cl]+ only 
induced the generation of hydroxyl radicals (•OH). This may be related 
to the different reactivities of these three complexes. ([2-OH]+ is more 
active than [2-I]+ and [2-Cl]+). More interestingly, under basic conditions 
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all these three osmium complexes can induce the mixture of free radicals, 
i.e. superoxide (O2
-), hydroxyl radicals (•OH), and hydrogen atoms (•H). 
On the contrary, under acidic conditions, no free radical signals were 
observed for all of them. The influence of pH on free radical generation 
was in line with the influence of pH on the hydrolysis process, which 
indicated deprotonated GS- rather than GSH was the active species which 
attacks the osmium complex. Moreover, no free radicals were detected 
when the reaction of the osmium azo complex with GSH was conducted 
under N2, which highlighted the importance of O2. The reaction of the 
imino analogue [2-impy-Cl]+ with GSH was also studied with EPR and 
no free radicals were generated. Comparison between the osmium azo 
complexes ([2-I]+, [2-Cl]+, [2-OH]+) with imino complexes ([2-impy-
Cl]+) supported the azo bond -N=N- as a key factor to induce free radicals. 
However, GSSG and H2O2 were detected from the reaction of osmium 
azo complexes with GSH. Based on all these findings, a mechanism 
involving attack of GS- on the azo bond -N=N- in the osmium complex 
and then donating electrons to O2 to produce superoxide and oxidized 
GSSG was proposed. DFT calculations suggested a osmium-dioxygen 
complex as a possible intermediate in this free radical-producing process. 
In Chapter 6, X-ray absorption spectroscopy was used in an attempt to 
detect the proposed thiolated-hydrazine 2-GS/NN intermediate for the 
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reaction [2-I]+ with GSH, because GSH reduction of the azo bond is the 
key to both the hydrolysis processes featured in Chapter 4 and free 
radical generation in Chapter 5. The results showed there was a 
maximum of ~20% abundance of 2-GS/NN in the reaction of [2-I]+ with 
GSH and this confirmed a mechanism involving GSH reducing the azo 
bond to induce hydrolysis and free radical production. 
 
7.3. Future Work 
7.3.1. Interactions Between [2-I]+ and Glycolytic Enzymes   
In previous studies performed on [2-I]+, cancer cells exposed to [2-I]+ 
were found to undergo a metabolic shunt from glycolysis to oxidative 
phosphorylation.2 In the studies of Chapter 4, the free thiols glutathione 
and N-acetyl-cysteine, which can be considered as models for cysteine 
containing enzymes,  were found to bind to the osmium centre or reduce 
the azo bond in [2-I]+. These studies suggested that interactions between 
[2-I]+ and enzymes involved in glycolysis might be of interest for future 
research related to [2-I]+. 
Cancer cells tend to favour metabolism via glycolysis rather than the 
much more efficient oxidative phosphorylation pathway even under 
aerobic conditions (Warburg effect),7 which renders glycolysis a key 
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metabolic route to provide cancer cells with energy and nutrition. There 
are ten steps in glycolysis and nine enzymes are involved.   
 
Figure 7.1. The glycolysis pathway in the cell (From Wikipedia)  
 
In the glycolysis pathway, GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase) is the enzyme that catalyzes the sixth step using GADP 
(glyceraldehyde 3-phosphate) as the substrate to produce 1,3PG (1,3-
bisphosphoglycerate).8 Cancer cells frequently upregulate GAPDH to 
meet higher energy requirements than normal cells.9-11 The catalysis 
mechanism of GAPDH involves a cysteine (Cys152) located at this 
enzyme’s active pocket which firstly reduces the carbonyl group of the 
substrate GADP to form a thiohemiacetal intermediate, then NAD+ 
accepts a hydride ion from thiohemiacetal intermediate to generate 
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NADH, whilst GAP is simultaneously oxidized to a thioester, and finally 
an inorganic phosphate attacks the thioester to release the product 1,3PG 
and free cysteine in the enzyme.12,13 It is clear that Cys152 is a key residue 
in the activity of GAPDH and could be a target site for [2-I]+. Preliminary 
molecular docking studies based on the reported crystal structure of [2-
I]+ and GAPDH (PDB code: 4WNC14) were performed  using the Ligand 
Fit Dock protocol of Discovery Studio 3.5.15 The results from this study 
showed that a fragment of [2-I]+ which has lost the arene function has the 
potential to enter into the active site of GAPDH. 
 
Figure 7.2. The catalysis mechanism of GAPDH.12  
 
Figure 7.3. A 3D model of osmium species docked into the active site of GAPDH  
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7.3.2. Chiral Isomer Separation and Evaluation 
In Chapter 3, several organo-osmium complexes were synthesised and 
characterized including lead complex [2-I]+, the chlorido analogue [2-
Cl]+, the hydroxido analogue [2-OH]+, the N-acetyl-cysteine adduct 2-
NAC and the glutathione adduct 2-SG. These complexes have one or 
more chiral centres and the chirality may influence their biological 
activities. Since the tragedy of severe birth defects caused by the S-
isomer of thalidomide which was initially used as an antisedative drug, 
strict rules have been defined for the development of new stereoisomeric 
drugs.16-18 Several osmium-based anticancer complexes have been 
reported to exhibit stereoselectivity for their intracellular targets.19,20 
 
Figure 7.4. Isomers of osmium complexes related to [2-I]+. 
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7.3.3. Quantification of Intracellular Reduced Cytochrome c 
In Chapter 6, it has been observed that osmium complexes ([2-I]+, [2-
OH]+) react with GSH to produce superoxide which is able to reduce 
cytochrome c. It will be interesting to quantify intracellular reduced 
cytochrome c and a spectroscopic method has been reported.9 In the cell, 
cytochrome c mainly has two functions and both of these are closely 
related to its redox state.21 One is to be a key participant in the electron 
transport chain in mitochondria. Normally, oxidized cytochrome c 
accepts one electron from Complex III and transfer the electron to 
Complex IV.21 The other function of cytochrome c is to be released from 
mitochondria into cytoplasm to induce apoptosis.21-24 However, only 
oxidized cytochrome c can activate caspase, which is required for 
apoptosis.25,26     
 
Figure 7.5. The role of cytochrome c in the electron transfer chain.27 
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7.3.4. Vibrational Spectroscopy of the Reactions of [2-I]+ with GSH 
In Chapter 4 and Chapter 5, the intermediate thiolated-hydrazine 2-
GS/NN and osmium-superoxido complex ([2-O2]+) were proposed to 
play key roles in the mechanism of the reaction of [2-I]+ with GSH. Even 
through XAS signals assignable to 2-GS/NN were captured in Chapter 
6, more characterizations are required to identify these intermediates. 
Vibrational spectroscopy (infrared (IR) and Raman), is an energy-
sensitive method and widely used for detecting intermediates.28-32 
Preliminary Raman studies of the reaction of [2-I]+ with GSH were 
carried out and the intensity of a peak assignable to the azo bond ( at 1236 
cm-1 by DFT calculations) in [2-I]+ was observed to change distinctly in 
the presence of GSH (Figure 7.6). 
  
Figure 7.6. Raman spectra for [2-I]+ (75 μM) in absence or presence of GSH (750 
μM) at pH 7.4 during a 450 min incubation at 298 K upon irradiation at 633 nm.  
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Figure A3. The molecular structures of compounds studied in this thesis. 
 
 
